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Summary 
The human immunodeficiency virus type 1 (HIV-1) has infected over 70 million people (and 
killed 36 million) since the start of the epidemic. This makes it one of the most successful 
pathogens in human history. Characteristic for the HIV-1 pathogenesis is a long-lasting 
battle between the virus and the human immune system, which eventually leads to immune 
exhaustion and onset of AIDS. A considerable part of HIV-1 research has focused on both 
defining the immune responses against the virus and understanding the mechanisms that 
drive immune dysfunction, in the hope to artificially boost these responses or to 
prevent/repair their deterioration. Type 1 interferon (IFN-I) responses are an interesting 
target in this regard. They have extremely potent antiviral effects and are a key part of the 
immune response against multiple viral pathogens. During chronic viral infections, such as 
HIV-1, the role of IFN-I is however dual: while early responses initially limit viral spread, 
prolonged exposure to IFN-I is associated with hyper-immune activation and dysfunction, 
both hallmarks of pathogenic HIV-1 infection. Our primary goal was to investigate 
mechanisms that could potentially drive and regulate IFN-I production during HIV-1 
pathogenesis.  
This mechanistic evaluation required the use of a large set of HIV variants and lentiviral 
vectors to perform shRNA knock-down of host genes. This introduced early-on the need for a 
method to evaluate lentiviral productions, to normalize infection experiments and quantify 
HIV replication. We found that most standard methods for retroviral quantification were not 
compatible with such high-throughput production, as they are usually quite labor-intensive 
or expensive. This led to optimization of a real-time PCR based technique for measurement 
of retroviral reverse transcriptase (RT) activity. The method outperformed the current gold 
standard for in vitro quantification (p24 ELISA) by a lower inter-run variation, lower cost and 
higher linear range. Furthermore, RT activity correlated well with levels of transducing or 
infectious viral particles. 
To subsequently pursue our main goal, we evaluated the ability of HIV to induce IFN-I 
responses in its main target cells, primary CD4+ T cells. By employing several assays, we 
show that infection of these cells leads to a bioactive IFN-I response, characterized by 
induction of IFN-I and several interferon stimulated genes (ISGs). This demonstrates that 
CD4+ T cells are able to sense HIV and indicates them as a potential source of elevated IFN-I 
levels in HIV-1 patients. 
In a second part, we investigated host and viral mechanisms that regulate the IFN-I 
induction by HIV-1 in primary CD4+ T cells. This led to three important findings: 1) the 
cytosolic DNA receptor cGAS and its downstream signaling molecules are required for IFN-I 
induction; 2) IFN-I induction only occurs upon successful integration and protein 
expression by the virus; 3) the IFN-I response is regulated by two HIV-1 accessory proteins: 
  Summary-Samenvatting 
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it is potentiated by Vpr, but counteracted by Vpu. Together, these results indicate a model 
in which HIV DNA is sensed by cGAS upon productive infection and this requires assistance 
of newly expressed Vpr and possibly other newly formed viral replication products. It also 
suggests that HIV-1 may have evolved partial counteraction of this process through Vpu.  
In summary, this work has led to new insights into innate immunity against HIV-1. We 
identify HIV-infected CD4+ T cells as a possible new source of IFN-I and delineate virus and 
host components that mediate IFN-I responses in these cells. Given the extensive viral 
regulation of this process and the potential harmful role of IFN-I in HIV-1 pathogenesis, 
these findings might form the basis for novel therapeutic strategies. 
  Summary-Samenvatting 
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Samenvatting 
Het humaan immunodeficiëntie virus 1 (HIV-1) is één van de belangrijkste ziekteverwekkers 
in de geschiedenis van de mensheid. Sinds de start van de epidemie werden al meer dan 70 
miljoen mensen besmet en zijn meer dan 36 miljoen mensen overleden aan de gevolgen van 
AIDS. Karakteristiek voor het HIV-1 ziekteproces is een langdurig gevecht tussen het virus 
en ons immuunsysteem. Dit gevecht leidt na vele jaren tot een volledige uitputting van het 
immuunsysteem en de ontwikkeling van AIDS. Een aanzienlijk deel van HIV-1 onderzoek 
richt zich daarom op het beter begrijpen van de immuunreacties die ontwikkeld worden 
tegen het virus en het begrijpen van de mechanismen die leiden tot immuun-uitputting. De 
hoop is om zo methodes te vinden om sterkere immuunreacties op te wekken en immuun-
uitputting tegen te gaan. In dit kader vormen de type I interferon (IFN-I) responsen een 
interessant doelwit. Dit type van immuunrespons wekt van nature zeer sterke antivirale 
effecten op en speelt bijgevolg een belangrijke rol in de afweer van vele virale 
ziekteverwekkers. Tijdens chronische virale infecties zoals HIV-1 heeft IFN-I echter een 
dubbele rol: vroege responsen zijn belangrijk om de initiële virale spreiding tegen te gaan, 
maar langdurige blootstelling aan IFN-I kan leiden tot hyper-immuunactivatie en dysfunctie, 
beiden kenmerkend voor het HIV-1 ziekteproces. Het doel van deze thesis was om mogelijke 
processen te identificeren die IFN-I productie veroorzaken en reguleren tijdens de HIV-1 
infectie. 
Dergelijk mechanistisch onderzoek vergde het gebruik van vele HIV varianten alsook van 
lentivirale vectoren voor shRNA knockdown van cellulaire eiwitten. Bijgevolg was al snel een 
methode nodig om op grote schaal o.a. lentivirale producties te evalueren, infectie te 
normaliseren en HIV replicatie te kwantificeren. Standaardmethodes voor retrovirale 
kwantificatie bleken niet te voldoen aan deze eisen, aangezien ze vaak te duur of 
arbeidsintensief zijn. Dit leidde tot optimalisatie van een real-time PCR gebaseerde techniek 
om retrovirale reverse transcriptase (RT) activiteit te meten. Deze assay bleek de huidige 
standaardmethode (p24 ELISA) te overtreffen met een lagere inter-run variabiliteit, lagere 
kost en groter lineair bereik. RT activiteit toonde bovendien een goede correlatie met het 
aantal transducerende of infectieuze partikels.  
In het kader van onze eigenlijke doelstelling, werd vervolgens de capaciteit van HIV 
geëvalueerd om IFN-I te induceren in zijn belangrijkste doelwitcellen, primaire CD4+ T 
cellen. Door gebruik te maken van verschillende assays, demonstreren we dat infectie van 
deze cellen leidt tot ontwikkeling van een bioactieve IFN-I respons. Dit gaat gepaard met 
inductie van zowel IFN-I alsook verschillende interferon-geïnduceerde genen. Dit toont aan 
dat CD4+ T cellen in staat zijn om HIV-1 replicatieproducten te detecteren en een mogelijke 
bron kunnen zijn van de verhoogde IFN-I niveaus in HIV-1 patiënten.  
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In een tweede deel werden vervolgens gastheer en virale mechanismen onderzocht die de 
IFN-I inductie door HIV-1 reguleren in primaire CD4+ T cellen. Dit leidde tot drie belangrijke 
bevindingen: 1) de cytosolische DNA receptor cGAS alsook signalisatie eiwitten in de cGAS 
pathway zijn noodzakelijk voor IFN-I inductie; 2) IFN-I inductie treedt enkel op wanneer 
succesvolle integratie en eiwitproductie door het virus plaatsvindt; 3) de IFN-I respons wordt 
gereguleerd door twee HIV-1 accessorische eiwitten: Vpr stimuleert de respons en Vpu 
onderdrukt de respons. Deze bevindingen suggereren een mechanistisch model waarin HIV 
DNA gedetecteerd wordt door cGAS tijdens productieve infectie, door toedoen van nieuw 
gevormd Vpr en eventueel andere nieuw gevormde replicatie producten. Mogelijks heeft het 
virus een mechanisme ontwikkeld om dit proces deels te onderdrukken via Vpu. 
Samenvattend heeft dit werk geleid tot verschillende nieuwe inzichten in onze aangeboren 
immuunrespons tegen HIV-1. We identificeren HIV geïnfecteerde CD4+ T cellen als een 
mogelijke nieuwe bron van IFN-I en determineren virale en gastheer factoren die de IFN-I 
respons in deze cellen mediëren. De sterke virale regulatie van IFN-I productie en de 
schadelijke rol van chronisch IFN-I in HIV-1 pathogenese, maken dit proces tot een mogelijk 
interessant doelwit voor nieuwe therapeutische strategieën. 
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Chapter I-1. Human immunodeficiency virus 1 
In 1983, a new retrovirus was isolated and identified as the causative agents of a rapidly 
spreading, deadly new disease called AIDS (acquired immunodeficiency syndrome) [1-3]. The 
Human Immunodeficiency Virus type 1 (HIV-1) has been one of the most successful 
pathogens in human history, having killed over 35 million people since the start of the 
epidemic [4]. In the thirty years since its discovery, a lot has been learned about the 
emergence, structure, life cycle and pathogenic properties of HIV-1. The purpose of this 
section is to introduce the virus and its disease as a foundation for the more complex virus - 
host innate immune interactions discussed in the next section and the original research 
work discussed in Chapter III. 
1.1 Back to the roots of HIV-1 
1.1.1 Classification 
HIV-1 is a lentivirus from the Retroviridae family and further comprises 4 different virus 
lineages or groups: M, N, O and P. The HIV-1 group M viruses are responsible for more than 
95% of all HIV-1 infections and as such for the global HIV pandemic. HIV-1 group O, on the 
other hand, is much less prevalent and caused only a few tens of thousands of infections, 
mainly in West-Central Africa. HIV-1 group N and P infections are extremely rare 
(respectively 15 and 2 identified cases) and were mainly detected in people from 
Cameroonian origin [5, 6]. Viruses within the different groups have further diversified over 
time and group M viruses can be classified in 9 additional subgroups or clades (A-D, F-H, J-
K), each with their own geographic spread [7]. Soon after the discovery of HIV-1, a 
morphologically similar but genetically distinct virus was found to also cause AIDS in 
patients in West Africa and named HIV-2 [8, 9]. However, this virus seems to have a lower 
transmission rate and less pathogenic course compared to HIV-1 and infections mainly 
remained restricted to Western Africa or countries with colonial links to the region [10].  
1.1.2 Origin 
AIDS was first recognized as a disease in 1981 in the United States [11]. However, 
retrospective analysis revealed the presence of HIV-1 sequences in African blood and tissue 
samples that were collected as early as 1959 [12, 13]. Based on the high level of diversity 
among HIV-1 group M strains from that period, the onset of the group M epidemics was 
dated back to the early 1920s and most likely originated in the region of Kinshasa (in what 
is now the Democratic Republic of Congo) [13-15]. Soon after the isolation of HIV-1 and HIV-
2, different African monkey and ape species were found to carry lentiviruses with a close 
phylogenetic relationship to HIV (Figure 1). These viruses were collectively named simian 
Chapter I          General Introduction 
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immunodeficiency viruses (SIVs) because of their genetic resemblance to the human AIDS 
viruses, although they usually do not cause an immunodeficiency in their natural hosts. 
Interestingly, HIV-1 and HIV-2 viruses seemed more closely related to different types of SIVs 
than to each other. This provided a first indication that both viruses had emerged from 
direct cross-species transmissions of SIV to humans [16, 17]. Based on phylogenetic 
analyses of different SIVs and HIVs, it is now assumed that the four different HIV-1 groups 
and HIV-2 all originated from independent zoonotic transmission events from chimpanzees, 
gorilla or sooty mangabeys, with SIVcpz from the chimpanzee Pan troglodytes troglodytes 
being the ancestor of the pandemic HIV-1 group M strains (Figure 1). Although many “wild” 
theories exist regarding the circumstances of transmission, it most likely occurred in the 
process of hunting and butchering of primates for bushmeat or through scratches and bites 
of monkeys that were kept as pets. The subsequent events that fueled the emergence of a 
global HIV-1 group M pandemic remain speculative. The rapid growth of the city 
populations, the increase in sexually transmitted diseases and the use of unsterile needles 
during large-scale injection campaigns could all have contributed to the explosive spread of 
HIV (reviewed in [6, 8]).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Origin of HIV-1. Over 40 different lentiviruses have been detected in African 
monkey and ape species and they have collectively been named simian immunodeficiency 
viruses (SIV). Transmission of these viruses across the species barrier, eg. to humans, has 
occurred on multiple independent occasions and has given rise to the different HIV-1 and 
HIV-2 groups. Reprint from Sharp et al. 2011 [8] with permission from the authors. 
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1.2 Structure of HIV-1 
HIV-1 viral particles have a spherical shape of approximately 100-150 nm diameter. They 
consist of an outer lipid bilayer that is of cellular origin and an inner cone-shaped core that 
is formed by structural proteins of viral origin. Like all retroviruses, HIV-1 has a positive 
sense, single-stranded RNA genome of which two copies are packed into the viral particles. 
This genome encodes for 15 final proteins that are synthesized from one primary 
alternatively spliced transcript. An envelope glycoprotein precursor (gp160), encoded by the 
env gene, is cleaved by cellular proteases, such as furin, into surface (gp120) and 
transmembrane (gp41) moieties. Complexes of these glycoproteins are inserted into the lipid 
bilayer of the virus and mediate interaction with the viral target cells. The gag-pol gene gives 
rise to two polyprotein precursors (Gag and Gag-Pol), which are both cleaved into smaller 
proteins by a virus encoded protease during maturation of the viral particle (see also 1.3). In 
this process, the Gag polyprotein (p55) is transformed in several structural proteins: matrix 
(MA or p17), capsid (CA or p24) and nucleocapsid (NC or p7), as well as a p6 protein and 
two small spacer peptides SP1 and SP2. Matrix proteins mainly associate with the inner 
part of the lipid bilayer, while capsid proteins assemble in a conical core structure that 
surrounds the viral genomic material. The Pol fragment of the Gag-Pol polyprotein on the 
other hand is further processed into three viral enzymes: protease (PR), reverse 
transcriptase (RT) and integrase (IN) and these proteins are also contained within the viral 
particles (Figure 1.2, reviewed in [18, 19]). The HIV-1 genome furthermore encodes two 
regulatory proteins, Tat and Rev, which are required for optimal viral protein production, as 
well as four accessory proteins (Vif, Vpr, Vpu and Nef). Based on in vitro cell-culture 
systems, the latter were initially thought to be dispensable for viral replication. However, 
they seem to be essential for in vivo infection and pathogenesis (see also 1.6). Vif, Nef and 
large quantities of the Vpr proteins are also incorporated into the viral particles (reviewed in 
[19, 20] ). Finally, virions contain a multitude of host proteins that are incorporated because 
of their presence at the sites of viral budding or through interaction with HIV proteins (eg. 
cyclophilin A – capsid interaction) [21]. HIV-2 and different SIV viruses have in general a 
similar genomic and structural organization as HIV-1. However, they clearly differ by the 
types of accessory genes they encode. While HIV-2 and certain SIV viruses do not encode a 
Vpu protein, some of them acquired an extra accessory protein, called Vpx, which is not 
encoded by HIV-1 (Figure 1.2) [22, 23].  
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Figure 1.2: Structure and genome of HIV. Left: organization of HIV-1 mature viral 
particles with indication of the different viral components. Reprint from Robinson 2002 [24] 
with permission from Macmillan Publishers Ltd: Nature Reviews Immunology, copyright © 
1998, and with permission from Elsevier, copyright © 1998. Right: genomic organization of 
HIV-1, HIV-2 and SIVcpz viruses. Adapted from Kirchhoff 2010 [23] with permission from 
Elsevier, copyright © 2010. 
 
1.3 HIV-1 replication cycle 
HIV-1 infects different types of immune cells in vivo, predominantly CD4+ T helper cells, 
monocytes/macrophages and to a lesser extent also dendritic cells [25-27] (see also 1.4.1). 
This viral tropism is largely determined by the presence of the primary HIV receptor CD4 
and a secondary co-receptor on the surface of these cells. Although alternative co-receptors 
have been proposed, most HIV-1 isolates use CXCR4 or CCR5 and the affinity for these 
receptors is mainly determined by the V3 region of the HIV envelope (Env). As such, viruses 
are termed X4-, R5- or R5X4-tropic based on their usage of CXCR4, CCR5 or both 
respectively. The sequence of events during a productive HIV-1 replication cycle are outlined 
in Figure 1.3 and described below. 
Entry of HIV in the target cells is initiated by binding of a gp120 subunit of HIV Env to CD4 
(see (1) on Figure 1.3). This induces a conformational change in gp120 that allows its 
subsequent binding to the co-receptor. This results in exposure and insertion of the 
hydrophobic fusion peptide of gp41 in the membrane of the cell, which in turn induces a 
conformational change that brings the viral and cellular membranes in closer proximity, 
allowing their fusion (reviewed in [28, 29]) (2). The actual site of HIV fusion is however still a 
topic of debate : both direct fusion at the plasma membrane and fusion after endocytotic 
uptake of the virus have been suggested as the predominant route of viral entry [30, 31]. 
Following fusion, the HIV capsid core is released into the cytoplasm of the cell and reverse 
transcription of the HIV RNA genome into double-stranded DNA (dsDNA) is initiated (3,4). 
Rearrangements of the virion core lead to formation of a mature reverse transcription 
complex (RTC), in which multiple viral and cellular proteins assist the HIV RT protein to 
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complete reverse transcription. During this process, the RTC is simultaneously transported 
towards the nucleus through interactions with the host cytoskeleton. The complex is 
gradually transformed into an integration-competent complex, termed pre-integration 
complex (PIC). Before this complex can enter the nucleus through the nuclear pores, 
disassembly of the viral capsid that surrounds the genomic material has to occur, a process 
known as uncoating (3). Initially, this was thought to take place immediately after viral 
entry in the cell. However, more recent data suggest that uncoating occurs several hours 
later and that the virion core serves important functions during transport towards the 
nucleus, reverse transcription and nuclear import (reviewed in [32-34]). After entry into the 
nucleus (5), linear dsDNA in the PIC is inserted into the host chromosomal DNA. This 
process is mediated by the HIV IN protein, again assisted by other proteins, and involves 
three subsequent steps. First, two nucleotides are removed from the 3’ end of both viral DNA 
strands by the IN protein. Subsequently, the two 3’ ends attack phosphodiester bonds on 
opposite strands of the target DNA, resulting in a covalent linkage between the host and 
viral DNA. Finally, the nucleotide overhang at the 5’ ends and the remaining gaps are 
repaired by cellular enzymes to complete viral integration (reviewed in [35]) (6).  
 
 
 
 
 
 
 
 
 
Figure 1.3 Overview of the HIV life cycle. Sequential steps in the HIV-1 life cycle, from 
initial attachment to the target cell (1) to release and maturation (12, 13) of the newly 
formed viral particle are depicted. Adapted from Engelman et al. 2012 [36] with permission 
from Macmillan Publishers Ltd: Nature Reviews Microbiology, copyright © 2012 
 
The integrated provirus then serves as a template for viral gene expression (7). The long-
terminal repeat (LTR) located in the 5’ region of the provirus, contains enhancer and 
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promoter elements and these are recognized by the host transcription machinery. Viral 
transcription is initially activated by cellular transcription factors, such as NF-ĸB, and this 
results in a suboptimal production of early viral proteins: Tat, Rev and Nef. Once sufficient 
levels of Tat have accumulated, transcription is drastically enhanced through a complex 
process that involves recruitment of the positive transcription elongation factor (P-TEFb) to 
the HIV transactivation-responsive region (TAR) by Tat and which relieves a block in 
transcription elongation of the viral RNA. Furthermore, the synthesized Rev proteins will 
mediate transport of incompletely spliced and unspliced viral RNA products to the 
cytoplasm (8) and thereby allow their translation into Env, Vpu, Vpr, Vif and the Gag-Pol 
polyprotein (reviewed in [37]) (9). Newly formed proteins, viral RNA and different host 
proteins subsequently assemble at the cell membrane under control of the Gag protein (10). 
These complexes bud through the cell membrane, thereby acquiring the host cell-derived 
lipid membrane that enwraps the viral core (11, 12). Budding activates the HIV-1 protease 
through an incompletely understood mechanism, which will cleave Gag and Gag-Pol 
polyproteins into fully processed structural and enzymatical viral proteins. These proteins 
rearrange within the virion core and transform the immature virion into a mature infectious 
virus [38] (13). 
1.4 HIV-1 Pathogenesis 
1.4.1 HIV-1 target cells 
As mentioned above, HIV-1 mainly infects CD4+ T cells and cells of the 
monocyte/macrophage lineage as these cells express the necessary receptors for HIV-1 
entry. CD4+ T cells are the primary targets in vivo and their ability to support productive 
infection is highly determined by their activation state. In vitro experiments in the early days 
of HIV research already revealed that HIV-1 efficiently replicates in activated, proliferating 
CD4+ T cells, while resting cells are largely non-permissive [39, 40]. It is now known that 
HIV-1 replication in the latter is blocked at the level of reverse transcription due to the 
actions of the host restriction factor SAMHD1 (see also 1.6). Furthermore, transcription of 
viral genes might be less efficient in resting T cells, since transcription factors required for 
initiation of LTR activity (eg. NF-ĸB and NFAT (nuclear factor of activated T cells)) are 
usually inactive [41]. The latter also contributes to establishment of a latent state of the 
virus in resting CD4+ T cells. HIV-1 DNA-containing resting T cells are indeed found in 
infected patients and serve as a latent reservoir, i.e. cells harbouring transcriptionally silent 
but replication-competent proviruses, from which virus replication can be initiated upon 
activation. These cells may arise from infection of activated CD4+ T cells that subsequently 
revert to a resting state and survive as long-lived memory T cells. However, HIV-1 DNA has 
also been detected in naive T cells in vivo, implying direct infection of resting cells. It is 
therefore thought that the presence of certain signals in vivo, such as chemokines or cell-to-
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cell signaling, might be sufficient to temporarily relieve the block to infection without 
completely activating the cells [41, 42].  
Macrophages are non-dividing, terminally differentiated cells. Although they generally resist 
HIV-1 infection better than activated CD4+ T cells, productively infected macrophages are 
detected in vivo and seem to contribute to the viral burden. The susceptibility of 
macrophages to HIV-1 is highly dependent on their activation and polarization state. 
Interestingly, macrophages are much more resistant to cytopathic effects of HIV-1 
replication compared to CD4+ T cells. Especially long-lived macrophages may therefore carry 
the virus for long periods of time and form a chronically infected reservoir for HIV-1 [43, 44]. 
Myeloid dendritic cells (mDCs) are usually inefficiently infected by HIV-1, due to high 
expression levels of SAMHD1 [45]. However, they may play an important role in HIV-1 
dissemination through trans-infection of CD4+ T cells. mDCs are able to capture and 
internalize intact HIV viral particles through interaction of gp120 with DC cell surface 
receptors, such as DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin) and Siglec-1 (sialic acid binding Ig-like lectin 1), and subsequently 
transmit these virions to contacting CD4+ T cells with high efficiency [46]. Langerhans cells, 
a subset of mDCs that line the epithelial layer of mucosal surfaces, can also interact with 
HIV through the C-type lectin langerin and dependent on their maturation status either 
destroy internalized viral particles or transmit them to CD4+ T cells [47]. The germinal 
centers in lymphoid tissue furthermore contain a unique population of cells, called follicular 
DCs. These cells can trap large amounts of HIV at their surface and retained virus can be 
transferred to surrounding CD4+ T cells. Since captured viral particles remain infectious for 
long periods of time, these cells may provide a reservoir for continuing viral dissemination 
[48, 49].  
1.4.2 Course of natural HIV-1 infection 
HIV-1 transmission results from exposure to the virus at mucosal surfaces (eg. by sexual 
contact, mother-to-child) or from percutaneous inoculation (eg. needlesticks). Especially in 
the case of mucosal transmission, infection is usually established by a single founder virus 
[50]. The course of natural, untreated HIV-1 infection is characterized by different stages 
(Figure 1.4).  
The acute phase of HIV-1 infection is the most critical stage, during which most events 
determining the clinical course of chronic infection are established. Following transmission, 
there is an initial period of 1-3 weeks in which HIV RNA remains undetectable in the 
plasma, known as the “eclipse phase”. During this period, small foci of infection are formed 
at the transmission site and the virus can subsequently disseminate to the local draining 
lymph nodes. This process is facilitated by DCs, that capture the virus and transport it to 
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local lymph nodes for transmission to CD4+ T cells. Furthermore, inflammatory responses 
orchestrated by DCs and macrophages lead to recruitment of CD4+ T cells to the infection 
site and amplify the pool of available target cells (although they also counteract viral 
replication by eg. secretion of type I interferon (IFN-I)). The virus subsequently spreads to 
other lymphoid tissues, particularly to the gut-associated lymphoid tissues (GALT) where 
the majority of activated CD4+ CCR5+ T cells reside. This is followed by a rapid increase in 
virus replication, which results in a massive depletion of CD4+ T cells in the GALT and an 
exponential rise in plasma viremia. In this phase, patients sometimes experience transient 
“flu-like” symptoms (eg. fever, enlarged lymph nodes,…). A peak in plasma viremia is usually 
reached within 2 to 4 weeks after infection. The viral load subsequently declines to a more 
stable level, which is known as the viral set-point. This is due to exhaustion of activated 
target cells and partial control of viral replication by the immune system. The latter is 
largely mediated by HIV-1 specific CD8+ T cell responses and at a later stage by the 
appearance of neutralizing antibodies. Innate immune responses, in particular those 
mediated by natural killer (NK) cells, might also contribute to viral suppression at this point. 
However, under pressure of the anti-HIV immune responses the viral population starts to 
diversify and viral escape mutants can be readily detected following peak viremia. 
Furthermore, a pool of latently infected cells is probably formed within days of infection and 
provide a long-lasting reservoir that remains invisible to the immune system [51-54]. 
 
 
 
 
 
 
Figure 1.4. Natural course of untreated HIV infection. (A) Acute infection is associated 
with high levels of plasma viral load (red line). Following development of HIV-specific 
immune responses, partial viral control is reached and associated with a drop in plasma 
viral RNA levels. CD4+ T cells in the gastrointestinal tract (GIT) are rapidly depleted early on 
(green line), while blood CD4+ T cell levels progressively decline during the chronic phase of 
infection due to continued systemic repletion/depletion (blue line). Ongoing destruction of 
the immune system eventually leads to loss of immune control and AIDS. (B) Immune 
response to HIV infection is characterized by a dramatic increase in markers of immune 
activation, production of HIV-specific CD8+ (and CD4+) T cells and development of antibody 
(Ab) responses. Reprinted from The Lancet, Maartens et al. 2014 [51] with permission from 
Elsevier, copyright © 2014. 
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The ongoing struggle between active viral replication and immune control leads to a more 
chronic phase of infection in which the patient remains asymptomatic and which can last 
for many years. However, continued destruction of HIV-1 target cells and the inability to 
completely repopulate these cells results in a progressive depletion of CD4+ T cells. Loss of 
CD4+ T cells occurs due to direct killing by the virus, but also as a bystander effect of 
immune activation and senescence (see also 1.4.3) [55, 56]. Eventually, CD4+ T cell levels 
drop below a critical limit and immune control of HIV-1 and other infectious agents is lost. 
As a result, the level of viremia rises during the AIDS phase and new infectious [57] and 
malignant complications [58] are common. In untreated infection, this inevitably culminates 
in death of the vast majority of infected patients [52, 53].  
1.4.3 Immune activation 
A hallmark of HIV-1 infection is the chronic state of systemic immune activation. This is 
reflected by eg. increased levels of activation (CD38, HLA-DR) and proliferation (Ki-67) 
markers on CD4+ and CD8+ T cells and increased inflammatory markers in the plasma (eg. 
neopterin, β2-microglobulin) of HIV-1 infected individuals [59]. Interestingly, it was noted 
early on that such markers are highly predictive for disease progression [60-62], to an equal 
or even higher extent than viral load levels [63-65]. This has led to the idea that suicidal 
overdrive of the immune system, more than viral cytopathic effects, is the major cause of 
immune deficiency and pathogenesis. In support of this, naturally infected hosts of SIV, in 
which the infection rarely progresses to AIDS, do not show signs of chronic immune 
activation despite high levels of viral replication and early CD4+ T cell depletion [66, 67]. 
Different factors have been suggested to contribute to the hyper-immune activation. The 
most obvious one are the direct innate and adaptive immune responses against the virus. In 
this regard, IFN-I produced upon innate sensing of HIV-1 has been highly associated with 
immune activation levels [68, 69]. Responses against other agents, such as translocated 
microbial products in the gut and viral co-infections (eg. cytomegalo-virus and hepatitis C 
virus) are also likely to contribute [70, 71]. Furthermore, specific imbalances in levels and 
functions of certain CD4+ T-cell subsets, such as Th17 and Treg cells, arise during HIV-1 
infection and may disturb immune homeostasis [59, 72, 73]. Finally, different viral proteins 
are able to directly activate or increase activation sensitivity of HIV-1 target cells [74-76].  
Continuous immune stimulation creates a permissive environment for viral replication, 
leading to a vicious cycle in which infection stimulates activation and activation stimulates 
infection. Depletion of CD4+ T cells, by direct viral killing and activation-induced cell death, 
will in turn trigger homeostatic responses that induce T cell activation and proliferation to 
replenish the T cell pool, further supplying viral target cells. Chronic activation can further 
inhibit normal functions of other immune cells [77, 78], leading to less viral control and 
again more activation. Over time, the perpetual induction of T cell regeneration most likely 
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leads to premature aging of the immune system [79] and architectural disruption of tissues 
important for immune homeostasis [80, 81]. As such, through continued stimulation, the 
virus gradually drives the immune system to a point of complete exhaustion [59, 82]. 
1.5 Antiretroviral therapy 
Over the last two decades, effective antiretroviral therapies have become available, which 
have transformed HIV infection from an inevitably lethal condition into a chronical 
manageable disease. They exist of combinations of drugs (combination antiretroviral 
therapy, cART) that are directed against viral enzymes (reverse transcriptase, protease or 
integrase) or target the viral entry or fusion process [83]. Although current treatment can 
suppress viral load to undetectable levels, the virus persists in a latent reservoir with a 
remarkably long half-life and viral rebound occurs when ART is discontinued. As such, ART 
is not curative and life-long treatment is required [42, 84, 85]. Futhermore, treatment does 
not fully restore health. Immune reconstitution is not always complete and markers of 
residual inflammation can be detected, even after many years of viral supression. Remaining 
elevated immune activation under cART is associated with increased mortality and co-
morbidities (eg. cardiovascular disease, liver disease,…) and is thought to contribute to 
persistance of viral replication and the viral reservoir [86, 87]. Toxic effects from decades of 
ART exposure can furthermore culminate in metabolic disturbance and organ damage [88]. 
An additional problem with current therapy is emergence of drug resistance. HIV-1 has a 
highly error-prone enzymatic machinery and any cause of residual replication under ART 
can therefore result in selection of resistant variants [89].  
Because of the reasons indicated above, new treatment strategies are highly pursued and 
actively being developped. These include the targeting of viral processes that are less prone 
to mutational escape, such as protein-protein interactions between viral and cellular 
proteins [90, 91]. Also approaches to counteract chronic immune activation and its 
associated effects are being evaluated, in order to improve immune reconstitution and 
decrease inflammation-associated morbidities in patients under cART [59, 92]. Other 
strategies are more ambitious and aim at curing the infection. In this regard, gene therapy 
approaches to target the HIV-1 coreceptor CCR5 are highly investigated. These are inspired 
by the apparent cure of the “Berlin patient” after receiving hematopoeitic stem cell 
transplantation from an CCR5∆32 homozygous donor [93]. Another line of research is 
focused on elimination of the viral reservoir. A pursued approach in this regard is to 
reactivate latent proviral genomes in infected cells, leading to virus-producing cells that 
either die or are cleared by host immune mechanisms [94, 95]. In order to be effective such 
strategies will likely need to be combined with approaches to 1) suppress residual viral 
replication and to 2) enhance host immune functions to recognize virus-producing cells and 
eliminate rebound virus. The latter is addressed by the field of immunotherapy and pursues 
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strategies to artificially boost anti-HIV responses and counteract abberant immune 
activation, in order to obtain functional immunity and life-long remission of HIV-1 [86, 96-
98]. 
1.6 HIV accessory proteins 
One of the features that distinguishes HIV and SIV from other retroviruses, is the set of 
“accessory” proteins they encode. Although these factors are often dispensable for viral 
replication in in vitro cell culture systems, they are strongly conserved in vivo and functional 
mutations in these genes have been associated with slower disease progression [99]. In 
general, they seem to modify the cellular environment for optimal viral replication, which 
often involves regulation of the host immune defense. These proteins do not have an 
enzymatic activity, but mediate their effects by interacting with cellular proteins and 
hijacking them into aberrant functions [100]. Here, we will discuss the known functions of 
the different accessory proteins, with a focus on Vpu and Vpr (see also Figure 1.5). 
NEF 
Nef enhances viral dissemination and protects infected cells from immune surveillance, 
through a remarkable number of activities in the infected cells. For example, Nef regulates 
cell surface expression of a wide range of host proteins, including CD4 and MHC-I. Down-
regulation of CD4 could eg. enhance viral release and prevent viral superinfection (see also 
Vpu), while selective counteraction of MHC-I by Nef protects infected cells from lysis by 
cytotoxic T cells, without rendering them susceptible to NK cell-mediated responses [101-
103]. Furthermore, by interacting with cellular kinases and signaling pathways Nef alters 
the activation threshold of infected T cells and affects cellular motility and migration [102, 
104]. Nef also enhances infectivity of progeny virions through an incompletely understood 
mechanism [105, 106].  
VIF 
The main function of Vif is to counteract members of the APOBEC3 (apolipoprotein B 
mRNA-editing enzyme catalytic polypeptide 3) family of retroviral restriction factors, 
especially APOBEC3G. These host proteins can mutate single-stranded DNA (ssDNA) by 
catalyzing deamination of cytosines into uracils. Although they are constitutively present in 
a wide variety of cells, their expression is often further induced by IFN-I. In absence of Vif, 
APOBEC3G is packaged into budding viral particles and induces C to U transitions during 
synthesis of the first (minus) HIV DNA strand. This leads to degradation of HIV DNA genome 
or fixed G to A mutations in the proviral sequences. Although alternative mechanisms have 
been proposed, Vif mainly prevents incorporation of APOBEC3G in the virion by targeting 
APOBEC3G for polyubiquitination and subsequent proteasomal degradation. This is 
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achieved by simultaneous binding of Vif to APOBEC3G and the EloB/C subunit of the cullin 
5 E3 ligase complex [107, 108].  
VPU 
Vpu contributes to viral egress by counteracting host antiviral immunity and promoting 
efficient release of newly formed viral particles. This is mainly achieved by down-regulation 
of two molecules from the surface of the cell: CD4 and tetherin (also known as bone marrow 
stromal cell antigen 2 (BST2)) [109-111]. Targeting of CD4 and tetherin by Vpu relies, at 
least in part, on induction of their ubiquitination and thereby targeting them for 
degradation. This is accomplished by connecting both molecules with the SKP1-cullin1-F-
box (SCF) E3 ubiquitin ligase complex through interaction of Vpu with the SCF subunit, β-
transducin repeat-containing protein (β-TrCP) [112, 113].  
Vpu is mainly localized in the endoplasmatic reticulum (ER), the trans-Golgi network (TGN) 
and the endosomes [114, 115]. In the ER, Vpu interacts with newly synthesized CD4 
molecules [109]. Subsequent poly-ubiquitination of CD4 induces both retention of CD4 in 
the ER as well as its delivery to the ER-associated degradation pathway (ERAD) for 
proteasomal degradation [112, 113, 116]. In this way, vpu might prevent sequestration of 
newly produced Env molecules by CD4 in the ER and decrease surface levels of CD4. The 
latter is also mediated by two other HIV-1 proteins, by Nef and to a lower extent also by Env, 
and seems therefore important for optimal viral spread. Several possible viral advantages of 
CD4 down-regulation have been proposed: enhancing release of viral particles by preventing 
the binding of newly formed virions to CD4, preventing lethal superinfection or inducing 
immune dysfunction of infected cells [117-119]. 
Tetherin on the other hand is a protein induced by IFN-I that can physically trap newly 
formed viral particles at the cell surface and thereby inhibit their release. This is due to the 
unusual structure of tetherin: it can insert both its C-terminal transmembrane domain as 
well as its N-terminal glycophosphatidylinositol anchor into membranes. By simultaneously 
binding to both cellular and viral membranes, it tethers viral particles to the cell [110, 111, 
120]. Although the mechanism of tetherin down-regulation by Vpu remains somewhat 
controversial, Vpu is thought to interact with recycling or newly synthesized tetherin 
molecules in the TGN and inhibit their transport to the plasma membrane [114, 121]. This 
interaction traps tetherin molecules in the cell, but also results in tetherin ubiquitination 
which most likely enhances its lysosomal degradation through an Endosomal Sorting 
Complexes Required for Transport (ESCRT)-mediated pathway and is thought to be required 
for full tetherin counteraction [119, 122-124]. 
While the ability to down-regulate CD4 is conserved among most primate lentiviruses 
encoding Vpu [125], counteraction of tetherin is more lineage- and species-specific. Most 
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SIVs, including the immediate ancestors of HIV-1 and HIV-2, use Nef rather than Vpu to 
target tetherin. However, human tetherin is resistant to SIV Nef due to a deletion in its 
cytoplasmic tail [125-127]. It is therefore believed that successful cross-species transmission 
to humans required the acquisition of other means to counteract tetherin. The pandemic 
HIV-1 M strains and (to a lesser extent) the non-pandemic HIV-1 N strains overcame this 
species barrier by evolving a mechanism of counteraction through Vpu [125, 128], while 
HIV-1 O strains  adapted their Nef protein [129]. HIV-2 strains, which do not encode a Vpu 
protein, most likely switched from Nef to Env to counteract tetherin [130]. 
Vpu further contributes to innate immune evasion by interfering with function of natural 
killer (NK) and NKT cells. Vpu down-regulates several NK(T) cell activating proteins from the 
surface of infected cells, such as CD1d, CD155 and NTB-A [131]. In addition, by preventing 
accumulation of viral particles on the surface of the cell through tetherin and CD4 down-
regulation, Vpu protects infected cells from NK cell elimination by antibody-dependent cell-
mediated cytotoxicity (ADCC) [132-134]. Recent studies also indicate that tetherin can 
induce activation of nuclear factor-κ light-chain-enhancer-of activated B-cells (NF-κB) upon 
restriction of viral particles [135, 136]. By targeting tetherin or by directly interfering with 
innate signaling pathways [137, 138], Vpu might counteract expression of pro-inflammatory 
cytokines or IFN-I (see also 2.4). 
 
 
 
 
 
 
 
 
Figure 1.5 Counteraction of host restriction factors by HIV-1 accessory proteins Vpr, 
Vif and Vpu. Counteraction of APOBEC3G (3G) by Vif and tetherin by Vpu is depicted. 
These viral proteins can induce proteasomal degradation of their target through recruitment 
of E3 ubiquitin ligase complexes and subsequent ubiquitination of the target. Vpr is also 
able to recruit such complexes and induces degradation of certain cellular proteins, 
although its main target remains elusive. Adapted from Malim et al. 2008 [139] with 
permission from Elsevier, copyright © 2008. 
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VPR 
In contrast to other accessory proteins, the prime role of Vpr in natural HIV infection is still 
enigmatic. Although Vpr is expressed at a late stage in viral life cycle, it is significantly 
present during early infection, because large amounts of Vpr are incorporated into the viral 
particle and thereby carried into the target cell by the virus [140]. This argues for an 
important role of Vpr during early steps of viral replication. Based on in vitro observations, a 
multitude of functions and effects have been ascribed to Vpr, including transactivation of 
the HIV-1 LTR, induction of cell cycle arrest, enhancing the fidelity of reverse transcription 
and induction of cell death [141-143]. HIV-1 replication in vitro is especially dependent on 
Vpr in non-dividing cells, particularly in macrophages [144-147]. This was initially 
attributed to facilitation of nuclear import by Vpr. Interaction between Vpr, members of the 
nuclear pore complexes and importin-α would promote docking of the viral PIC to the 
nuclear membrane or facilitate its transport across the membrane [148-152]. However, more 
recent studies suggest that other components of the PIC (eg. integrase, MA or the central 
DNA flap) have redundant properties and that these properties are not an absolute 
requirement for infection of non-dividing cells [153-155]. 
Like Vpu and Vif, Vpr is known to engage an E3 ubiquitin ligase complex, in this case the 
DDB1-cullin4 complex, which is recruited by Vpr through interaction with DDB1-cullin4-
associated factor 1 (DCAF1) [156]. One of the proteins targeted by Vpr for ubiquitination and 
subsequent proteasomal degradation is uracil DNA glycosylase (UNG2). However, the exact 
role of UNG2 during HIV infection is controversial, since both positive and negative effects 
on viral replication have been described [157-161]. In analogy with other ubiquitination-
inducing HIV/SIV accessory proteins, it is likely that inducing degradation of a cellular host 
factor is a crucial function of Vpr. However, UNG2 and the few other suggested cellular Vpr 
targets [162, 163] do not fully explain the ability of Vpr to enhance in vitro replication in 
non-dividing cells nor its importance during natural infection in vivo. Therefore, other 
cellular targets of Vpr probably remain to be identified [100, 143]. Engagement of the DDB1-
cullin4-DCAF1 E3 ligase complex is also essential for Vpr’s ability to induce G2 arrest in 
dividing cells [164-167]. This Vpr function is highly conserved among primate lentiviruses, 
but its biological role and precise mechanism remain unclear. Vpr somehow activates the 
DNA damage sensor ATR and thereby hijacks the downstream host DNA damage response 
pathway to trigger G2 arrest. Given the necessity of the E3 ubiquitin ligase complex, a 
model has emerged in which Vpr-induced degradation of an unknown cell cycle regulating 
protein triggers ATR activation [139, 156]. Laguette et al. recently demonstrated that 
induction of G2 arrest is dependent on recruitment and premature activation of the specific 
endonuclease regulator SLX4 complex by Vpr, which may result in faulty cleavage of host 
DNA replication intermediates and replication stress [168]. However, it is not clear yet how 
Vpr-induced proteasomal degradation fits into this process. Also the functional relevance of 
G2 arrest during natural infection remains speculative. It was shown that the HIV LTR 
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promoter is more active in the G2 phase [169-171]. As such, induction of G2 arrest might 
therefore provide a way for the virus to enhance viral protein expression and replication. 
Alternatively, Laguette et al. suggested that the SLX4 complex is engaged by Vpr to degrade 
excess viral DNA, thereby preventing it’s sensing and subsequent IFN-I induction. 
Accordingly, the biological endpoint of SLX4 complex activation would be to evade innate 
immune responses [168]. Finally, since Vpr has a limited effect on HIV-1 replication in 
dividing cells in vitro, induction of G2 arrest in these exact cells may also be an unavoidable 
consequence of Vpr-induced degradation of an unknown host protein that is unfavourable 
for viral replication in vivo (eg. in a specific cell type) [139, 156] . 
VPX 
Vpx is only encoded by HIV-2 strains and certain SIVs and is homologous to HIV/SIV Vpr 
[172]. Like Vpr, it is packaged into viral particles through interaction with the p6 domain of 
Gag [173]. The main function of Vpx is counteraction of the IFN-I induced retroviral 
restriction factor SAMHD1 (sterile alpha motif and HD-domain-containing protein 1). 
SAMHD1 is a deoxynucleoside-triphosphate (dNTP) triphosphohydrolase and reduces the 
pool of dNTPs available for reverse transcription in both resting T cells and non-cycling 
myeloid cells [45, 174-178]. A recent study also suggest that SAMHD1 is able to degrade 
viral RNA. This activity would be lost in activated cells due to phosphorylation of SAMHD1 
[179]. Vpx targets SAMHD1 for poly-ubiquitination and proteasomal degradation by 
hijacking the same E3 ubiquiting ligase complex (DCAF1-DDB1-cullin4) employed by Vpr, 
through interaction with DCAF1 [174, 180]. Interestingly, HIV-1 did not evolve anti-
SAMHD1 activity and replicates less efficient in myeloid cells and resting T cells. It was 
shown that the absence of such activity protects HIV-1 from innate immune recognition in 
myeloid dendritic cells and might therefore be beneficial for the virus as it prevents 
activation of dendritic cells and induction of antiviral responses [181-183].  
1.7 Mimicking HIV-1 infection in vitro 
Key to the emergence of HIV-1 was its adaptation to overcome human restriction factors and 
exploit cellular cofactors to support its replication. As a consequence, the virus is unable to 
replicate or cause disease in most other species besides humans. This species-specificity 
has seriously hampered the development of animal models for in vivo HIV-1 research. SIV 
infection of Asian macaques is commonly used to evaluate new therapeutics or vaccines 
prior to human trials, but often too expensive for use in basic research [184]. Therefore, a 
substantial part of HIV-1 research relies on in vitro models of HIV-1 infection, employing 
isolated human HIV-1 target cells. CD4 and CCR5/CXCR4 expressing T cell lines (eg. MT4 
or Jurkat) and monocytic cell lines (eg. THP-1) are most commonly used in this regard. 
Alhtough they efficiently support HIV-1 replication and are very easy to culture and 
manipulate, such transformed cell lines do not always reflect the behavior of the virus in 
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primary cells [185-187]. In context of this thesis it is important to note that selection against 
the IFN-I system may occur during malignant transformation, given the anti-proliferative 
role of IFN-I [188, 189]. Primary CD4+ T cells can be readily isolated in substantial amounts 
from human peripheral blood. However, since most peripheral cells are in a resting state 
and will therefore not support efficient HIV-1 replication, activation of the cells is usually 
performed prior to infection by eg. stimulation with phytohaemagglutinin (PHA)/IL-2 or anti-
CD3/CD28 beads. Primary macrophages and DCs, on the other hand, are difficult to obtain 
in sufficient amounts from human blood or tissue. A commonly used alternative is therefore 
to isolate monocytes from peripheral blood and differentiate them into macrophages or DCs 
in vitro by providing appropriate cytokine cocktails. Monocyte-derived dendritic cells 
(MDDCs) can for instance be generated upon culture with granulocyte-macrophage colony 
stimulating factor (GM-CSF) and IL-4 and currently represent the most wide-spread used 
model to study HIV biology in DCs [190].    
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Chapter I-2. HIV and type I interferon response 
In this section, the type I interferon (IFN-I) response is introduced, as a foundation for the 
research presented in Chapter III-2. This type of innate immune response is an important 
part of the host antiviral defense system, but has a rather complex role during HIV-1 
pathogenesis. Both general biology of IFN-I and its association with HIV-1 infection are 
discussed. 
2.1 General biology of type I interferon responses 
IFN-I was first described in 1957, as a substance produced by influenza virus exposed cells 
and able to “interfere” with the replication of other viruses in non-exposed cells [191, 192]. It 
is now known that these “substances” represent a wide range of cytokines that are usually 
secreted upon detection of certain “foreign” molecular structures in the cell, so-called 
pathogen-associated-molecular patterns (PAMPs), by pattern-recognition receptors (PRRs). 
These cytokines exert their antiviral and other effects by inducing the expression of 
hundreds of IFN-stimulated genes (ISGs) in both the infected and surrounding cells [193-
195] (Figure 2.1). In humans, the most well-defined members of the IFN-I family are IFN-α 
(represented by 13 different subtypes) and IFN-β. Additional IFN-I cytokines have been 
described (IFN-ε, IFN-κ and IFN-ω), but their expression is often restricted to specific tissues 
or cell types and their regulation and antiviral effects are less well characterized [196]. 
Nearly all human cells are capable of producing IFN-α/β. Humans and certain mammals 
furthermore possess professional IFN-I producing cells, known as plasmacytoid dendritic 
cells (pDCs). These cells have the potential to secrete large amounts of IFN-α in response to 
viral infections [197].  
2.1.1 Induction of type I interferon 
Production of IFN-α/β by a cell is primarily regulated at the transcriptional level. The 
sensing of certain PAMPs by specific PRRs leads to activation of transcription factors that 
induce the expression of IFN-α and IFN-β (Figure 2.1). Members of the IFN-regulatory factor 
(IRF) family, in particular IRF3 and IRF7, are the key regulators of IFN-I gene expression. 
The IFNB gene is activated by the binding of IRF3/IRF7 homo- or heterodimers to the 
promoter region and also requires coordinated binding of NF-κB and AP-1 (activator protein 
1). Most IFNA genes on the other hand, require binding of IRF7 homodimers for efficient 
transcription. IRF3 is constitutively expressed in most cells and resides in the cytosol in 
inactive form, until its nuclear translocation is induced by PRR activation. In contrast, IRF7 
is present at low amounts in most cell types (except in pDCs), but highly induced as an ISG 
by IFN-I. Therefore, IFN-I production will occur in different phases in most cell types. Small 
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amounts of mostly IFN-β are produced in direct response to PRR activation and these will 
further amplify the production of IFN-β and many IFN-α proteins in a later phase [198, 199].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 General overview of type I IFN response signaling pathways. Recognition of 
viral replication products by host pattern recognition receptors activates cellular signaling 
pathways and results in transcription of IFN-I. Secreted IFN-I can bind to the IFN-α/β 
receptor on the infected cell or surrounding cells and induce hundreds of interferon-
stimulated genes with direct or indirect antiviral effects. Reprint from Honda et al. 2006 
[198], with permission from Elsevier, copyright © 2006.  
 
Various PRRs can activate IRF3 (and IRF7) upon viral infection. Since viruses do not have 
many features that are suitable for detection, activation often occurs in response to sensing 
of viral DNA and RNA replication products (although other types of viral PAMPs have also 
been described [200]). The PRRs that recognize nucleic acids and in turn induce IFN-I in 
cells can be divided into two groups based on their cellular localization (Figure 2.2).  
The first group includes several members of the Toll-like receptor (TLR) family and are found 
on the endosomal membranes. As such, they monitor the lumen of endosomes and 
lysosomes for different types of pathogen-derived nucleic acids. TLR3 recognizes double-
stranded RNA viruses or replication intermediates, while TLR7 and TLR8 mainly sense 
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guanosine- and uridine-rich ssRNA. TLR9 is a DNA sensor, that recognizes non-methylated 
cytidine-phosphate-guanosine (CpG) DNA motifs which are present in some viruses and 
bacteria [201-203]. The expression patterns of these TLRs are quite different and highly cell 
type specific. TLR7 and TLR9 are predominantly found in pDCs and to some extent in other 
immune cells, such as B cells and monocytes/macrophages. On the other hand, TLR8 is 
primarily expressed in monocytes/macrophages and myeloid dendritic cells. TLR3 has a 
broader expression range and is found in both hematopoietic cells and others cell types, 
such as epithelial cells and fibroblasts. The engagement of different TLRs with nucleic acids 
also triggers distinct signaling pathways. TLR3 activates TRIF (TIR-domain-containing 
adapter-inducing interferon-β), whereas TLR7/8/9 activate MyD88 (myeloid differentiation 
primary response gene 88). Both TRIF and MyD88 in turn activate AP-1 and NF-κB. These 
proteins will mainly induce expression of pro-inflammatory cytokines and chemokines, 
although they also contribute to IFN-β induction if activated IRFs are present in the cell. 
IRF3 and IRF7 are also activated by the TRIF signaling cascade. This occurs through 
activation of TBK1 (TRAF family member-associated NF-κB activator (TANK)-binding kinase 
1), which will in turn phosphorylate IRF3/7. MyD88 signaling on the other hand only 
activates IRF7 and will therefore only contribute to relevant IFN-I production in cells with 
constitutively high IRF7 levels, such as pDCs [202, 203].  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Sensing of nucleic acids by different pattern-recognition receptors (PRRs) 
Overview of different known PRRs that sense DNA (red), dsRNA (dark blue) or ssRNA (light 
blue) and the signaling pathways used to induce type I IFN and inflammatory proteins. 
Reprint from Gürtler et al. 2013 [204] with permission from Elsevier, copyright © 2013. 
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The second group of nucleic acid binding PRRs is formed by the cytosolic DNA and RNA 
sensors. In contrast to most TLRs, they are expressed in both immune and non-immune 
cells. Sensing of cytosolic RNA, derived from an incoming viral genome or created during 
viral replication, is mainly performed by members of the RIG-I (retinoic acid inducible gene-
I)-like receptor (RLR) family. RIG-I preferentially binds to short dsRNA molecules and ssRNA 
molecules with an exposed 5’-triphosphate group. The latter are produced by many viruses 
and allows discrimination from self-ssRNA entities with eg. a capped (mRNA) or cleaved 
(tRNA) 5’ end. MDA5 (melanoma differentiation–associated gene 5) is another member of the 
RLR family and is thought to mainly recognize long dsRNA. RNA-binding of both RIG-I and 
MDA5 leads to interaction with the mitochondrium-associated protein MAVS (mitochondrial 
antiviral signaling protein), which results in aggregation of MAVS proteins and eventually 
induces activation of IRF3/7 and NF-κB, through respectively TBK1 and IKKβ (IĸB kinase 
β). A third member of the RLR family, LGP2 (laboratory of genetics and physiology 2), can 
bind to RNA but lacks the N-terminal domains required for MAVS interaction and would 
mainly serve as a modulator of RIG-I and MDA5 sensing [203, 205].  
Cytosolic DNA on the other hand, has been long known to trigger innate immune responses, 
but the PRRs involved are only recently being identified. An important breakthrough in the 
field was the discovery of the STING (stimulator of IFN genes) protein as a crucial signaling 
molecule in the innate response to both transfected DNA and DNA pathogens. STING is a 
transmembrane protein predominantly found in the ER and induces TBK1-mediated 
activation of IRF3 as well as NF-ĸB activation upon stimulation of cells with DNA [206-211]. 
How cytosolic DNA can trigger the STING-TBK1-IRF3 pathway is still a topic of intense 
research and many different sensing mechanisms have been proposed [204, 205, 212]. 
STING can directly bind to cyclic dinucleotides, which are often produced during bacterial 
replication cycles. However, sensing of actual DNA fragments is thought to occur via PRRs 
upstream of STING. The cGAS (cyclic GAMP synthase), IFI16 (IFN-Ƴ-inducible protein 16) 
and DDX41 (DEAD box polypeptide 41) proteins were all shown to bind to cytosolic DNA 
and to be required for innate immune responses to transfected DNA and infection with DNA 
viruses in a STING dependent manner [213-215]. For cGAS, it’s known that its activation by 
DNA leads to production of cyclic GMP-AMP (cGAMP) from ATP and GTP. cGAMP in turn 
functions as a second messenger to activate STING [213, 216]. IFI16 and DDX41 on the 
other hand co-localize with STING upon DNA stimulation [214, 215], but how this leads to 
activation of STING is still unclear. Other DNA sensors with a less obvious STING-
dependence have also been described. The DAI (DNA-dependent activator of IRFs) protein 
mediates IFN-I responses to DNA in some specific cell types. RNA polymerase III was shown 
to transcribe transfected poly(dA-dT) dsDNA into dsRNA, which would in turn serve as a 
ligand for RIG-I mediated sensing [212, 217, 218]. Finally, two members of the DNA-damage 
response pathways, the DNA-PKcs/Ku70/Ku80 complex and Mre11 (meiotic recombination 
11 homolog A), were also suggested as potential DNA PRRs [219, 220]. Given the recent 
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discovery of most cytosolic DNA sensors, it remains largely unclear if these proteins have a 
different preferential affinity for specific DNA ligands or if they operate in different cell types 
or different cellular compartments. It is also possible that the different DNA receptors 
cooperate during viral infections to initiate an optimal IFN-I response [212, 221, 222].  
2.1.2 Biological effect of type I interferon 
Once produced and secreted, all type I interferons exert their effects by binding to a 
transmembrane IFN-α/β receptor (IFNAR), which consists of an IFNAR1 and IFNAR2 
subunit (figure 2.1). In the canonical IFN-I signaling pathway, engagement of the receptor 
results in activation of the receptor-associated tyrosine kinases, JAK1 (Janus kinase 1) and 
TYK2 (Tyrosine kinase 2), and subsequent phosphorylation of the receptor. This leads to 
recruitment and phosphorylation of STAT1 (signal transducer and activator of transcription 
1) and STAT2. These molecules will in turn dimerize and translocate to the nucleus where 
they subsequently recruit IRF9 and form a heterotrimeric complex called ISGF3 (IFN-
stimulated gene factor 3). The ISGF3 transcription factor eventually activates transcription 
of ISGs by binding to IFN-stimulated response elements (ISRE) in the promoter region of 
these genes [223]. However, signaling of IFN-I extends beyond this primary pathway and 
ultimately affects a complex network of signaling cascades and regulatory mechanisms. In 
addition to activation of ISGF3, IFNAR stimulation also induces formation of STAT1 homo-
dimers, which activate expression of ISGs that contain gamma activating sequence (GAS) 
promoter elements and often have a more pro-inflammatory function. Other types of STATs 
and other signaling pathways, such as MAPK pathways, can also be activated by IFNAR 
engagement depending on the cell type. Furthermore, different types of IFN-I induce 
different downstream responses. This probably depends on a different affinity and 
interaction pattern with the IFNAR subunits. Finally, IFN-I responses are strictly regulated 
by both autologous ISG-mediated feedback mechanisms as well as heterologous signals 
generated by other cytokines or microbial factors. These mechanisms altogether regulate the 
nature and the number of ISGs that are expressed and thereby determine the biological 
outcome of the IFN-I response [224, 225].  
By inducing different ISGs, type I IFNs can exert three broad types of effects on the cells: 
direct antiviral, anti-proliferative and immune modulatory. The antiviral effects were 
identified first [191] and are currently best characterized. Several ISGs are known to directly 
target specific stages of the viral life cycle [195]. Although these different ISGs have different 
viral specificities and antiviral potentcies, the collective action of multiple ISGs renders the 
cell in a state that is incompatible with viral replication, the so-called “antiviral state”. The 
importance of the IFN-I antiviral activity is illustrated by the increased susceptibility of 
IFNAR deficient mice to infection with a broad range of viruses [226]. Among the best 
studied ISGs are those with a potent and broad antiviral activity, such as PKR (protein 
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kinase R), OAS (2'–5' oligoadenylate synthetase) proteins and Mx1 (myxovirus resistance 
protein 1). PKR and OAS proteins both require additional activation by binding of dsRNA. 
PKR inhibits translation of (viral) RNA by phosphorylating EIF2α (eukaryotic translational 
initiation factor 2 EIF2α), while OAS proteins synthezise 2'- to 5'-linked oligoadenylates 
which in turn activate RNAseL to induce cleavage of (viral) RNA. Mx1 is a dynamin-like 
GTPase and binds to the nucleocapsid of viral particles to trap them in the cell, thereby 
restricting viral replication [227]. Recently, the Mx1 paralog, Mx2, was also shown to 
possess potent antiviral activity against primate immunodeficiency viruses, including HIV-1 
[228-230]. Mx2 is thought to target the viral capsid proteins and prevent viral integration by 
a still poorly understood mechanism that affects uncoating [231], nuclear import [228, 229, 
232] and/or additional post-nuclear entry steps [230, 232]. In addition, most of the well-
characterized host HIV-1 restriction factors, such as APOBEC3G, tetherin, SAMHD1, are 
also induced by IFN-I [233]. Since IFN-I treatment can enhance the expression of up to 1000 
different genes in a cell, many more ISGs with specific antiviral effects probably remain to be 
identified [234]. 
The anti-proliferative activity of IFN-I formed the basis for its first application in the clinic, 
as an anti-tumor agent. These effects result from regulation of multiple pro-apoptotic genes 
and genes involved in cell cycle control by IFN-I. Several mechanisms for IFN-I-induced cell 
cycle arrest have been proposed, including the induction of cyclin-dependent kinase 
inhibitors (CKI), downregulation of the proto-oncogene c-myc and suppression of the 
growth-promoting transcription factor EF2. Induction of apoptosis or increasing the 
sensitivity to apoptotic stimuli of cells is mediated through upregulation of pro-apoptotic 
proteins by IFN-I such as Fas, TRAIL, caspases and Bcl-2 family members [235]. By 
inducing death of infected cells or prohibiting their proliferation, this IFN-I activity further 
contributes to limiting the viral spread. In this regard it has to be noted that the effect on 
immune cells is more complex and IFN-I can both counteract or stimulate their survival and 
proliferation, depending on the context of IFN-I signaling [236] (see below).  
The immune modulatory effects of IFN-I are mainly aimed at further activating innate and 
adaptive immune responses. IFN-I highly enhances the function and proliferation of NK 
cells, the differentiation and function of DCs and the function of macrophages. The 
stimulation of professional antigen-presenting cells (APCs), especially DCs, will in turn 
enhance activation of adaptive immune cells. In addition, IFN-I regulates cytokine 
production of APCs and induces secretion of different chemokines, which will further affect 
the recruitment, activation and function of other immune cells [237]. IFN-I can also target 
adaptive immune cells directly. Antibody responses by B cells, including plasma cell 
formation and isotype switching, are stimulated by IFNAR signaling on these cells [238-240]. 
IFN-I was also shown to promote the development of type 1 immune responses, eg. 
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differentiation of naïve CD4+ T cells into Th1 cells [241, 242] and activation of CD8+ T cells 
[243, 244].  
However, in conditions of sustained IFN-I expression such as chronic viral infections or 
certain auto-immune diseases, pro-longed IFN-I signaling may lead to hyper-immune 
activation and exhaustion of immune cells. Recent studies also suggest that IFN-I can adopt 
immune suppressive functions during chronic infections, possibly to limit host toxicity, and 
thereby impede antiviral T cell functions. As such, IFN-I could enhance both persistence and 
pathogenesis of chronic viral infections [245-247]. 
2.2 Tools to evaluate in vitro type I IFN responses  
2.2.1 Detection and quantification of IFN-I responses 
Similar to most cytokines, type I IFN proteins are extremely potent molecules with biological 
activity at femtomolar concentration [248]. As such, the sensitivity of an assay is an 
important factor to consider when selecting methods to detect and quantify IFN-I 
production. Since IFN-I proteins are secreted by the cell, levels of production can be readily 
assessed in the supernatant of the cultured cells. This is commonly done by direct protein 
measurement using sensitive enzyme-linked immunosorbent assays (ELISA) for IFN-β or 
specific or multiple IFN-α subtypes. Prior to development of such immunoassays, IFN-I 
activity in biological samples was typically assessed by evaluating the level of interference 
with replication of a virus (eg. Vesicular Stomatitis Virus (VSV)) in an IFN-I sensitive cell 
line, so-called antiviral assays [249, 250]. Although these assays are quite tedious, they offer 
the advantage of specifically measuring biologically active IFN-I. Less labour-intensive IFN-I 
“bioassays” have more recently become available, by introduction of reporter genes under 
control of an ISG promoter, into highly IFN-I sensitive cell lines (Figure 2.3). These assays 
are usually much cheaper compared to ELISA and sometimes even offer higher detection 
sensitivities [250-252]. Alternatively, very sensitive detection of IFN-I induction can be 
achieved by measuring IFN-I mRNA transcript abundance in a cell population by real-time 
quantitative PCR (qPCR). For IFN-α, primers are available targeting regions either specific to 
or conserved among different subtypes [253-255].  
In addition to quantifying IFN-I levels, biological IFN-I activity can be assessed directly in the 
experimental system by measuring induction of ISGs at protein or mRNA level. Microarray 
studies indicate simultaneous induction of hundrerds of different genes by IFN-I, usually 
varying among different cell types and IFN-I (sub)types [193, 234, 256]. Several of these 
studies have recently been collected in an online database 
(http://interferome.its.monash.edu.au/interferome/) that allows ISG search by questioning 
for experimental parameters such as cell type, IFN-I concentration and subtype, treatment 
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time…. [194, 257]. As such, it can present a helpfull tool to select appropriate ISGs for IFN-I 
response evaluation in your system.  
Figure 2.3. HL116 reporter cell line 
to measure biological IFN-I activity. 
HL116 cells were generated by stable 
introduction of a construct carrying the 
luciferase gene under control of the IFN-
I inducible 6-16 promoter into HT1080 
cells [252]. IFN-I activity can be 
quantified by addition of the IFN-I 
containing samples to cultured HL116 
cells. Binding of IFN-I to IFNAR will 
subsequently activate a JAK-STAT 
signaling pathway, resulting in 
activation of the 6-16 promoter and 
luciferase expression. The latter can be 
easily quantified by measuring light 
emission upon addition of luciferin. 
Adapted from Sadler and Williams 2008 
[227] with permission from Macmillan 
Publishers Ltd: Nature Reviews 
Immunology, copyright © 2008 
 
2.2.2 Investigating pathways of IFN-I induction 
As described above, many different PRRs are equipped to initiate signaling cascades that 
lead to IFN-I transcription. Identification of the PRRs and downstream pathways triggered 
by specific pathogens or PAMPs, is a topic of great research interest in the field of infectious 
and autoimmune diseases. Similar to most pathways, signal transduction from PRRs is 
mediated by a series of sequential protein phosphorylation events [258, 259]. As such, 
analysis of protein phosphorylation status upon PAMP stimulation, eg. by using 
phosphorylation-state specific antibodies , can provide a first indication on the nature of the 
activated pathway. However, it has to be noted that most signaling molecules are commonly 
used by multiple PRRs (Figure 2.2) and therefore this type of analysis will usually not allow 
to pinpoint a specific PRR. For certain signaling molecules and PRRs, inhibitory molecules 
have become available, in the form of either small molecule inhbitors [260-262], inhibitory 
peptides [263] or oligonucleotide-based antagonists [264]. Especially among the TLR family 
of PRRs, several IFN-I inducing receptors can be efficiently blocked with these molecules 
[260, 262, 264]. However, for most RLRs and the more recently discovered DNA-sensing 
PRRs, specific inhibitors are still lacking.  
As such, researchers often resort to manipulating the expression of PRRs, in order to 
evaluate specific PRR involvement in their experimental system. “RNA interference (RNAi)” is 
the most commonly used technique in this regard, mainly due to its established use and the 
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wide availability of validated reagents to target almost any one of the known human genes. 
RNAi allows for knock-down of gene expression by taking advantage of conserved cellular 
machinery that can process small non-coding RNAs and use them to target complementary 
RNA for degradation or translational repression (Figure 2.4). Such small RNAs are naturally 
generated from exogenous long dsRNA molecules or from endogeneously expressed 
precursor RNAs (eg. microRNAs (miRNA), endogenous small interfering RNAs and piwi-
interacting RNAs) and serve important functions in anti-viral defense and regulation of 
many cellular processes [265-267]. Artificial knock-down of a gene of interest can be 
achieved by introducing short double-stranded RNA molecules, directed against the target 
mRNA, into cells. Two main approaches are commonly used in this regard: 1) direct delivery 
of synthetic dsRNA molecules of 20-25 nucleotides (small interfering RNA (siRNA)) by eg. 
transfection or 2) delivery of a construct expressing short hairpin RNA (shRNA). The latter 
mimics a precursor (pre)-miRNA structure and will be processed upon expression by the 
cellular protein Dicer to yield a mature siRNA duplex. siRNA is subsequently loaded into an 
RNA-induced silencing complex (RISC) in which one strand of siRNA is ejected (the 
“passenger strand”), while the other strand will serve as a “guide” to target the RISC 
complex to complementary mRNA. Hydrolysis of the target mRNA is catalysed by Ago2, the 
“slicer” component of RISC [268, 269]. A major advantage of shRNA is the ability to use 
integrating lentiviral vectors for cellular delivery, which does not only allow their 
introduction into cell types that are difficult to transfect (eg. primary cells) but also ensures 
stable long-term expression of the RNAi-mediating molecule. Lentiviral shRNA libraries 
covering the majority of the human genome, such as the Broad Institute TRC Library [270], 
are now commercially available and allow fast implementation of RNAi to research almost 
any gene of interest.  
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Figure 2.4. RNA interference pathways. (A) Exogenous RNAi pathway mediated by siRNA 
and shRNA. dsRNA molecules are bound by Dicer and processed to form 21- to 23-
nucleotide siRNAs. Alternatively, synthetic siRNA duplexes can be artificially introduced in 
the cell or generated from shRNA through the pre-miRNA processing pathway (see B). The 
Dicer complex then recruits Ago2 and forms the RISC. After strand separation, the complex 
hybridizes to the complementary sequence in an mRNA and mediates its cleavage. (B) 
Endogenous pathway mediated by miRNAs. Primary mRNAs (pri-miRNAs) are synthesized in 
the nucleus and processed by Drosha to form the precursor miRNA (pre-miRNA). Pre-
miRNAs are exported to the cytoplasm via exportin5 (Exp5), where they are bound and 
processed by Dicer to form mature miRNAs. Similar to siRNA, miRNAs are loaded into RISC, 
but they target an imperfectly matched mRNA. This usually leads to repression of 
translation of this mRNA, although in some cases, cleavage of the target mRNA may also 
occur (dotted arrow). Reprint from Daniels and Gatignol 2012 [271] with permission from the 
American Society for Microbiology, copyright © 2012. 
 
2.3 Type I IFN responses during HIV-1 infection 
Elevated levels of IFN-I were already described in AIDS patients before the viral etiology of 
the disease was demonstrated [272]. They can be detected at various stages of the infection 
course. During acute infection, a rapid but transient increase in IFN-α coincides with the 
appearance of HIV-1 RNA in the plasma [273]. Levels of IFN-α again accumulate in the 
plasma during progression of the disease and are particularly elevated in patients with 
advanced disease [274, 275]. However, signatures of IFN-I activity, e.g. increase in ISG 
expression, are clearly detectable at earlier stages in peripheral blood of patients [276-278], 
suggesting that release of IFN-I primarily occurs in lymphoid tissue [279, 280]. Several lines 
of evidence indicate that pDCs are important producers of IFN-I during HIV infection. They 
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secrete high levels of IFN-I upon exposure to HIV-1 in vitro [281] and depletion of pDCs in a 
humanized mouse model of HIV-1 infection highly decreased IFN-I levels [282]. In rhesus 
macaques, recruitment of pDCs to the mucosal site of SIV inoculation was observed within 
one day after exposure [283]. However, the frequency of circulating pDCs declines during 
the chronic phase of HIV-1 infection [78, 284-286]. Furthermore, pDCs seem to have a 
decreased ability to produce IFN-I during chronic infection [78, 287, 288]. A recent study 
suggested that pDCs may only contribute to a transient IFN-α response in the acute phase 
of SIV infection [289]. Furthermore, IFN-α did not co-localize with pDCs in the spleens of 
chronically HIV-1 infected patients [285]. Therefore, although pDCs are likely the main 
source of IFN-I during acute HIV-1 infection, other cell types may contribute to IFN-I levels 
in the chronic phase of infection [290].  
The role of IFN-I responses during HIV and SIV infection is highly ambiguous (Figure 2.3). 
Early responses may prevent establishment of infection or limit viral spread through 
upregulation of viral restriction factors (ISGs), apoptosis of infected cells or stimulation of 
anti-viral innate and adaptive immune responses [69]. The protective potential of early IFN-I 
is for example illustrated by the protective effect of high APOBEC3G levels in HIV-exposed 
seronegative individuals [291] and by the higher resistance of HIV-1 founder viruses to in 
vitro IFN-I [292]. During acute SIV infection, high IFN-α levels are also associated with lower 
viral loads [293]. Furthermore, inhibition of IFN-I signaling in rhesus macaques prior to SIV 
infection resulted in higher viral loads and accelerated disease progression [294].  
However, these same IFN-I responses might in the long-term contribute to chronic hyper-
immune activation, depletion or dysfunction of lymphocytes and thereby eventually enhance 
disease progression [69]. In contrast to acute infection, higher IFN-α levels indeed correlate 
with higher viral loads during chronic infection in both SIV-infected rhesus macaques and 
HIV-1 infected humans [279, 293]. Additional evidence for a link between IFN-I and viral 
pathogenesis comes from studies of pathogenic versus non-pathogenic models of SIV 
infection, in which a marked difference in IFN-I activity is observed: IFN-I responses are 
completely down-regulated after acute infection in non-pathogenic models, while they 
remain elevated throughout the pathogenic infection course [295-297]. Furthermore, a 
recent study showed that prolonged administration of IFN-α resulted in an increase of cell-
associated viral load and CD4+ T cell loss in SIV-infected rhesus macaques [294]. Sustained 
IFN-I responses might enhance HIV pathogenesis in different ways. Several studies indicate 
a link between IFN-α activity and T cell activation, eg. IFN-α treatment enhances expression 
of the activation marker CD38+ on T cells of HCV (hepatitis C virus)- or HIV-infected patients 
and CD38 expression correlates with IFN-I activity in HIV-1 patients [278, 279, 298]. IFN-I 
signaling is also associated with increased expression of pro-apoptotic TRAIL and Bak 
during HIV-1 infection and could thereby contribute to CD4+ T cell depletion [280, 293, 299-
301]. Chronic IFN-I signaling during HIV/SIV infection may also cause desensitization to 
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IFN-I and T cell dysfunction [278, 294, 302], which would further impede the anti-viral 
responses. Therefore, IFN-I seems to act as a double-edged sword during HIV-1 infection, of 
which the protective effects during the early stages of infection are eventually overshadowed 
by disease-aggravating effects during the chronic phase of infection. 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Role of type I IFN responses during HIV-1 infection. IFN-I responses have a 
dual role during HIV-1 infection. In the early stages of infection protective effects probably 
dominate through induction of antiviral restriction factors and stimulation of adaptive 
immune responses. Once infection is established, protective and damaging effects are often 
seen in parallel. Prolonged exposure to IFN-I during chronic infection is likely to fuel 
pathogenesis by enhacing chronic immune activation and this eventualy overshadows the 
IFN-I protective effects. Adapted from Sivro et al. 2014 [69] with permission from Permanyer 
Publications, copyright © 2014.  
 
2.4 Innate immune recognition of HIV-1: to sense or not to sense? 
The elevated production of IFN-I in HIV-1 patients implies that HIV-1 is recognized or 
“sensed” by PRRs during infection in vivo. In the course of an HIV-1 replication cycle, several 
products that could serve as a potential PAMP are created. “Foreign” structures such as 
ssDNA and RNA:DNA hybrids are produced during HIV reverse transcription and dsRNA 
structures are present in the entering or newly produced HIV ssRNA genome. Molecular 
structures shared by host and HIV could also be recognized as “foreign” because of to their 
aberrant location (eg. HIV ssRNA in the endosomes or dsDNA in the cytosol). Since different 
HIV target cells express a different range of PRRs and since HIV has a varying potential to 
complete its lifecycle in these cells, sensing of HIV replication products is a cell type specific 
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phenomenon. Analysis of IFN-I induction by HIV-1 in vitro has revealed multiple possible 
sensing mechanisms. Some of them are successfully triggered by HIV-1 in certain cell types, 
while other mechanisms seem to be avoided due to viral and host evasion mechanisms. 
2.4.1 Sensing of HIV RNA 
pDCs produce high levels of IFN-I upon in vitro exposure to HIV-1 [281]. They most likely 
sense HIV through recognition of endosomal HIV ssRNA by TLR7 [303, 304]. Although pDCs 
are only minimally productively infected by HIV-1 [305], binding of HIV-1 Env to the CD4 
receptor is thought to induce endocytosis of the virus and exposure of the HIV genome to 
endosomal TLRs after endosome acidification [303, 306]. IFN-I is induced by both infectious 
and non-infectious free viral particles and to a larger extent by exposure of pDCs to HIV-
infected cells [304, 306, 307]. It was suggested that the latter involves sensing by both TLR7 
as well as a yet unidentified cytosolic PRR [304]. In monocytes, HIV-1 endocytosis might 
similarly result in sensing of ssRNA by endosomal TLR8, which leads to production of pro-
inflammatory cytokines but not IFN-I [308, 309], due to lack of constitutive IRF7 expression 
in these cells.  
Transfection of genomic HIV-1 RNA can also induce an IFN-I response in both peripheral 
blood mononuclear cells (PBMCs) and cell lines, indicating that cytosolic HIV RNA can be 
sensed. The RIG-I receptor was identified as responsible PRR [310, 311]. However, this type 
of sensing is not present during regular HIV-1 infection and one study suggested that 
sensing is counteracted through degradation of RIG-I by the HIV-1 protease [310]. 
2.4.2 Sensing of HIV DNA 
Similarly to HIV RNA, transfection of HIV-1 ssDNA and dsDNA could trigger IFN-I 
production in primary macrophages and the cytolosolic DNA sensors IFI16, cGAS and 
DDX41 were shown to contribute to the response [222]. Furthermore, HIV-1 replication 
induces IFN-I responses in the human monocytic cell line THP1 prior to viral integration and 
this was prevented by knock-down of cGAS or IFI16 [222, 312]. Therefore, different DNA 
sensors have the potential to recognize HIV reverse transcription (RT) products. However, 
during infection of primary HIV target cells, the occurrence of HIV DNA sensing is more 
controversial and both successful sensing as well as specific mechanisms of immune 
evasion have been described in different target cells. This is discussed in more detail below. 
In primary macrophages, evasion of DNA sensing was suggested through recruitment of 
cellular host factors to the entering viral capsid, such as cyclophilin A (CypA) and Cleavage 
and Polyadenylation Specificity Factor subunit 6 (CPSFE6). These factors are thought to 
“shield” the replicating virus from the innate sensors, since IFN-I could be artificially 
induced by depleting these proteins or using HIV-1 interaction mutants. In these conditions, 
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HIV DNA was sensed prior to integration by cytosolic DNA sensors, including cGAS [313]. In 
contrast, another group showed that knock-down of IFI16 enhances HIV-1 replication in 
these macrophages, which suggests that triggering of IFI16-mediated antiviral activity can 
occur during regular HIV-1 infection, although direct induction of IFN-I by HIV-1 was not 
demonstrated [222]. HIV may also exploit the host factors to degrade excess HIV DNA and 
prevent sensing. Yan et al. showed that knock-down of TREX1 (three prime repair 
exonuclease 1) in primary macrophages and CD4+ T cells resulted in accumulation of 
cytosolic HIV DNA and IFN-I induction [314]. Later studies suggested that both cGAS and 
IFI16 mediate DNA sensing in TREX1 deficient cells [222, 312]. However, it remains unclear 
if the different HIV RT products are all efficiently degraded by TREX1, since HIV DNA is able 
to induce IFN-I despite the presence of TREX1 in both macrophages (see above) and 
quiescent CD4+ T cells (see below) [313, 315].  
Successful sensing of HIV DNA has been described in lymphoid tissue derived quiescent 
CD4+ T cells. HIV-1 infection of these cells was shown to induce IFN-β as well as cell death 
through inflammasome activation and pyroptosis [316, 317]. Entry of HIV-1 in these resting 
cells does not result in productive infection, but leads to cytosolic accumulation of 
incomplete reverse transcription products derived from multiple abortive infection events 
[316]. The same group recently demonstrated that these products are recognized by the DNA 
sensor IFI16, which triggers both IFN-I production and caspase-1 activation through 
different pathways [315]. Inhibition of productive infection in quiescent CD4+ T cells is at 
least in part due to restriction of reverse transcription by SAMHD1. The latter is 
counteracted by viral Vpx, which is encoded by HIV-2 and certain SIVs, but not HIV-1 [45, 
174, 175]. Interestingly, although the lack of Vpx seems to enhance innate immune 
responses in quiescent CD4+ T cells, it protects HIV-1 from sensing in myeloid DCs. Indeed, 
when resistance to productive HIV-1 infection in MDDCs is artificially circumvented by co-
introduction of Vpx, sensing of HIV-1 DNA and IFN-I induction occurs through cGAS [181, 
312]. Surprisingly, IFN-I induction was only observed after integration of the virus, because 
it required interaction of newly expressed HIV-1 capsid with the host factor cyclophilin A 
(CypA) [181, 182]. This interaction was suggested to relieve the “shielding” and unmask 
remaining cytosolic HIV DNA for sensing [181, 318, 319]. A similar requirement of both Vpx 
and viral integration was observed when MDDCs were infected through viral cell-to-cell 
transmission from HIV-1 infected T cells. Interestingly, coculture with infected T cells 
resulted in higher levels of IFN-I production compared to infection of MDDCs with free viral 
particles [183]. This is in line with the higher multiplicity of infection that is reached during 
intercellular transmission of virus, a mode of infection that likely predominates during viral 
spread in vivo [320, 321].  
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2.5 Regulation by HIV-1 accessory proteins 
VPU 
Vpu was shown to counteract IFN-I induction by HIV-1 in different cell types [135, 322], 
however the mechanism behind this is not clear. Doehle et al. reported that Vpu induces 
degradation of IRF3 and thereby prevents transcription of IFN-I after sensing [138, 322]. 
However, such degradation was not observed by others [135, 323]. A recent study suggested 
that Vpu rather induces cleavage of IRF3 and that resulting IRF3 fragments act in a 
dominant-negative fashion [324]. Alternatively, Vpu might suppress IFN-I induction by 
preventing NF-ĸB activation [135, 323]. Neil et al. showed that the restriction factor tetherin 
can initiate NF-ĸB signaling when tetherin molecules are clustered by restricted viral 
particles. Counteraction of tetherin by Vpu would prevent such signaling [135]. Other 
studies indicate that Vpu also inhibits tetherin-independent activation of NF-ĸB [136, 137, 
323, 325, 326] by interfering more downstream in the NF-ĸB signaling pathway [137, 325].  
VIF 
Similar to Vpu, the Vif protein was also suggested to induce degradation of IRF3 and was 
able to counteract IFN-I responses induced by other viruses [327]. However, this was not 
confirmed by others [328] and a direct effect of Vif on HIV-1 induced IFN-I production has 
not been demonstrated yet.  
VPR 
The role of Vpr in regulating innate immune responses to HIV-1 seems more complex and 
both inhibiting and stimulatory effects have been described. Vpr-deleted HIV-1 viruses were 
shown to induce higher levels of IFN-I in either primary MDDCs [329], primary macrophages 
[330] or HeLa cells [168], suggesting an inhibiting effect. In HeLa cells, counteraction of IFN-
I induction was attributed to activation of the structure-specific endonuclease (SSE) 
regulator SLX4 complex by Vpr. Similar to TREX1, this complex may process excess HIV 
DNA and prevent its sensing [168]. Vpr was also suggested to induce degradation or 
cleavage of IRF3 [324, 328]. In contrast, another study showed that Vpr can stimulate 
expression of ISGs in primary macrophages [331]. Furthermore, different groups have 
demonstrated highly variable effects of Vpr on NF-ĸB signaling, resulting in either 
suppression [332, 333] or stimulation of NF-ĸB activation [334, 335], which might in turn 
affect IFN-I induction.  
2.6 Interplay between IFN-I responses and HIV-1 replication 
Despite several proposed evasion mechanisms, innate sensing occurs during HIV-1 infection 
in vivo and the virus has to replicate in face of elevated IFN-I levels. The anti-HIV activity of 
IFN-I is in part counteracted by targeting of IFN-I induced HIV restriction factors by the 
virus, eg. counteraction of tetherin by Vpu and APOBEC3G by Vif . Furthermore, the virus 
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may have evolved to use the innate immune responses to its own advantage. For example, 
HIV-1 Tat was shown to inhibit activation of the antiviral IFN-I induced kinase PKR. This 
interaction however leads to phosphorylation of Tat, which enhances its capacity to 
transactivate the HIV-1 LTR [336, 337]. The interferon regulatory factor 1 (IRF1), also 
induced by IFN-I, can bind to the HIV-1 LTR and stimulate transcription of viral genes both 
in the absence of Tat or in cooperation with Tat [338]. Similarly, activated NF-ĸB is an 
essential inducer of LTR activity [339]. Finally, innate immune responses might indirectly 
enhance HIV-1 replication by promoting recruitment and activation of HIV-1 target cells or 
in the long-term by causing immune exhaustion and dysfunction during chronic responses 
[68, 340].  
2.7 Regulating IFN-I responses in HIV-1 patients: treatment potential? 
Soon after the start of the AIDS epidemic, IFN-α was one of the first drugs tested for the 
treatment of HIV patients with AIDS-related Kaposi's sarcoma, based on its well-known 
antiviral and anti-proliferative properties. Although reduction in circulating HIV-1 p24 levels 
was observed in several studies [341], the interest in IFN-I for treatment of HIV-1 infection 
highly decreased when more tolerable and directly acting antiretroviral drugs, like AZT 
(azidothymidine), became available. Following these early studies, the therapeutic potential 
of IFN-I has mostly been investigated in combination with AZT or cART or in HIV/HCV co-
infected patients. Treatment with pegylated IFN-α during HIV/HCV co-infection is known to 
decrease HIV viral loads in addition to HCV loads [342-345]. However, the added value of 
IFN-α administration to cART is less clear : while some studies report beneficial effects on 
viral load and anti-HIV immune responses [346-349], others have observed only short-term 
effects [350] or no effect [351, 352]. Interestingly, a recent study by Azzoni et al. showed that 
a subset of patients receiving pegylated IFN-α after cART interruption were able to control 
viral replication up to 24 weeks and showed decreased levels of integrated HIV-1 DNA. This 
suggests that IFN-α treatment may have potential to reduce the viral reservoir [353]. 
However, given the limited sample size and treatment period in this study, larger long-term 
trials are required to further investigate this observation. 
The rationale behind IFN-I therapy is to take advantage of the antiviral effects of IFN-I. 
However, since IFN-I has a dual role in HIV-1 infection and likely contributes to the hyper-
immune activation and disease progression, strategies to counteract IFN-I activity have also 
been evaluated. Vaccination against IFN-α has been tested in two related studies and was 
associated with lower rates of disease progression in HIV-1 patients that responded to the 
vaccine [354, 355]. Another approach was the use of chloroquine, which inhibits endosomal 
acidification and thereby IFN-α production by pDCs in response to HIV-1. In two separate 
studies, chloroquine administration significantly reduced T-cell activation as well as other 
markers of chronic immune activation in HIV patients [356, 357]. However, a third study, in 
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patients at earlier stages of infection, observed no effect on T-cell activation and even a 
greater decline in CD4+ T cell count and increase in viral replication [358]. These opposing 
effects might reflect the different role of IFN-I at different stages of the infection: antiviral 
responses are important to limit viral spread at early stages, while immune activating effects 
of IFN-I outweigh the antiviral effects at later stages.  
The mixed results obtained by either stimulating or inhibiting IFN-I responses in HIV-1 
treatment indicate that patients may benefit from different approaches at different stages of 
disease [68, 69]. It furthermore highlights that a better understanding of the cellular 
sources and IFN-I action mechanisms at different stages of disease is required.  
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Chapter I-3. Quantification of retroviruses and retroviral vectors 
In Chapter III-1, an optimized assay for rapid quantification of retroviruses is presented and 
evaluated. As introduction to the research data, the next section will give an overview of 
commonly applied methods for retroviral quantification and their application. 
3.1 Use of retroviral quantification for clinical and research purposes 
Detection and quantification of retroviruses is performed in a variety of settings and can 
serve different purposes. First, in a clinical setting, direct measurement of retroviral nucleic 
acids or proteins in plasma or peripheral blood mononuclear cells (PBMCs) is used for early 
detection of HIV infection (i.e. before seroconversion) or for diagnosis in seropositive infants 
[359-361]. Furthermore, levels of virus in the plasma need to be monitored after diagnosis in 
HIV-infected patients, in order to evaluate the efficacy of antiretroviral therapy and disease 
progression [360]. Similar to HIV, human T-cell lymphotropic virus (HTLV) levels can be 
measured for diagnostic and monitoring purposes in symptomatic HTLV-infected patients 
[362, 363]. Second, biological products intended for medical use often need to be screened 
for the presence of contaminating retroviruses. Material from human origin, such as blood 
and blood-derived products, can be specifically tested for human retroviruses (HIV, HTLV) 
[364]. Many other biologicals (eg. vaccines, monoclonal antibodies,…) are produced in living 
cells or supplemented with reagents derived from living systems. These are known sources 
of retroviral contamination and screening for a wide range of retroviruses is therefore 
recommended [365-367]. Third, quantification of retroviruses is also required when using 
these viruses for research or clinical purposes. This includes the field of retroviral research 
itself, but also applies to the widespread use of retroviral vectors in research and clinical 
trials for gene therapy. Retroviral vectors are genetically engineered retroviruses which are 
exploited to stably insert nucleic acid sequences in the cellular genome and thereby allow 
for long-term manipulation of gene expression. These vectors can be used to deliver new 
genes of interest into the target cells or alternatively, they may encode sequences that are 
able to disrupt the expression of specific genes via different methods (eg. shRNA (small 
hairpin RNA), ZFN (zinc-finger nucleases), CRISPR (clustered regularly interspaced short 
palindromic repeats,…)). Conventional retroviral vectors are derived from oncoretroviruses 
(eg. mouse leukemia virus (MLV) and can therefore only integrate in dividing cells. However, 
vectors based on lentiviruses, such as HIV and FIV, can efficiently transduce non-dividing 
cells and are therefore more suitable for use in primary cells and in vivo [368-372]. 
Quantification of retroviruses and retroviral vectors in these settings is performed for several 
reasons, eg. to perform quality control of retroviral productions, to standardize experiments 
when using different batches of virus or when comparing different types of viruses, to 
evaluate retroviral replication in an experimental setting or to obtain a fixed range of 
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retroviral copies per cell (multiplicity of infection or MOI) in both research and clinical 
settings.  
Several different methods are available to quantify retroviruses. It is important to note that 
depending on the purpose of quantification, the preferred performance of the method may 
differ. While quantification for diagnostic or contamination screening purposes requires the 
highest possible level of sensitivity, methods to measure retroviral production in vitro may 
benefit more from a higher accuracy or broader linear range. Furthermore, quantification 
can be subtype-specific or alternatively require detection of a broad group of retroviruses. In 
the next paragraph, several commonly used methods are discussed with a focus on methods 
to quantify retroviruses/retroviral vectors in vitro, either for research or gene therapy 
purposes. 
3.2 Methods for retroviral quantification  
In general, methods for retroviral quantification can be divided into techniques that only 
measure functional viral particles (i.e. particles that are able to transduce or infect a specific 
cell type) and techniques that measure the total amount of “physical” viral particles, both 
functional and non-functional [373-375].  
3.2.1 Methods for total quantification of retroviral particles 
Assays to estimate total amounts of virus usually measure specific components associated 
with the retroviral particles, such as structural proteins, RNA or reverse transcriptase (RT) 
activity [374, 375]. HIV-1 and HIV-1 based lentiviral vectors are routinely quantified by 
using an ELISA directed against the p24 capsid protein. Although this method is 
straightforward and easily standardized, it suffers from several drawbacks. Inherent to the 
use of ELISA are the limited dynamic range of detection and the sometimes lower sensitivity 
compared to PCR based methods. Furthermore, it does not only detect virion-associated 
p24, but also free p24 derived from disintegrated viral particles or released by the virus-
producing cells [369, 376-379]. Another frequently applied method involves quantification of 
viral RNA genomes. Here, viral RNA is isolated from the retrovirus-containing sample, 
transformed into cDNA and quantified by PCR [374]. Such assays can be optimized to reach 
very high sensitivities and are the gold standard for monitoring plasma viral load in HIV-
infected patients [380]. A disadvantage is that they are dependent on specific primers 
targeting the viral/vector genome and accurate quantification of in vitro retroviral 
productions requires removal of plasmid DNA from sample [374, 375, 381]. These methods 
may also detect free, non-incorporated viral RNA, although the stability of free RNA is 
expected to be smaller than the one of viral proteins (eg. p24). A third type of methods is 
based on measuring RT activity in retroviral samples. Usually this is done by adding an RNA 
template and quantifying the amount of DNA that is synthesized by the endogenous 
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retrovirus associated RT [374]. The sensitivity of such assays has highly increased by 
performing PCR-based amplification of the newly synthesized DNA prior to detection, which 
are known as product-enhanced RT (PERT) assays [382-384]. DNA is subsequently 
quantified by using DNA gel electrophoresis [382, 385, 386], southern blot [383, 384, 387, 
388] or qPCR [389-393]. The latter allows an improved accuracy of quantification and is less 
labor-intensive [388-390]. A major advantage of RT assays is that they detect most, if not 
all, types of retroviruses. As such, PERT assays are the first method of choice to 
demonstrate the absence of retroviral contamination in biologicals [365, 386, 390, 394, 
395]. However, their use for determination of HIV viral loads [379, 396, 397] and for 
quantification of in vitro produced retroviruses [393] has also been suggested. Similar to p24 
assays, RT-based assays also detect viral particles that do not contain viral RNA [398] and 
might detect free RT proteins. However, a better correlation with infectious particles has 
been suggested, possibly because these assays only quantify functional RT enzymes which 
may have a short half-life in culture [399, 400]. 
 
 
 
 
 
 
 
 
Figure 3.1. Overview of methods for retroviral quantification. Total quantification 
methods measure both functional and non-functional viral particles by quantifying viral 
components. Functional quantification methods require infection/transduction of target 
cells and measure post-integration events to quantify functional viral particles. RT: reverse 
transcriptase. 
 
3.2.1 Methods for quantification of functional retroviral particles 
Retroviral particles generated in vitro or in vivo often have intrinsic defects that render them 
incapable of infecting/transducing a target cells [401-403]. Depending on the methods used 
for viral production and quantification, functional to physical particle ratios of 1/102 –1/107 
have been reported for in vitro produced retroviruses [373-375, 402, 404]. Therefore, if a 
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fixed amount of transduced/infected target cells is required for experimental purposes or an 
estimate of functional particles has to be made for other reasons, the use of functional 
quantification methods is recommended. These methods are more labor-intensive because 
they require transduction/infection of target cells and subsequent quantification of 
successful events [374, 375]. The latter can be done in several ways. Relatively fast 
assessment is possible if the virus/vector in question contains a reporter gene. Fluorescent 
proteins such as GFP (green fluorescent protein) or antibiotic resistance markers are 
commonly used in this regard [405]. For several retroviruses, indicator cell assays are also 
available, in which easy detectable proteins are produced upon successful infection or 
replication [406-410]. If these options are not applicable and other viral/vector proteins are 
difficult to quantify, measurement of transgene expression at mRNA level can be used to 
estimate functional infection/transduction levels [375, 411]. Alternatively, the number of 
integrated proviral copies per cell can be determined by qPCR. An inherent drawback of the 
latter is that not all integrated proviral genomes may lead to gene expression, due to 
integration in DNA regions with reduced transcriptional activity. In this regard, several 
groups have demonstrated that proviral titers largely overestimate titers based on protein 
expression [373, 411, 412]. A general critical point with functional quantification methods is 
that both efficiency of infection/transduction and of gene expression are highly dependent 
on the cell type used for titer determination. It is therefore important to keep in mind that 
the number of particles that are “functional” in the titration cell line will be different in the 
cell type used for experimental purposes and that titers estimated on different cell-types are 
difficult to compare. 
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Scope and research objectives  
Type 1 interferons (IFN-I) have extremely potent antiviral effects and are a key part of the 
immune response against multiple viral pathogens. However, during chronic viral infections, 
such as HIV-1, the role of IFN-I is dual. While early IFN-I responses can counteract 
establishment of infection and early viral spread, prolonged exposure to IFN-1 is associated 
with hyper-immune activation and dysfunction, both hallmarks of pathogenic HIV-1 
infection. Accordingly, targeted modulation of IFN-I responses during HIV-1 infection may 
have therapeutic potential. This first requires an in depth understanding of the cellular 
sources and mechanisms that could contribute to elevated IFN-I levels, as detected in HIV-1 
patients. So far, very few cell-types have been shown to produce IFN-I during HIV-1 infection 
in vitro. As such, the origins of in vivo IFN-I, especially during the chronic phase of infection, 
remain incompletely understood. 
Therefore, a primary goal of this thesis was to evaluate if the main HIV target cells, 
activated CD4+ T cells, are able to produce IFN-I during HIV-1 infection. To this end, 
several assays were implemented to evaluate induction of both IFN-I and ISGs during in 
vitro infection of primary cells. This included an assessment of induction kinetics during 
viral replication and evaluation of both laboratory adapted and primary HIV-1 or HIV-2 
strains. The potential antiviral effect of HIV-induced IFN-I on viral replication was also 
investigated. 
It is known that several isolated HIV replication products have affinity for pattern-
recognition receptors (PRRs). However only some of these sensing mechanisms have been 
shown to be activated during actual HIV-1 infection and this often occurs in a cell-type 
specific manner. Furthermore, strategies adopted by the virus to evade IFN-I induction have 
been suggested. A second goal was therefore to investigate host and viral mechanisms 
that regulate HIV-induced IFN-I production in primary CD4+ T cells. In order to identify 
potential host innate immune sensors and signaling pathways that are triggered by HIV-1 in 
these cells, we performed shRNA-mediated knock-down of several host genes and evaluated 
the effect on IFN-I induction. We also assessed at which stage of the HIV-1 replication cycle 
IFN-I induction occurred, to obtain further information on the HIV-1 replication products 
that are required to trigger the IFN-I response. Finally, we evaluated the potential role of 
HIV-1 accessory proteins in this regard. These viral proteins are known to modify immune 
responses in order to optimize the viral replication environment. Two of them, Vpr and Vpu, 
have been previously implicated in regulation of IFN-I responses. We therefore assessed 
their involvement in IFN-I induction in primary CD4+ T cells. Several HIV-1 variants 
containing targeted mutations in these genes or encoding alternative HIV/SIV alleles were 
also evaluated, in order to obtain a preliminary insight in the underlying mechanism of 
regulation. 
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The mechanistic evaluation of IFN-I induction by HIV-1 required the use of a large set of 
modified HIV variants and the use of lentiviral vectors to perform shRNA knock-down of host 
proteins. This introduced the need for a method to evaluate lentiviral productions, to 
normalize infection experiments and quantify HIV replication. The current standard 
methods for in vitro retroviral quantification suffer from several drawbacks, including a 
limited dynamic range of detection, a narrow virus specificity, a high cost and labor-
intensiveness. As such, they are not compatible with high-throughput production of 
different lentiviruses or lentiviral vectors. A third goal that emerged during this project was 
therefore to optimize and evaluate a general method for retroviral quantification that 
is both fast, cheap as well as accurate. Although qPCR-based PERT assays aimed at 
quantifying viral RT activity have not yet found their way to basic research environments, 
they can be easily modified to obtain these very qualities. We optimized such an assays for 
use with commercially available reagents, allowing an easier implementation and option for 
better standardization. The performance of this assay was evaluated for both HIV-1 and 
retroviral vectors and in comparison to the gold standard method, p24 ELISA. We also used 
the assay to assess the informative value of RT activity by comparing it to methods for 
functional lentiviral quantification. 
 67 
 
 
 
 
 
 
Chapter III-1 : 
 
Quantification of reverse transcriptase activity by 
real-time PCR as a fast and accurate method for 
titration of HIV, lenti- and retroviral vectors. 
 68 
 
Chapter III  Results 
 
69 
 
Quantification of reverse transcriptase activity by a real-time PCR-based assay 
as a fast and accurate method for titration of HIV and retroviral vectors 
 
Authors: 
Jolien Vermeire1, Evelien Naessens1, Hanne Vanderstraten1, Alessia Landi1, Veronica 
Iannucci1, Anouk Van Nuffel1, Tom Taghon1, Massimo Pizzato2, Bruno Verhasselt1 
 
1Department of Clinical Chemistry, Microbiology, and Immunology, Ghent University, Belgium 
2 Centre for Integrative Biology (CIBIO), University of Trento, Trento, Italy  
 
 
PLoS ONE 7(12): e50859. doi:10.1371/journal.pone.0050859 (2012) 
 70 
 
 
Quantification of Reverse Transcriptase Activity by Real-
Time PCR as a Fast and Accurate Method for Titration of
HIV, Lenti- and Retroviral Vectors
Jolien Vermeire1, Evelien Naessens1, Hanne Vanderstraeten1, Alessia Landi1, Veronica Iannucci1,
Anouk Van Nuffel1, Tom Taghon1, Massimo Pizzato2, Bruno Verhasselt1*
1Department of Clinical Chemistry, Microbiology, and Immunology, Ghent University, Ghent, Belgium, 2Centre for Integrative Biology (CIBIO), University of Trento,
Trento, Italy
Abstract
Quantification of retroviruses in cell culture supernatants and other biological preparations is required in a diverse spectrum
of laboratories and applications. Methods based on antigen detection, such as p24 for HIV, or on genome detection are
virus specific and sometimes suffer from a limited dynamic range of detection. In contrast, measurement of reverse
transcriptase (RT) activity is a generic method which can be adapted for higher sensitivity using real-time PCR quantification
(qPCR-based product-enhanced RT (PERT) assay). We present an evaluation of a modified SYBR Green I-based PERT assay
(SG-PERT), using commercially available reagents such as MS2 RNA and ready-to-use qPCR mixes. This assay has a dynamic
range of 7 logs, a sensitivity of 10 nU HIV-1 RT and outperforms p24 ELISA for HIV titer determination by lower inter-run
variation, lower cost and higher linear range. The SG-PERT values correlate with transducing and infectious units in HIV-
based viral vector and replication-competent HIV-1 preparations respectively. This assay can furthermore quantify Moloney
Murine Leukemia Virus-derived vectors and can be performed on different instruments, such as Roche LightcyclerH 480 and
Applied Biosystems ABI 7300. We consider this test to be an accurate, fast and relatively cheap method for retroviral
quantification that is easily implemented for use in routine and research laboratories.
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Introduction
Retroviral vectors have become an indispensable tool in any
modern molecular biology laboratory. They allow stable expres-
sion of a gene of interest in dividing cells, as well as stable gene
knock-down by expression of short hairpin RNA (shRNA). A
subset of vectors, derived from lentiviruses such as human
immunodeficiency virus (HIV-) 1 and 2 and feline immunodefi-
ciency virus (FIV), can be used for efficient transduction of non-
dividing cells and have therefore received increased attention for
both basic research and clinical applications [1,2,3,4]. Although
methods for accurate quantification of retroviral vector titers will
be indispensable in a clinical setting, also the basic research
environment can benefit from a fast and inexpensive method to
evaluate the quality of retroviral vector productions. Furthermore,
research laboratories investigating the replication of retroviruses,
such as HIV, require routine assays to determine retroviral titers
after production and during viral infection. Multiple methods for
retroviral titer quantification are currently available (see [5,6] for
an overview of lentiviral titration methods), but they often have
some inherent drawbacks. Determination of the proportion of
transduced/infected cells, by evaluating viral integration or
transgene expression, provides a good estimate of the number of
functional viral particles, but is time-consuming as it requires
transduction/infection of the cells and several days of incubation.
Other more rapid methods measure both functional and non-
functional viral particles in the supernatant, by quantifying the
levels of retroviral Gag protein (such as the HIV p24 protein) and
the levels of viral genomic RNA. The former is often done by
enzyme-linked immunosorbent assay (ELISA) and consequently
has a limited linear range and high cost. The latter relies on
quantitative real-time PCR (qPCR)-based amplification of cDNA
of virion-associated RNA and requires target-specific primers.
Furthermore, both methods are still quite labor-intensive.
An alternative retroviral titration method involves quantifica-
tion of the reverse transcriptase (RT) activity, which is associated
with all retroviral particles. In these assays, an exogenous RNA
template is added to the viral supernatant and RT activity is
estimated by determining the amount of RNA that is converted to
cDNA by the retroviral RT. In the first generation RT assays,
cDNA production was monitored by measurement of labeled
nucleotide incorporation [7,8,9]. Sensitivity was highly increased
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when a PCR amplification step of the synthesized cDNA was
introduced prior to product detection. These types of assays are
commonly known as product-enhanced RT (PERT) assays.
However, quantification of PCR products still required labor-
intensive techniques such as DNA gel electrophoresis, Southern
Blot or ELISA [10,11,12,13,14,15]. The newest PERT generation
therefore uses integrated qPCR techniques for fast cDNA
quantification, further increasing both the accuracy and linear
range of the assays. Most qPCR based PERT assays use cDNA-
specific fluorogenic labeled probes (TaqmanH chemistry) for signal
generation (F-PERT) [16,17,18,19,20], although a one-step PERT
assay using the more accessible and cost-efficient SYBR Green-I
chemistry (SG-PERT) was also recently developed [21]. PERT
assays are now routinely used for detection of retroviral
contaminants in biological products intended for human use
[22,23,24,25,26,27,28,29,30,31]. However, in basic research
environment, the implementation of real-time PCR based PERT
assays is still limited, despite their low cost and fast procedure.
In this paper, we present an adapted version of the SG-PERT
assay described before by Pizzato et al. [21]. The assay was
adapted for use with different commercial ready-to-use SYBR
Green I qPCR reaction mixes, to allow an easy implementation of
the assay in any research lab with qPCR experience and to avoid
possible compositional variation inherent to in house prepared
qPCR mixes. In addition, RNA from bacteriophage MS2, which
also lacks a DNA phase in its life-cycle, was used instead of RNA
from the Brome Mosaic Virus (BMV) that was used as a template
in the original assay, but is no longer commercially available.
Sensitivity and specificity of the assay were determined, as well as
the variation on repeated RT activity measurement within and
between runs. We used the assay to evaluate the informative value
of the RT activity for lentiviral titer determination, by comparing
it to more commonly used titration methods. We observed
excellent correlation with the p24 antigen concentration in both
replication-competent HIV-1 virus supernatant and replication-
incompetent HIV-based lentiviral vector preparations, as well as
with the levels of transducing units or infectious units. This
particular assay outperformed p24 ELISA by its lower inter-run
variation, lower cost and higher linear range. Furthermore, it was
far less time-consuming than both p24 ELISA and determination
of transducing or infectious units. We therefore believe that this
assay forms an attractive alternative to routine retroviral and
lentiviral titer determination in routine and research laboratories.
Materials and Methods
Cell Culture
Human lymphoblastoid Jurkat E6.1 (ATCC Cell Biology
Collection, Manassas, VA, USA), Jurkat CD4 CCR5 (Programme
EVA Centre for AIDS Reagents, NIBSC, UK), human embryonal
kidney 293T (DZSM, Braunschweig, Germany), 293TN (System
Biosciences, Mountain View, CA, USA), Phoenix-Amphotropic
packaging (Phoenix A) cells (Dr P. Achacoso and Dr G.P. Nolan,
Stanford University School of Medicine, Stanford, CA, USA) [32]
and P4.R5 MAGI cells (AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, Germantown, MD,
USA) [33] were cultured at 37uC in a 7% CO2 humidified
atmosphere, in IMDM complete medium: Iscove’s modified
Dulbecco’s medium (Life Technologies, Merelbeke, Belgium)
supplemented with 10% fetal bovine serum (Hyclone, Thermo-
fisher Scientific, Waltham, MA, USA), 100 U/mL penicillin (Life
Technologies) and 100 mg/mL streptomycin (Life Technologies).
Production of Replication-competent HIV-1 Virus
Replication-competent HIV-1 virus was produced by trans-
fection of 293T cells with one of the following pNL4-3 proviral
constructs: the NLENG1-IRES vector (kindly provided by Dr.
D.N. Levy, New York University college of Dentistry, New York,
NY) [34], the NL4-3-IRES-HSA vector (kindly provided by Dr.
M.J. Tremblay, Faculte´ de Me´decine, Universite´ Laval, Que´bec,
Canada) [35] or the HIV-1 NL4-3-IRES-eGFP vector (kindly
provided by Dr. F. Kirchhoff, Institute of Virology, University of
Ulm, Ulm, Germany) [36]. Transfection was performed with
Calcium Phosphate Transfection Kit (Life Technologies) or
JetPeiH (Polyplus, Se´lestat, France), according to manufacturer’s
instructions. Viral supernatant was harvested 48 hours or 72 hours
after transfection and centrifugated at 900 g for 10 min, to clarify
the supernatant from remaining cells. High-titer viral supernatant,
that was used to produce a standard curve for the SG-PERT assay,
was obtained by infection of Jurkat CD4 CCR5 cells with HIV-1
(140 ng p24 equivalent per mL) and subsequent collection of the
culture medium 12 days after infection. During infection, culture
medium was refreshed every two or three days.
Production of Replication-incompetent Lentiviral and
Retroviral Vectors
All replication-incompetent lentiviral vectors used in this study
were produced using the pLKO.1-puro Non-Mammalian shRNA
control plasmid from the Sigma MISSIONH product line (Sigma-
Aldrich, Bornem, Belgium), in which the puromycin resistance
gene was replaced by an eGFP encoding sequence. 293T or
293TN cells were transfected with this plasmid using Calcium
Phosphate Transfection Kit, LipofectamineH 2000 (Life Technol-
ogies) or FugeneH 6 (Promega, Leiden, The Netherlands). HIV
packaging genes and the VSV-G heterologous viral envelope gene
were provided in the cells by simultaneous cotransfection with
either the MISSIONH Lentiviral Packaging Mix (Sigma-Aldrich)
or the p8.91/pMD.G plasmids [32] and virus was harvested two
days after transfection. The Moloney Murine Leukemia Virus
(MoMLV)-based retroviral vector was produced by transfection of
Phoenix Amphotropic packaging cells with the LZRS-IRES-
EGFP vector using the Calcium Phosphate Transfection kit, as
described before [37,38].
Reagents Required for the SG-PERT Assay
MS2 RNA was purchased from Roche Diagnostics (Vilvoorde,
Belgium; Catalog #10165948001). Primers to amplify MS2
cDNA in the SG-PERT reaction were obtained from Eurogentec
(Seraing, Belgium) and had the following sequence: FWD (59-
TCCTGCTCAACTTCCTGTCGAG-39) and REV (59-CA-
CAGGTCAAACCTCCTAGGAATG-39), as published [19].
RibolockTM RNase inhibitor was from Fermentas (St. Leon-Rot,
Germany; Catalog # EO0381). For SG-PERT on the Light-
CyclerH 480 (Roche Diagnostics), the LightCyclerH 480 SYBR
Green I Master mix from Roche was used as reaction mix (Catalog
#04707516001). For SG-PERT on the ABI 7300 real-time PCR
system (Applied Biosystems, Foster City, CA, USA), a reaction mix
was made using the ROX-containing qPCR Core kit for SYBR
Green I from Eurogentec (Catalog #RT-QP73-05). Recombinant
HIV Reverse Transcriptase was purchased from Ambion (Life
Technologies, Catalog # AM2045). 26 concentrated lysis buffer
was composed of 0.25% Triton X-100, 50 mM KCL, 100 mM
TrisHCL pH 7.4, 40% glycerol and prepared as described
previously [21]. 2 mL of RNAse inhibitor was added per 100 mL
of the 26 lysis buffer immediately prior to use.
Quantification of Reverse Transcriptase Activity
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SG-PERT Assay
Cell-free viral supernatant was generally used without prior
dilution as input for the assay. 10-fold dilution series of viral
supernatant or HIV recombinant RT were generated in IMDM
complete. 5 mL of the viral supernatant or recombinant RT
solution was added to a well of a 96-well U-bottom plate (Beckton
Dickinson, Erembodegem, Belgium) and mixed with 5 mL of 26
concentrated lysis buffer, already containing RNAse inhibitor.
Samples were incubated for 10 minutes at room temperature and
subsequently diluted by addition of 90 mL nuclease-free water (Life
Technologies). After brief centrifugation, the lysates were resus-
pended and used as input for the assay. For SG-PERT assays on
the LightCyclerH 480 instrument, 9.6 mL of the lysate was
transferred to a 384-well plate (LightCyclerH 480 Multiwell Plates
384, white, Roche Diagnostics), that already contained 10.4 mL of
a reaction mix consisting of 10 mL 26 Roche SYBR Green I
Master mix, 0.1 mL 106 diluted RNAse inhibitor, 0.1 mL MS2
RNA and 0.1 ml of both the MS2 FWD and REV primer
(100 mM, to obtain final concentration of 500 nM in 20 mL
reaction volume). After brief centrifugation of the plate, the
reaction was carried out according to the following program: 20
minutes (min) at 42uC for RT reaction, 5 min at 95uC for
activation of FastStart Taq DNA polymerase and 40 or 50 cycles
of amplification: 5 seconds (sec) at 95uC for denaturation, 5 sec at
60uC for annealing and acquisition, 15 sec at 72uC for elongation.
Fluorescence acquisition was done at the end of annealing phase in
our experiments, but can alternatively be done at the end of
elongation phase. For SG-PERT assays on the ABI 7300 qPCR
system, 9 mL of the lysate was added to a 96-well plate (MicroAmp
Optical 96-well reaction plate, Applied Bisosystems) together with
11 mL of a reaction mix consisting of 10.6 mL mastermix from the
Eurogentec qPCR core kit for SYBR Green I (2 mL 106 reaction
buffer, 1.4 mL of 50 mM MgCl2, 0.8 mL of 5 mM dNTP mix,
0.1 mL of HotGoldSTar Taq polymerase, 0.6 mL SYBR Green I
and 5.7 mL of nuclease-free water.), 0.1 mL 106 diluted RNAse
inhibitor, 0.1 mL MS2 RNA and 0.1 ml of both the MS2 FWD
and REV primer (100 mM). Following reaction conditions were
used on the ABI 7300 instrument: 20 min RT reaction at 42uC,
2 min activation of the HotGoldStar Taq enzyme at 95uC and 40
cycles of amplification: 5 sec denaturation at 95uC, 30 sec
annealing and acquisition at 60uC, 15 sec elongation at 72uC.
All reagents were kept on ice or on a cooling block during
preparation of the assay. For each sample lysate, an SG-PERT
reaction was always performed in duplo. Cycles of quantification
(Cq) values were generated by the software of the qPCR
instruments, after manual threshold determination for the ABI
7300 instrument and according to the second-derivative maximum
method for the LightCyclerH 480. Melting peaks were calculated
automatically by the software of both instruments.
To perform absolute quantification of RT activity values,
a standard curve of replication-competent HIV-1 containing
supernatant with known RT activity levels was run in parallel in
each assay and values were extrapolated from the obtained Cq
values. The standard curve was produced by serial dilution of
a large batch of high-titer supernatant. Dilutions were aliquoted
for use in different SG-PERT assays, to avoid loss of RT activity
by repeated freeze-thaw cycles. RT activity values of the standard
curve were determined by running a dilution series of commercial
recombinant RT in parallel in at least four independent
experiments.
Calculations and Statistics
Standard deviation (STDEV), coefficient of determination (R2)
and regression equations were calculated with Excel 2007
(Microsoft). Coefficient of variation (CV) was calculated as follows:
(STDEV/AVERAGE) x 100%. Column scatter plots were created
with GraphPad Prism version 5.04. Statistical significance of
difference between inter-run coefficient of variation of p24 ELISA
test and SG-PERT assay was analyzed with the one-tailed non-
parametric Mann-Whitney U test (GraphPad Prism).
Determination of p24 Concentration, Transducing and
Infectious Units in Viral Supernatant
Concentration of the p24 antigen was measured in HIV-1 or
HIV-based lentiviral vector containing supernatant with the
INNOTESTH HIV Antigen mAb ELISA kit (Innogenetics,
Zwijnaarde, Belgium), according to manufacturer’s instructions.
Multiple dilutions of each sample were tested, to ensure that
concentration was within the linear range of the assay. For
correlation analysis of p24 antigen and RT activity values, all
samples were measured within the same ELISA assay, to avoid the
introduction of inter-run variation. For lentiviral vectors, the
number of transducing units per volume of supernatant (TU/mL)
was determined by transduction of Jurkat E6.1 cells with a limiting
dilution series of each sample, using polybrene (8 mg/mL; Sigma-
Aldrich) and spinoculation (30 min, 950 g, 32uC). The percentage
of transduced cells was determined 72 hours after transduction by
FACS analysis (MACSquantH Analyzer, Miltenyi Biotec, Leiden,
The Netherlands) of eGFP expression. Vector titers (TU/mL)
were calculated in cultures with 0.5% to 4% of eGFP expressing
cells according to following formula: { (% eGFP expressing cells/
100) x number of cells at moment of transduction x dilution factor
}/volume of viral supernatant used for transduction (mL).
For replication competent HIV-1 virus, relative levels of
infectious units (IU) were determined by single-cycle infection of
P4.R5 MAGI indicator cells. Briefly, 10,000 cells were plated per
well of a 96-well flat bottom plate (Beckton Dickinson). Twenty-
four hours after plating, HIV-1 NL4-3 viral supernatant was
added to the cells in the presence of 1 mM of the HIV protease
inhibitor ritonavir (AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, Germantown, MD,
USA), to avoid multiple rounds of infection. Cells were sub-
sequently spinoculated at 950 g for 90 min at 32uC. Forty-eight
hours after infection b-galactosidase activity was assessed using
a colorimetric assay (Mammalian b-galactosidase Assay kit;
Thermofisher Scientific) according to manufacturer’s instructions.
Optical density at 405 nm was quantified using a Versa Max Plate
Reader (Molecular Devices, Sunnyvale, CA, USA) and obtained
values were corrected for background signal by subtraction of the
optical density value obtained with non-infected cells. For
correlation analysis of RT activity and relative levels of infectious
units, we used cell-free HIV NL4-3 viral supernatant harvested 48
hours or 72 hours after transfection, with the Calcium Phosphate
Transfection Kit, of 293T with either the NLENG1-IRES vector
or the NL4-3-IRES-HSA vector. To ensure that b-galactosidase
activity levels were within the linear range of the assay, the viral
concentration in the culture was limited to maximum 360 mU RT
activity/mL. To determine absolute levels of infectious units/mL,
P4.R5 MAGI cells were infected with serial dilutions of HSA
encoding HIV-1 virus in presence of ritonavir. Forty-eight hours
after single-cycle infection, cells were stained with APC (allophy-
cocyanin)-labeled anti-mouse-CD24 antibody (HSA, heat stable
antigen; clone M1/69, BioLegend, San Diego, CA, USA) and the
percentage of infected cells was determined by FACS analysis
(FACSCalibur flow cytometer; Becton Dickinson)of HSA expres-
sion. Viral titers (IU/mL) were calculated according to the
following formula: {(% HSA expressing cells/100)6number of
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plated cells6dilution factor}/volume of viral supernatant used for
infection (mL).
Results
Sensitivity and Specificity of the SG-PERT Assay
A one step SYBR Green I-based real-time PERT assay (SG-
PERT) was developed, that uses MS2 RNA as a substrate for
reverse transcription and commercially available ready-to-use
reaction mixes for MS2 cDNA quantification by SYBR Green I-
based qPCR (Figure 1). We first performed experiments using the
Roche Master Mix for qPCR on the LightCyclerH 480. Inherent
to such a SYBR Green I-based detection system, is the possible
contribution of non-specific PCR fragments to the measured
signal. To evaluate the presence of any non-specific products, we
performed a melting curve analysis on the PCR products. Only
a single PCR fragment with a melting peak of 80.6uC was detected
in the final PCR product of both highly and weakly positive
samples (Figure 2A).
In order to determine the sensitivity and linear range of the
assay, 10-fold serial dilutions of a recombinant HIV-1 reverse
transcriptase (RT) enzyme were used as input for SG-PERT.
Amplification of the MS2 substrate correlated with the input
amount of recombinant RT (Figure 2B). When plotting the RT
input against the obtained Cq, the correlation was linear over 7
orders of magnitude, ranging from 1011 pU to 104 pU recombi-
nant HIV-1 RT per reaction (Figure 2C). Lower amounts of
recombinant RT (103 and 102 pU) were still detected, but Cq
values were considered to be outside the linear range of the assay.
Furthermore, when using nuclease-free water (NFW) as input for
the assay, a weak signal was occasionally obtained after 37 or more
cycles (Figure 2D). This signal might indicate a weak background
reverse transcriptase activity of the Taq DNA polymerase in the
Roche mix or might be caused by carry-over contamination
between SG-PERT experiments. Since Cq values obtained in
reactions with 103 and 102 pU input HIV-1 RT enzyme were not
consistently above these occasional background values, the de-
tection limit of this assay is considered to be 104 pU recombinant
HIV-1 RT.
Subsequently, the ability of the assay to measure the RT activity
associated with complete viral particles was tested. When using
cell-free supernatant of replication competent HIV-1 infected
Jurkat CD4 CCR5 cells as input for the assay, a linear correlation
between the input virus dilution and Cq values was again obtained
over six 10-fold serial dilutions of the original supernatant. Similar
to the results with recombinant HIV-1 RT, higher dilutions of
viral supernatant were still detectable (Cq $35), but outside the
linear range of the assay (Figure 2D and 2E). The undiluted
sample used here, had a p24 antigen concentration of 3,100 ng/
mL according to ELISA measurement. Therefore, this SG-PERT
assay can detect and quantify RT activity in HIV-1 supernatant
with a p24 equivalent as low as 0.0031 ng/mL. Since only
0.48 mL of supernatant is used per reaction, this corresponds to
a detection limit of 1.5 fg p24 or 620 viral particles (assuming that
an HIV core is composed of 2,000 p24 capsid molecules [6]).
Alternatively, when the lowest detectable number of virions is
calculated based on virion associated RT activity (400- 200 pU/
virion [9,18]), a similar detection limit of 25–50 virions is obtained.
Since RT activity is associated with all retroviruses, a more
prominent application of this assay can be the quantification of
recombinant lenti- and retroviral vectors, for instance to check the
quality of retroviral production. We used two types of commonly
used replication-defective viral vectors, HIV-based and MoMLV-
based, to evaluate the correlation between vector concentration
and RT activity measured by SG-PERT. Both the RT activity
associated with HIV-based MISSIONH lentiviral particles as well
as the activity of the MoMLV RT enzyme could be detected in
supernatant of lentivirus producing 293T cells and retrovirus-
producing Phoenix A packaging cells respectively. Activity of both
enzymes showed a linear correlation with the input vector dilution
over four to five 10-fold dilutions (Figure 2E). When plotting the
input concentration versus the obtained Cq values, a curve with
similar slope was obtained for recombinant RT, replication
competent HIV-1, HIV-based lentiviral vectors and MoMLV-
based retroviral vectors (Figure 2C and Figure 2D; varying from
23.6 to 23.8). Therefore, PCR efficiencies must be in the same
range and the linear range for retro- and lentiviral vector
quantification might be similar to the one of recombinant RT
quantification. In order to express the sensitivity of viral vector
quantification by the SG-PERT assay, the functional titer of both
the lenti- and retroviral vector supernatant used here was
determined by limiting dilution titration on Jurkat E6-1 cells and
was found to be resp. 1.126107 transducing units (TU)/mL and
4.96105 TU/mL. Since the assay could quantify a 105 dilution of
the HIV-based lentiviral supernatant, a sensitivity of
1.126102 TU/mL or 0.056 TU/reaction can be assumed.
Similarly, for MoMLV-based retroviral vector supernatant,
Figure 1. Principle of the SG-PERT assay. Cell-free retrovirus containing supernatant is lysed and added to a reaction mix containing the MS2
RNA template, MS2 complementary primers and a SYBR Green I qPCR mastermix. During a one-step reaction, the reverse transcriptase (RT) enzymes
derived from the retroviral particles will convert the MS2 RNA into cDNA and cDNA is subsequently quantified by qPCR amplification of the MS2
cDNA. The amount of synthesized cDNA represents the level of RT activity in the viral supernatant and is thereby a measure of the amount of
retroviral particles.
doi:10.1371/journal.pone.0050859.g001
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quantification of up to 49 TU/mL or 0.024 TU/reaction is
possible.
Inter- and Intra-run Variation of the SG-PERT Assay
When determining RT activity in lenti- or retroviral superna-
tant with the SG-PERT assay, absolute quantification can be done
by running a standard curve of recombinant reverse transcriptase
in the same assay as the sample of interest. For frequent use of the
assay, a cheaper alternative is the use of a retroviral standard
curve. In this case, the RT activity of high titer retroviral
supernatant is determined once, using a standard curve of
recombinant reverse transcriptase. For subsequent assays, a di-
lution series of this retroviral supernatant can be used as standard
curve and absolute quantification can be done by using the known
RT activity of the retroviral standard curve.
To obtain such a standard curve, supernatant of HIV-1 infected
Jurkat CD4 CCR5 cells with an RT activity of 47,000 mU/mL
was serially diluted and aliquots of each dilution were stored for
use in different assays. Cq values of this standard curve, obtained
in 12 independent SG-PERT experiments on the LightCyclerH
480, are shown in Figure 3A. They were found to be highly
reproducible, with a standard deviation of maximum 1 Cq value
over the different assays for each dilution point, corresponding to
a variation of two-fold over the measurement average. If a precise
determination of RT activity is not required, it is therefore possible
to only occasionally include a standard curve in the SG-PERT
experiment and directly derive the RT activity from the obtained
Cq value instead (using a fixed standard curve for calculations).
Subsequently, the reproducibility of RT activity quantification
using the SG-PERT assay and the HIV-1 standard curve, was
evaluated on the LightCycler. To determine intra-run reproduc-
ibility, 8 aliquots from each of 6 different HIV-containing samples
were separately lysed and RT activity in the different lysates was
determined in the same run. The coefficient of variation (CV)
ranged between 8.6% to 15% of the RT activity (Figure 3B), with
an average CV of 12%. Inter-run variation was evaluated on 11
different HIV-1 containing samples by determining their RT
activity in at least 3 independent SG-PERT experiments. We
found an average CV of 19.9%. Except for the sample with the
lowest titer, CV was lower than 30%. The sample with very low
RT activity (0.2 mU/mL; sample 1 in Figure 3C) showed a CV of
43%, which might indicate a decreased reproducibility of the SG-
PERT measurement in the region close to the detection limit of
the assay (Figure 3C).
Figure 2. Sensitivity and specificity of the SG-PERT assay. (A) Melting curves of PCR products obtained by SG-PERT assay on the LightCyclerH
480 when using 1011 or 104 pU recombinant HIV-1 RT or nuclease-free water (non-template control =NTC) as input for the assay, as indicated. (B, D)
Amplification curves of indicated amount of (B) recombinant HIV-1 RT (pU), (D) replication competent HIV-1 (NL4-3 strain) (ng p24/mL) or nuclease-
free water (NTC) obtained by SG-PERT on the LightCyclerH 480. (C,E) Relation between input of (C) recombinant HIV-1 RT, (E) replication competent
HIV-1 (HIV-1), HIV-1 based lentiviral vectors (HIV-1 based vector) or Moloney Murine Leukemia-based retroviral vectors (MoMLV) and obtained cycle of
quantification (Cq) values by SG-PERT on the LightCyclerH 480. Viral titers in the undiluted samples in (E) (value of ‘‘0’’ on x-axis) were 3,100 ng p24/
mL for the replication competent HIV-1 virus, 1.126107 transducing units/mL (TU/mL) for the HIV-1 based viral vector and 4.96105 TU/mL for the
MoMLV-based vector. Only input levels within linear range of the assay were included for correlation analysis.
doi:10.1371/journal.pone.0050859.g002
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Comparison of the SG-PERT Assay with Other Lentiviral
Titration Methods
Currently, the most frequently used methods for lentiviral titer
determination measure the concentration of the p24 antigen in the
supernatant or determine the number of transducing units (TU) or
infectious units (IU) per volume of the supernatant. The latter can
be done by assessing the level of transduced or infected cells after
limiting dilution of replication incompetent or replication compe-
tent lentiviruses respectively. Alternatively, for HIV viruses,
relative levels of infectious units are often determined by single-
cycle infection of indicator cell lines. To evaluate the informative
value of the RT activity determined by SG-PERT, we investigated
its correlation with the p24 antigen concentration levels and the
levels of TU or IU in the same samples.
Supernatants with HIV-1 virus (NL4-3 strain) or replication
incompetent HIV-based MISSIONH lentiviral particles were used
for both p24 antigen concentration and RT activity determination
by ELISA and SG-PERT respectively. We found a very strong
correlation between the obtained p24 and RT values, both for
combined and separate analysis of the lentiviral vectors and HIV-1
viruses. The two values correlated with each other according to
a power function, with a power number very close to 1, indicating
an almost linear relation. The ratio between the RT and p24
values was calculated, that seemed higher for the lentiviral vectors
compared to the replication competent HIV-1 viruses (Figure 4A
Figure 3. Intra- and inter-run variation of the SG-PERT assay. (A) Standard curve composed of a pre-made six 10-fold serial dilution series of
replication-competent HIV-1 containing supernatant measured in 12 independent SG-PERT experiments. For each experiment obtained Cq values are
plotted versus the RT activity in each sample. RT activity values were determined by running a dilution series of recombinant HIV-1 RT in parallel.
Standard deviation on the obtained crossing point values is indicated for each dilution. (B) RT activity values obtained for 8 repeated measurements
of different HIV-1 samples (sample number 1 to 6) within the same run. The average RT activity value for each sample is indicated by a red line, error
bars represent standard deviation on the obtained RT activity values. Numbers indicate intra-run variation for each sample, expressed as percentage
of the average RT activity values (coefficient of variation). (C) RT activity values obtained for different HIV-1 samples (sample number 1 to 11) in at
least 3 independent SG-PERT experiments. The average RT activity value for each sample is indicated by a red line, error bars represent standard
deviation on the obtained RT activity values. Numbers indicate inter-run variation for each sample, expressed as percentage of the average RT activity
values (coefficient of variation). Experiments were performed on the LightCyclerH 480.
doi:10.1371/journal.pone.0050859.g003
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and Table 1). Of note, the excellent correlation between the p24-
RT values of HIV-1 viral supernatants was not caused by the
sample with very low titer, since the coefficient of determination
(R2) was still 0.92 if this sample was removed from the analysis
(data not shown).
The MISSIONH lentiviral particles used in this experiment
express eGFP as a marker gene and therefore allow easy
determination of TU/mL, by FACS measurement of the pro-
portion of transduced cells. The number of TU/mL obtained after
limiting dilution of the different lentiviral supernatants on Jurkat
E6-1 cells strongly correlated with the RT activity levels in these
samples (Figure 4B). When calculating the number of viral
particles in the supernatant, assuming an RT activity of 300 pU
per virion [9,18], we found a ratio of 865 to 2,319 RT-containing
viral particles per functional transducing unit. Viral particle
numbers in the same range were obtained when calculations were
based on p24 content, although the estimated particle concentra-
tion was slightly higher when based on RT activity (‘‘RT based/
p24 based’’ ratio of 1.5–3.8 for HIV-1 containing supernatant and
1.9–4.8 for lentiviral vector containing supernatant) (Table 1). This
shows that as for p24, RT activity is representing both transducing
and non-transducing viral particles.
For replication competent HIV-1 virus, relative levels of
infectious units in the supernatants were assessed by infection of
P4.R5 MAGI indicator cells. These CD4, CXCR4 and CCR5
expressing HeLa cells express bacterial b-galactosidase under
control of the Tat-responsive HIV long terminal repeat and
therefore express b-galactosidase upon productive HIV infection
[33]. The levels of b-galactosidase activity induced by HIV-1
supernatant in these types of assays have been shown to correlate
with infectious titers determined by end-point dilution (tissue
culture infectious dose 50% or TCID50) [39]. When infecting the
cells with a serial dilution of HIV-1 supernatant, the input viral
concentration linearly correlated with the b-galactosidase activity
measured in the cell culture 48 h after single-cycle infection. For
high levels of viral input a saturation of b -galactosidase activity
occurred at a level corresponding to an optical density value
around 2 (Fig. 4C). To compare levels of infectious units present in
different productions of HIV-1 NL4-3 viral supernatant, an
appropriate dilution of each supernatant was used for single cycle
infection. We found a high correlation between the levels of b-
galactosidase activity and the RT activity, indicating a correlation
between the number of infectious units and RT activity in the
supernatant (Fig. 4D).
Furthermore, we evaluated the inter-run variation of p24
concentration measurement by ELISA and compared this to the
SG-PERT inter-run variation determined above. For 7 different
HIV-1 containing samples, from the same set that was used to
determine SG-PERT reproducibility, p24 concentration was
determined in at least 3 independent ELISA experiments. Due
to the restricted linear range of p24 ELISA, careful consideration
was given to appropriate dilution of the supernatants in each
experiment. Coefficient of variation ranged from 16% to 51.4%
and was on average higher than the inter-run variation of the SG-
PERT assay (p-value = 0.0426 with Mann-Withney U test)
(Figure 4E–F and compare to Figure 3C). Quantification of the
sample with low viral titer and high inter-run variation of RT
activity determination (sample 1 in Figure 4E), was only slightly
more reproducible with p24 ELISA compared to SG-PERT
(Figure 4E, compare to Figure 3C).
Table 1. Evaluation of different lentiviral titration methods.
RT activity
(mU/mL) p24 (ng/mL)
ratio RT/
p24 TU/mL
p24 based
# VP/mL
RT based
# VP/mL
ratio p24 based/
RT based # VP
ratio TU/p24
based # VP
ratio TU/RT
based # VP
HIV-1 sup 1 1.96E-01 2.78E-02 7.0 3.33E+05 6.52E+05 1.95
HIV-1 sup 2 7.41E+02 1.30E+02 5.7 1.56E+09 2.47E+09 1.58
HIV-1 sup 3 5.03E+03 7.69E+02 6.5 9.23E+09 1.68E+10 1.82
HIV-1 sup 4 5.44E+03 7.57E+02 7.2 9.08E+09 1.81E+10 2.00
HIV-1 sup 5 5.52E+03 9.26E+02 6.0 1.11E+10 1.84E+10 1.66
HIV-1 sup 6 6.34E+03 1.14E+03 5.6 1.37E+10 2.11E+10 1.55
HIV-1 sup 7 8.00E+03 1.43E+03 5.6 1.72E+10 2.67E+10 1.55
HIV-1 sup 8 1.26E+04 2.00E+03 6.3 2.40E+10 4.19E+10 1.75
HIV-1 sup 9 1.39E+04 2.01E+03 6.9 2.41E+10 4.64E+10 1.92
HIV-1 sup 10 2.00E+04 1.46E+03 13.7 1.75E+10 6.65E+10 3.81
HIV-1 sup 11 2.06E+04 3.76E+03 5.5 4.52E+10 6.88E+10 1.52
LV sup 1 7.32E+00 9.24E-01 7.9 2.82E+04 1.11E+07 2.44E+07 2.20 393 865
LV sup 2 4.91E+01 2.85E+00 17.2 1.03E+05 3.42E+07 1.64E+08 4.78 330 1581
LV sup 3 3.84E+02 5.54E+01 6.9 9.40E+05 6.65E+08 1.28E+09 1.92 708 1362
LV sup 4 8.14E+02 1.12E+02 7.2 1.72E+06 1.35E+09 2.71E+09 2.01 786 1580
LV sup 5 1.13E+03 1.21E+02 9.3 2.68E+06 1.45E+09 3.76E+09 2.59 541 1401
LV sup 6 1.66E+03 1.31E+02 12.7 2.39E+06 1.58E+09 5.54E+09 3.52 659 2319
LV sup 7 3.53E+03 3.78E+02 9.3 1.13E+07 4.54E+09 1.18E+10 2.60 402 1045
Table shows SG-PERT RT activity measured on the LightCyclerH 480 and p24 antigen concentration in different productions of replication-competent HIV-1 virus
supernatant (HIV-1, sup 1–11) and replication-incompetent HIV-1-based MISSIONH lentiviral vectors (LV, sup 1–7). TU/mL: transducing units/mL (only determined for
lentiviral vectors). The number of viral particles (#VP) was calculated from p24 values by assuming 12 viral particles per fg p24. For viral particle calculation from RT
activity values, an activity of 300 pU per viral particle was assumed.
doi:10.1371/journal.pone.0050859.t001
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SG-PERT Assay for Applied Biosystems qPCR Instruments
For the characterization of the SG-PERT assay above we used
the Roche SYBR Green I Master Mix for qPCR quantification on
the LightCycler. However, other qPCR platforms, such as most of
the Applied Biosystems qPCR instruments, require the presence of
a passive reference dye in the master mix to normalize for non-
PCR related fluorescence signal variations. To compare, we
performed the assay on an ABI 7300 Real-Time PCR System
using the ROX containing qPCR core kit for SYBR Green I from
Eurogentec as reaction mix (see material and methods). Sensitivity
and linear range of the assay were determined by using the same
10-fold serial dilution of HIV-1 supernatant as was used before on
the LightCycler for this purpose. Similar to the results on the
LightCycler, the SG-PERT assay could quantify RT activity in
a sample with p24 antigen concentration as low as 0.0031 ng/mL
and Ct values correlated linearly with the input virus dilution over
six orders of magnitude (Figure 5A and 5B). When using samples
with even higher RT activity, by using recombinant RT, we did
notice a loss of linearity, probably by saturation of the assay (data
not shown). However, such RT activity levels are far above the
ones commonly obtained in supernatant of viral productions or
medium of HIV infected cells. Nuclease-free water did not
generate a detectable signal on the ABI 7300 instrument when
used as input for SG-PERT (Figure 5A). Furthermore, melting
curve analysis of the PCR products confirmed the absence of non-
specific amplification in the assay (data not shown). Therefore,
retroviral quantification by SG-PERT can be performed on ABI
qPCR instruments with equal efficiency as on the LightCycler.
Discussion
Assessment of retroviral titers is a requisite in quality assurance,
virology and molecular biology research laboratories for quality
control of cell derived preparations; quality control of viral
productions; for standardization of experiments using different
batches of virus preparations and for normalization of viral
particles numbers when comparing different types of viruses. In
this paper, we present the first one-step SYBR Green I qPCR-
based PERT assay using commercial ready-to-use reaction mixes
and show that quantification of RT activity in viral supernatant by
this assay, can provide a robust and accurate alternative for other
frequently applied methods of retroviral titer determination.
The SG-PERT assay presented here, uses MS2 RNA as
a substrate for reverse transcription by retrovirus-associated RT
molecules and subsequently quantifies MS2 cDNA by SYBR
Green I-based qPCR, using commercially available reagents and
ready-to-use reaction mixes. Since the introduction of a qPCR
cDNA quantification step to conventional PERT, a number of
assays applying this modification have been published
[16,17,18,19,20,21]. Most of these assays follow a two-step
protocol, separating the reverse transcription and qPCR step
[17,18,19,20]. While such a separation offers the possibility to
remove non reverse transcribed RNA templates after the RT step,
thereby avoiding possible background signals of the Taq poly-
merase [20], it renders the assay more labor-intensive and time-
consuming. For quantification of retroviral titers in research
laboratories, easiness and speed of the assay is often more
important than the elimination of minute background levels, that
are often far below the signal generated by the retroviral
supernatant. Based on assay durations reported in literature, the
SG-PERT assay described here seems considerably faster com-
pared to other published two-step and one-step qPCR-based
PERT assays [16,18,20]. Furthermore, most available qPCR
based PERT assay use cDNA-specific fluorogenic labeled probes
(TaqmanH chemistry) for signal generation [16,17,18,19,20], while
SYBR Green I chemistry is more accessible and is not sensitive to
possible DNAse activity present in the test samples, as has been
reported for fluorogenic labeled probes in one-step qPCR based
PERT assays [17]. Subsequently, the ability to perform the SG-
PERT assay with commercial ready-to-use SYBR Green I qPCR
reaction mixes largely facilitates its implementation in laboratories
equipped for qPCR and eliminates possible compositional
variation inherent to in house prepared qPCR mixes. Of note,
we have confirmed that another commercially available SYBR
Green PCR ready mix (the widely used Qiagen QuantiTect SYBR
Green PCR Kit), is fully compatible with the linear quantification
of HIV-1 RT activity and therefore most likely is an alternative to
the Roche and Eurogentec mixes evaluated in this report.
During evaluation of the one-step SG-PERT assay, we found
that obtained RT activity values correlated with input levels over
six to seven orders of magnitude. Because of this extraordinary
linear range, prior extensive serial dilution of the viral supernatant
is not required for titer determination, thus potential introduction
of variation is avoided. The sensitivity of the assay corresponded to
a p24 equivalent of 3 pg/mL for HIV-1 supernatant and to 650
or 6110 TU/mL for MoMLV-based and HIV-based retroviral
vectors respectively. The original SG-PERT assay described by
Pizzato et al. was reported to have a sensitivity of 102–103 pU
recombinant HIV-1 RT per reaction [21]. Although similar input
levels were still detected in the current modified assay on the
LightCyclerH 480, the obtained values were outside the linear
range of the assay. The higher sensitivity observed by Pizzato et al.
could be due to the use of a different qPCR instrument, the BMV
RNA template-primer combination or the performance of home-
Figure 4. Comparison of SG-PERT assay with other lentiviral titration methods. (A) Correlation between RT activity levels measured with
SG-PERT and p24 antigen concentration levels measured with ELISA in supernatant containing replication-competent HIV-1 virus or HIV-1 based
MISSION lentiviral vectors. Coefficient of determination and correlation functions are shown for HIV-1 virus (- - -) and lentiviral vectors (-?-?) separately
or combined (-). To avoid introduction of interrun variation, p24 ELISA measurements for all samples were performed in the same experiment. (B)
Correlation between RT activity levels measured by SG-PERT and levels of transducing units determined by limiting dilution on Jurkat E6.1 cells in
HIV-1 based MISSIONH lentiviral vector preparations. (C) Relation between the level of b-galactosidase activity, as a marker of HIV-1 Tat production
and the relative amount (serial dilution) of replication competent HIV-1 NL4-3 virus used to infect the cells, in the culture of P4.R5 MAGI indicator cells
48 h after single-cycle infection. Viral input in the undiluted samples (value of ‘‘1’’ on x-axis) was 1.766103 mU RT/mL for HIV sup 12 and
2.336102 mU RT/mL for HIV sup 13. For HIV sup 12, the undiluted sample was outside the linear range of the assay and was therefore not included
for calculation of the determination coefficient (R2) shown in panel C. (D) Correlation between the level of b-galactosidase activity in the culture of
P4.R5 MAGI indicator cells 48 h after single-cycle infection with different productions of HIV-1 NL4-3 supernatant and the RT activity measured in the
supernatant by SG-PERT. (E) p24 antigen concentration values obtained for different HIV-1 containing samples in at least 3 independent ELISA
experiments. Sample numbers in x-axis correspond to those in Figure 3C. The average p24 concentration value for each sample is indicated by a red
line, error bars represent standard deviation on the obtained p24 concentration values. Numbers indicate inter-run variation for each sample,
expressed as percentage of the average p24 concentration (coefficient of variation=CV). (F) Average inter-run coefficient of variation for SG-PERT and
p24 ELISA assays, calculated from the CV’s obtained in Figure 3C and Figure 4E respectively. Error bars indicate standard deviations. The asterix (*)
indicates a statistical significant difference between the two values according to a one-tailed Mann-Withney U test (p-value = 0.0426).
doi:10.1371/journal.pone.0050859.g004
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made PCR reaction mix. Nevertheless, the sensitivity of the
current assay is sufficient for most applications in virology research
laboratories and similar to the one of most commercial p24 ELISA
kits (eg. Innogenetics INNOTESTH: 10 pg/mL; Perkin-Elmer
ALLIANCEH test: 12.5 pg/mL). The assay was furthermore able
to accurately quantify RT activity in samples containing retro-
viruses of different origins (HIV-1 and MoMLV). This offers the
advantage that viral (vector) preparations of different origins can
all be evaluated within a single assay. In this regard, Ma et al.
recently demonstrated that a standard curve of recombinant HIV-
1 RT can be used to perform absolute quantification of other types
of retroviruses by qPCR-based PERT [18], although the efficiency
of different viral reverse transcriptase enzymes should be evaluated
in our SG-PERT assay. However, for routine evaluation of
a specific type of retrovirus, we recommend to determine absolute
RT activity levels of a high-titer preparation of this virus by
running a standard curve of the appropriate recombinant RT in
parallel. For subsequent assays, a dilution series of this high-titer
preparation can then be used as a standard curve.
Due to the accurate quantification capacity of qPCR, a low
intra- and inter-run variation has been reported for different
PERT assays [17,18,21]. However, variation is usually determined
on the obtained Cq values and consequently underestimates the
variation on the actual RT activity values. Therefore, we
expressed variation of the SG-PERT assay as percentage of the
actual RT values, which are calculated from the obtained Cq
values by running a standard curve with known RT activity in
parallel. We show an acceptable intra- and inter-run reproduc-
ibility of the assay, although, as expected, an increase in variation
is observed in regions close to the detection limit of the assay.
Inter-run variation of viral titer determination was on average
lower when using the SG-PERT assay compared to p24 ELISA. A
high inter-run variation for p24 antigen quantification by ELISA
has been reported by others [5,40], and might be due to extensive
sample dilution or the multiple handling steps inherent to the
assay, which are both sources of variance introduction.
Since the use of qPCR-based PERT assays as a retroviral
titration method is still limited, one goal of this paper is to evaluate
the informative value of retroviral titers based on RT activity
levels. We show an excellent correlation of RT activity with both
p24 antigen concentration and levels of transducing and infectious
units.
For replication-incompetent lentiviral vectors, we calculated the
number of viral particles from the obtained RT activity and found
an average 1/1,450 ratio between transducing units and RT-
containing particles. A functional/physical particle ratio in the
same range has been reported for lentiviral vectors, when the latter
was determined by quantification of viral RNA copies [5,41,42,43]
or p24 antigen concentration [44,45]. However, these ratios are
highly dependent on different characteristics of the both the vector
and transduction process, such as the vector backbone and
envelope protein, the transduction method and the cell line used to
determine functional titers [5,43]. Therefore, it is important to
note that the correlation between RT activity and levels of
transducing units was evaluated on lentiviral vector preparations
produced with the same transfer plasmid, although the packaging
plasmids and transfection methods used were different. We also
calculated the ratio between the absolute number of infectious
units and RT-containing viral particles for two productions of
replication competent HIV-1 virus. The former was determined
by analysis of the HSA marker gene expression, encoded by HIV-
1 replication competent reporter viruses, in P4.R5 cells infected
with a serial dilution of supernatant, the latter based on an RT
activity of 300 pU per virion [9,18]. We found ratios of 1/63,500
and 1/111,800 between infectious units and total viral particles
(data not shown). In line with replication-incompetent lentiviral
vectors, highly variable ratios of infectious/noninfectious units
have been reported in literature for in vitro produced HIV-1
supernatant (ranging from 1/102 to 1/107) [46,47,48,49]. These
ratios are influenced by several factors, such as the type of virion
producing cell, type and density of the target cell, the infection
protocol and the HIV-1 strain [40,48,49,50,51]. If a precise
estimation of the transducing or infectious capacity is necessary, it
is therefore recommended to establish titers of the particular
vector or HIV virus with a functional titration method immedi-
ately on the cell line of interest [5,52]. However, if fixed
transduction or infection levels are not necessary, a more rapid
estimation of physical particle content, with for instance the SG-
Figure 5. SG-PERT assay on ABI 7300 Real-Time PCR System. (A) Amplification curves of indicated amount of replication competent HIV-1
(NL4-3 strain) (ng p24/mL) obtained by SG-PERT on the ABI 7300 instrument. The horizontal line represents the threshold line used to calculate Cq
values. (B) Correlation between input levels of replication-competent HIV-1 virus and Cq values obtained by SG-PERT on the ABI 7300 instrument. p24
antigen concentration in the undiluted samples (value ‘‘0’’ on x-axis) was 3,100 ng/mL.
doi:10.1371/journal.pone.0050859.g005
Quantification of Reverse Transcriptase Activity
PLOS ONE | www.plosone.org 10 December 2012 | Volume 7 | Issue 12 | e5085980
PERT assay, is often sufficient to assess quality control of the viral
production or to normalize the number of viral particles before
transduction or infection. It should be noted that the actual
number of RT-containing viral particles might be different from
the ones estimated in Table 1, since the RT activity per virion
might be dependent on both the origin of the HIV RT packed in
the viral particles as well as the source of the recombinant RT used
for quantification in the SG-PERT assay. In addition, we cannot
exclude that some of the RT activity is not bound to a viral
particle. Nevertheless, these results indicate that, similar to the p24
antigen concentration, the virion associated RT activity most likely
provides an estimate of the physical particle content in lentiviral
supernatant, which strongly correlates with the functional particle
content for both replication-incompetent lentiviral vectors and
replication-competent HIV-1 virus.
Correlation between RT activity and infectious units of
replication competent HIV-1 virus has been investigated by others
in the past [39,40,53,54]. Although one study found RT activity to
be a poor predictor of virion infectivity [54], most of them
observed a correlation between infectivity and the RT activity
measured in the supernatant by conventional non-PERT RT
assays [39,40,53]. It has to be noted that these studies were done
on primary HIV isolates and the presence of correlation appeared
to be dependent on whether or not viruses were grouped
according to coreceptor usage or subtype [39,40]. Since our study
evaluated different productions of the same HIV-1 strain (NL4-3),
a correlation between RT activity and relative levels of infectious
units is in agreement with these studies and indicates that the SG-
PERT assay is a fast and worthy alternative for non-PERT RT
assays in these types of studies. In contrast to RT activity, p24
antigen levels show a poor correlation with levels of infectious HIV
units in most studies [39,40,53,54]. In this regard, it has been
reported that RT activity might present an intermediate of
physical and functional particle concentration. This was based on
the observation that the levels of RT activity and infectious units in
HIV-1 infected cell cultures over time show a rapid decrease after
reaching peak levels, while p24 antigen levels further accumulate
and subsequently reach a plateau phase. These authors therefore
assume a short half life of RT activity, while p24 proteins are still
detected upon decay of infectious particles [39,40]. In the present
study, p24-RT activity correlation was evaluated in supernatant
collected from transfected 293T or 293TN cells at 2 or 3 days post
transfection. Since the levels of transducing units in these
preparations also correlated with p24 levels (data not shown),
viral particle decay is probably still limited at this time-point [5].
However, when monitoring lentiviral replication levels over
prolonged periods of time, assessment of RT activity levels might
provide a more accurate result compared to p24 antigen levels.
Implementation of the SG-PERT assay in our laboratory was
found to be easy. A lab equipped for qPCR assays only needs to
acquire the MS2 RNA template, MS2 specific primers, and a small
amount of the recombinant RT of interest. The Triton X-100
based lysis buffer can be prepared from routine chemical
ingredients and a standard curve can be established from any
high-titer retroviral preparation of choice. We calculated that the
current reagents cost of the SG-PERT assay using the Light-
CyclerH 480 and associated reaction mix is about 10 times lower
per retroviral quantification compared to determination of p24
antigen levels with a commercial ELISA kit. Moreover, since the
limited linear range of quantification of the ELISA assay often
requires the measurement of 3 different dilutions per sample, cost
and labor increase even more. Furthermore, while titer quantifi-
cation of 30 samples by ELISA can take up to six hours of hands-
on labor time, the SG-PERT assay requires less than 2 hours
hands-on time and is amenable to automation and further
reduction in reaction volumes.
In summary, this paper shows that the SG-PERT assay with
commercially available MS2 RNA and qPCR reaction mixes is
a robust and accurate method for retroviral quantification. Titer
determination by this assay correlates well with those of other
frequently applied methods. Combined with its low cost, fast
procedure and easy implementation, it is an attractive alternative
for use in virology and molecular biology research.
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Summary: 
Viral replication products are recognized by different cellular pattern recognition receptors. 
During HIV infection, viral sensing and subsequent type I interferon (IFN-I) production indeed 
occurs in specific cell types and infection conditions, however it was considered to be 
virtually absent in the main HIV target cells. Here, we show that activated CD4+ T cells sense 
HIV through the cytosolic DNA sensor cGAS and this induces a bioactive IFN-I response. 
Surprisingly, efficient induction of IFN-I by HIV-1 requires proviral integration of the virus and 
is subject to regulation by newly expressed viral proteins: Vpr potentiates, while Vpu 
represses IFN-I induction. Notably, Vpr also amplified innate sensing of HIV-1 in Vpx treated 
dendritic cells. These results identify cGAS as an immune sensor of HIV-1 in CD4+ T cells 
and demonstrate that the IFN-I response is modulated by the viral accessory proteins Vpr 
and Vpu. 
 
Introduction 
Type I interferons (IFN-I) are key players in the innate immune response against viral 
pathogens. They comprise a group of heterogeneous cytokines, including IFN-β and different 
subtypes of IFN-α. IFN-I production is induced through recognition of specific viral replication 
products by a multitude of pattern recognition receptors. IFN-I proteins mediate their powerful 
antiviral effects by binding to an interferon receptor and activating transcription of a large 
number of immunomodulatory and antiviral interferon-stimulated genes (ISGs) (reviewed in 
Goubau et al., 2013). Over the last years, different ISGs with profound activity against HIV, 
such as APOBEC3G, TRIM5α, BST2/tetherin and SAMHD1, have been identified (reviewed 
in Harris et al., 2012).  
The induction of IFN-I in response to HIV infection itself has become a subject of great 
interest. In HIV-infected patients, serum levels of IFN-I are strongly elevated during acute 
infection (Stacey et al., 2009) and higher levels of IFN-I protein and activity are detected in 
chronic infections (Hyrcza et al., 2007; Hardy et al., 2013). Although IFN-I responses initially 
limit viral spread, prolonged exposure to IFN-I in the chronic phase of HIV/SIV infection is 
associated with desensitization and detrimental hyper-immune activation and can therefore 
paradoxically contribute to disease progression (Sivro et al., 2014). During SIVmac infection 
this was clearly illustrated, since both the in vivo blockage of IFN-I receptors as well as 
prolonged treatment with IFN-I accelerated the progression to AIDS in rhesus macaques, 
characterized by reduced sensitivity to IFN-I and enhanced cell-associated viral load and 
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CD4+ T-cell depletion (Sandler et al., 2014). Furthermore, sustained IFN-1 activity in the 
chronic phase of infection is only detected in pathogenic models of SIV infection, while a 
complete down-regulation is observed after acute infection in non-pathogenic models 
(Bosinger et al., 2009; Harris et al., 2010). Accordingly, modulation of IFN-I responses might 
have therapeutic potential.  
Plasmacytoid dendritic cells (pDCs) are known to produce high levels of IFN-I in response to 
HIV (Fonteneau et al., 2004; Lepelley et al., 2011 ). During acute infection, they are most 
likely the main source of IFN-I (Kader et al., 2013; Li et al., 2014). However, levels of 
circulating pDCs as well as their capacity to produce IFN-I decreases during progressive 
infection, suggesting that other cell types contribute to IFN-I levels, particularly during the 
chronic phase of HIV infection (Soumelis et al., 2001; Tilton et al., 2008; Nascimbeni et al., 
2009). Yet in the main HIV target cells, IFN-I induction during HIV infection is generally 
thought to be modest (Rasaiyaah et al., 2013; Yan et al., 2010), suggesting a lack of sensing 
or evasion by the virus. Therefore, we investigated whether sensing does occur in HIV-
infected activated CD4+ T cells, which sensor is involved and how sensing is regulated by the 
virus. 
We show that HIV infection induces a bioactive IFN-I response in its main target, activated 
CD4+ T cells. Interestingly, IFN-I induction was dependent on integration of the virus, 
indicating that productive infection is required for the sensing to occur. We identified the 
cytosolic receptor cGAS as an HIV sensor inducing IFN-I in infected CD4+ T cells. 
Furthermore, we found that the HIV-1 Vpr protein potentiates the IFN-I response, in both 
CD4+ T cells and dendritic cells. Conversely, the HIV-1 Vpu protein suppresses IFN-I 
induction, independently of its ability to downregulate the innate sensor tetherin. These 
findings indicate that cGAS sensing of HIV reverse transcription products is enabled through 
the assistance of newly expressed viral replication products with a pivotal role for the Vpr 
protein and that HIV evolved counteraction of innate sensing by Vpu. 
 
Results 
HIV induces an IFN-I response in activated primary CD4+ T cells 
In order to determine if HIV replication induces IFN-I responses in CD4+ T cells, PHA/IL-2 
activated primary cells were infected with the HIV-1 NL4-3 strain and expression of IFN-I and 
different ISGs was evaluated (Figure S1A). A clear induction of IFN-α and IFN-β mRNA 
(Figure 1A) as well as secretion of bioactive IFN-I protein (Figure 1B) was observed in the  
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Figure 1. HIV induces an IFN-I response in primary CD4+ T cells.  
(A). Fold change in IFN-α and IFN-β mRNA levels in HIV NL4-3-GFP-I infected (black bars) primary 
CD4+ T cells, at 2, 4 or 6 days after infection, relative to non-infected (grey bars) cells at day 2 (n=8).  
(B) IFN-I protein activity in supernatant of cells in described in (A).  
(C) Fold change in IFIT1 mRNA levels in cells in described in (A). 
(D) Flow cytometric analysis of non-treated, IFN-α treated (1000 IU/mL, IFNα1b) or HIV NL4-3 infected 
primary CD4+ T cells after intracellular staining for MxA, 3 days after infection or treatment. Histograms 
show expression of MxA in a representative of 4 experiments.  
(E) Infection levels and IFN-I response in primary CD4+ T cells infected with T cell-line grown HIV-1 
and HIV-2 primary isolates (n=6). (Left) Percentage of infected cells at different time points, measured 
by intracellular p24 staining (HIV-1) or by surface CD4 staining (HIV-2); (middle) fold change in IFIT1 
mRNA levels 5 days after infection relative to non-infected cells; (right) IFN-I protein activity measured 
in supernatant of cells described above.  
Graphs in (A-C), (E) represent mean (± SEM). * p<0.05; ** p<0.01; *** p<0.001 (Wilcoxon matched 
pairs test). See also Figure S1. 
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HIV infected cultures. CD4+ T cells purified by standard methods contain very few remaining 
plasmacytoid dendritic cells (pDCs) (Figure S1B). In all experiments, additional depletion of 
pDCs was furthermore performed prior to infection (typically ≤1 pDC per well of 250,000 
cells), excluding them as the source of IFN-I. The levels of HIV-induced IFN-I varied in CD4+ 
T cells derived from different donors, but usually progressed simultaneously with the level of 
HIV infection in the culture (Figure S1C). Similarly, IFN-I induction correlated with the amount 
of spreading infection when different initial inocula of HIV were used (Figure S1D). In addition 
to IFN-I, multiple ISGs were induced in the HIV infected CD4+ T cell cultures, including IFIT1 
mRNA (Figure 1C, Figure S1D) and intracellular MxA (MX1) protein. The induction of the 
latter by HIV was comparable to the one obtained after treatment of cells with recombinant 
IFN-α (IFNα1b, 1000 IU/mL) (Figure 1D). Altogether, these results demonstrate that HIV is 
capable of inducing a bioactive IFN-I response in primary CD4+ T cells.  
In order to ascertain that IFN-I induction by HIV was not restricted to the HIV-1 NL4-3 strain, 
CD4+ T cells were infected with three different T-cell line expanded HIV-1 and HIV-2 primary 
isolates. Both HIV-1 group M as well as the HIV-2 isolate clearly induced IFIT1 and bioactive 
IFN-I during infection, indicating that different HIV strains efficiently trigger an IFN-I response 
in primary CD4+ T cells (Figure 1E).  
HIV-induced IFN-I affects HIV-1 replication levels 
Type I IFNs are known to block both early and late stages of the HIV life cycle, at least in part 
by inducing cell-intrinsic antiviral restriction factors (reviewed in Boasso, 2013). To determine 
if the IFN-I induced by HIV in CD4+ T cells suppresses HIV replication, neutralizing 
antibodies against IFN-α and/or IFN-β were added to T cell cultures during HIV infection. 
Addition of both types of antibodies largely decreased induction of the ISG IFIT1 by HIV 
(Figure 2A). When added separately, the IFN-α and –β antibodies each enhanced HIV 
replication to a similar extent. Combining both antibodies had a more potent effect (Figure 
2B). This indicates that both IFN-α and –β contribute to the antiviral effect of IFN-I induced by 
HIV in CD4+ T cells. On average, we observed a 1.6 fold increase in the number of HIV 
infected cells by IFN-α and –β blockage (Figure 2B). This effect is rather modest, consistent 
with previous reports describing a partial resistance of HIV-1 to IFN-I in culture (Vendrame et 
al., 2009, Cordeil et al., 2013). 
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Figure 2. HIV-induced IFN-I suppresses HIV replication.  
Primary CD4+ T cells were infected with HIV NL4-3-GFP-I in presence or absence of neutralizing 
antibodies (Ab) against IFN-α and IFN-β as indicated. 
(A) Fold change in IFIT1 mRNA levels at different time points after infection relative to non-infected 
non-treated cells at day 2 (n= 7 or 8).  
(B) (Left) Percentage of infected cells (GFP+) at different time points in a representative experiment; 
(right) fold change in percentage of infected cells at peak of infection relative to infection in absence of 
antibodies (n=7). 
Graphs in (A) and (B) (left) represent mean ± SEM. * p<0.05, ** p<0.01 ((A) Wilcoxon matched pairs 
test; (B) (left) Kruskal-Wallis ANOVA followed by Dunn's multiple comparisons post hoc test, treated 
compared to untreated control).  
 
HIV proviral integration is required for IFN-I induction in primary CD4+ T cells.  
To determine which steps of the HIV-1 replication cycle are required for IFN-I induction in 
CD4+ T cells, cells were infected with HIV NL4-3 in the presence of reverse transcriptase 
(nevirapine) or integrase inhibitors (raltegravir). Induction of an IFN-I response was 
compared to the levels obtained in the presence of a protease inhibitor (ritonavir), in order to 
limit replication to a single cycle of infection. Inhibition of reverse transcription blocked IFN-I 
and IFIT1 mRNA induction by HIV, while a small induction was observed in presence of the 
integrase inhibitor. However, induction was clearly enhanced when integration was allowed 
(Figure 3A and Figure S2A). The importance of viral integration for IFN-I induction was 
further confirmed with an HIV NL4-3 virus containing a point mutation that inactivates 
integrase (HIV D116N) (Engelman et al., 1995). This virus failed to trigger IFN-I and IFIT1 
mRNA induction (Figure 3B and Figure S2B). Since the number of remaining p24-expressing 
cells was much lower during infection with HIV D116N compared to infection in the presence 
of raltegravir (Figure S2B and S2A), remaining levels of integration might account for the 
small IFN-I induction by HIV observed with raltegravir (Figure 3A). Similar to the integrase-
deficient virus, a tat-mutated virus did not induce significant levels of IFN-I and IFIT1 mRNA 
during single cycle infection of CD4+ T cells (Figure 3C and Figure S2C), indicating that Tat-
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dependent expression of viral genes, rather than the integration process itself, triggers IFN-I 
induction. Together, these results indicate that induction of an IFN-I response by HIV-1 in 
primary CD4+ T cells is dependent on integration and subsequent expression of the proviral 
genome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Type I IFN induction in primary CD4+ T cells requires HIV integration.  
Fold change in IFN-β mRNA levels relative to non-infected cells in primary CD4+ T cells infected with:  
(A) HIV NL4-3 in presence of a reverse transcription inhibitor (nevirapine, nevi), integration inhibitor 
(raltegravir, ralt) or protease inhibitor (ritonavir, rito) 48 h after infection (n=8);  
(B) HIV NL4-3 wild-type (HIV WT) or D116N integrase mutant (HIV D116N) 24 h after infection (n=8);  
(C) HIV NL4-3-HSA-I wild-type (HIV WT) or tat-mutated virus (HIV TatStop) in the presence of ritonavir 
48h after infection (n=7). 
Graphs represent mean ± SEM.” ns” not significant, **p<0.01; ***p<0.001 (Friedman test followed by 
Dunn's multiple comparisons post hoc test, infected compared to non-infected control).  
See also Figure S2. 
 
IFN-I induction by HIV in primary CD4+ T cells is mediated through the cGAS pathway 
Next, we aimed to identify host innate sensing pathways that are triggered by HIV-1 in CD4+ 
T cells, using shRNA-mediated knock-down of different IFN pathway genes. Initial screening 
experiments with shRNA-encoding lentiviral vectors indicated a role for the DNA-sensing 
cGAS receptor in IFN-I induction by HIV-1 (data not shown). We therefore performed knock-
down of the known cGAS pathway members (reviewed in Cai et al., 2014) (MD21D1/cGAS, 
TMEM173/STING, TBK1 and IRF3) in primary CD4+ T cells and measured the effect on IFN-
β expression upon HIV infection. Transduction with shRNA-encoding lentiviral vectors 
decreased expression of all target genes (Figure S3A). The transduced primary CD4+ T cells 
were subsequently infected by co-culturing them with HIV-1 infected MT4 T cells, which 
allows for efficient infection of primary cells within 24 hours (Figure 4A). This system was 
chosen to avoid the use of long-term cultures of HIV-infected lentivirally transduced primary 
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CD4+ T cells, in which the effect of knock-down of any IFN pathway gene on IFN-I induction 
was difficult to establish. IFN-β induction was neither detected in HIV infected MT4 cells 
cultured alone, nor in co-cultures of non-infected MT4 cells with primary CD4+ T cells (Figure 
S3B). It was however clearly induced in infected co-cultures verifying that HIV-infected 
primary CD4+ T cells are the source of IFN-I in this system. Knock-down of cGAS in the 
primary CD4+ T cells highly decreased IFN-β induction (Figure 4B). This was further 
confirmed with two independent shRNA sequences targeting cGAS (Figure S3C). A similar 
effect on type-1 IFN response was observed after knock-down of the downstream signaling 
molecules in the cGAS pathway: STING, TBK1 and IRF3 (Figure 4B). Together, these 
results indicate that the cGAS pathway is triggered during HIV-1 infection of primary CD4+ T 
cells, resulting in induction of IFN-I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. cGAS and downstream signaling molecules are required for IFN-I induction by HIV in 
primary CD4+ T cells. 
(A) Experimental set-up to measure host protein involvement in IFN-I induction by HIV-1: primary 
CD4+ T cells are transduced with pLKO.1 shRNA-encoding vectors, activated with PHA/IL-2 and 
efficiently transduced cells are selected with puromycin. MT4 are in parallel infected with HIV NL4-3-
GFP-I virus cells. Both cell types are subsequently co-cultured and IFN-β mRNA levels are measured 
24 h after the start of co-culture.  
(B) Fold change in IFN-β mRNA levels in co-cultures of non-infected or HIV infected MT4 cells with 
primary CD4+ T cells transduced with vectors encoding shRNA targeting the indicated genes, with the 
shRNA control vector (CTRL) or non-transduced cells (NTD) (n=6).  
Graph represent mean ± SEM. **p<0.01 (Mann-Whitney test).  
See also Figure S3. 
 
IFN-I induction by HIV-1 is regulated by Vpu and Vpr  
The involvement of the cGAS, a DNA sensor, suggests that recognition of reverse 
transcribed HIV cDNA is driving the innate immune response to HIV-1 in CD4+ T cells. 
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Paradoxically, our previous results also indicated that IFN-I induction is dependent on 
integration and expression of the HIV provirus. We reasoned that newly expressed viral 
proteins might be required for cGAS-mediated IFN-I induction. In monocyte-derived dendritic 
cells (MDDCs), such a mechanism was recently demonstrated during HIV-1 infection in the 
presence of Vpx. Indeed, Manel et al. showed that sensing of HIV DNA by cGAS is 
prevented before integration by the HIV-1 capsid (CA), which might “shield” the viral DNA by 
forming complexes with the host factors cyclophilin A (CypA) (Lahaye et al., 2013; Manel et 
al., 2010) and/or CPSF6 (Rasaiyaah et al., 2013). The interaction of newly expressed HIV-1 
capsid (CA) with CypA was required for sensing by cGAS after integration (Lahaye et al., 
2013; Manel et al., 2010), and might function by relieving the “shielding”. We therefore 
evaluated the importance of this interaction for IFN-I induction in CD4+ T cells, by using the 
same panel of HIV-1 CA mutated viruses, complemented with a wild-type capsid protein 
during production, as described by these authors (Manel et al., 2010). Surprisingly, in T cells, 
viruses expressing capsid that is able (wild-type, T54A/N57A, Q63A/Q67A) or not (G89V) to 
interact with CypA induced a similar IFN-I response (Figure S4A). This indicates that IFN-I 
induction in primary CD4+ T cells does not require CypA interaction with the newly expressed 
capsid.  
We subsequently evaluated the role of two HIV-1 accessory proteins, Vpu and Vpr, in IFN-I 
induction by HIV in CD4+ T cells. These proteins were previously implicated in IFN-I 
induction, although both were found to counteract rather than enable the IFN-I response in 
some (Doehle et al., 2012a; Galao et al., 2012; Laguette et al., 2014) but not all (Zahoor et 
al., 2014) studies. 
We first evaluated the effect of Vpr on IFN-I response, by infecting CD4+ T cells with wild-
type (WT) or vpr-mutated HIV NL4-3 viruses. Surprisingly, vpr-mutated virus induced much 
lower levels of IFN-I and IFIT1, despite comparable infection rates (Figure 5A, Figure S4B). 
This indicates a potentiating rather than suppressing effect of Vpr on IFN-I induction by HIV 
in CD4+ T cells. A similar lower IFN-I induction was observed with viruses containing a single 
Q65R substitution in the vpr gene, which is known to disrupt binding of Vpr to DCAF1 
(DeHart et al., 2007). Viruses expressing the Vpr R77Q variant, associated with reduced pro-
apoptotic activity of Vpr (Lum et al., 2003), were able to induce a potent IFN-I response 
(Figure 5B, Figure S4C). Infection with vpr-mutated viruses that were complemented with a 
wild-type Vpr protein during production resulted in a similarly reduced IFN-I response (Figure 
5C, Figure S4D). This suggests that Vpr protein produced after integration of the virus, and 
not virion-incorporated Vpr is responsible for enhancing IFN-I induction. The potentiating 
effect of newly expressed Vpr could therefore explain why the IFN-I response occurs post-
integration. 
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Figure 5. Effect of Vpu and Vpr on IFN-I response in primary CD4+ T cells.  
IFN-I response relative to non-infected (non inf) cells in HIV infected primary CD4+ T cells.  
(A) IFN-β mRNA levels 48-72 h after infection with HIV NL4-3-HSA-I wild-type (WT) or vpr- mutated 
virus (dVpr) (n=7).  
(B) IFN-β mRNA levels 3 days after infection with HIV NL4-3 viruses: wild-type (WT), vpr- deleted 
(dVpr), viruses with Q65R or R77Q mutation in the vpr gene (n=4).  
(C) IFIT1 mRNA levels 48 h after infection with HIV NL4-3-HSA-I wild-type (WT) or vpr- mutated 
(dVpr) viruses, not complemented (-), complemented with a control vector (Ctrl) or Vpr (Vpr) during 
production. Infection was done in the presence of ritonavir (n=5). (D) IFN-β mRNA levels 48 h after 
infection with VSV-pseudotyped HIV NL4-3-I-EGFP wild-type (WT) or vpu-deleted (dVpu) virus (n=7).  
(E) IFN-α mRNA levels 48 h after infection with VSV-pseudotyped HIV NL4-3-Vpu-IRES-Env viruses 
in which the original vpu allele was replaced by the vpu allele of the indicated HIV or SIV strain. Black 
bars show viruses with mutated NL4-3 vpu alleles, blue bars show viruses with vpu alleles that have 
antagonizing activity against human tetherin, red bars show viruses with vpu alleles that do not have 
antagonizing activity against human tetherin (n=4).  
(F) IFN-β mRNA levels 48 h after infection with VSV-pseudotyped HIV NL4-3-I-EGFP wild-type (WT), 
vpu-deleted (dVpu), vpr-deleted (dVpr) or vpu- and vpr-deleted (dVpu dVpr) viruses (n=4).  
Graphs represent mean ± SEM. *p<0.05 (Wilcoxon matched pairs test).  
See also Figure S4. 
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We confirmed the suppressing effect of the Vpu protein: vpu-deleted HIV NL4-3 viruses 
induced a larger IFN-I response compared to WT viruses in primary CD4+ T cells (Figure 5D, 
Figure S4E). The mechanism behind Vpu’s effect on IFN-I induction is currently unclear, but 
might be related to its ability to inhibit NF-ĸB activation (Galao et al., 2012; Hotter et al., 
2013; Wang et al., 2010), which in turn might (Galao et al., 2012) or might not (Bour et al., 
2001; Pickering et al., 2014) be dependent on counteraction of the restriction factor and 
innate sensor tetherin by Vpu. To asses if Vpu’s ability to downregulate tetherin is required to 
suppress the HIV-induced IFN-I response in primary CD4+ T cells, we infected cells with HIV 
NL4-3 viruses containing vpu alleles with varying abilities to antagonize tetherin. While Vpu 
proteins from HIV-1 M viruses were previously shown to efficiently counteract tetherin, Vpu’s 
from HIV-1 group O and SIVcpz viruses have no activity against human tetherin (Sauter et 
al., 2009). Interestingly, all these viruses induced a comparable IFN-I response that was 
lower than the one induced by Vpu-defective HIV NL4-3 viruses (Figure 5E, Figure S4F). 
This indicates that Vpu can dampen the IFN-I response induced by HIV in CD4+ T cells, 
independent of its ability to antagonize tetherin. On the other hand, an HIV NL4-3 construct 
containing a mutation in the β-TrCP binding motif of Vpu (S52A) lost the ability to suppress 
the HIV-induced IFN-I response (Figure 5E, Figure S4F). 
To simultaneously evaluate the effect of Vpu and Vpr on IFN-I induction during HIV infection, 
CD4+ T cells were infected with matched HIV NL4-3 viruses carrying a deletion in vpr, vpu or 
both genes. The vpr-vpu-deficient virus induced an intermediate IFN-I response, usually 
larger than the one generated by a vpr-mutated virus, but smaller than the one obtained in 
absence of Vpu alone (Figure 5F, Figure S4G). This indicates that both proteins can exert 
their effect on IFN-I induction independently from each other.  
Given the unexpected potentiating effect of Vpr on IFN-I production in activated CD4+ T cells, 
we determined if Vpr plays a similar role in other immune cells. Myeloid dendritic cells are 
generally largely resistant to productive HIV-1 infection due to restriction by SAMHD1 
(Hrecka et al., 2011; Laguette et al., 2011). However, the addition of Viral-like Particles (VLP) 
carrying Vpx allows HIV-1 infection and promotes cGAS dependent IFN-I release (Lahaye et 
al., 2013; Manel et al., 2010). As we previously reported that HIV-infected T cells are much 
more potent inducers of IFN-I in MDDCs compared to cell-free virions (Puigdomenech et al., 
2013), we measured bioactive IFN-I levels in co-cultures of Vpx-treated MDDCs and MT4 
cells, infected with either HIV NL4-3 vpr-deficient or WT viruses (Figure 6A). MDDCs became 
productively infected and similar levels of Gag+ cells were observed with WT or vpr-mutated 
viruses (Figure 6B). HIV-1 infection of MDDCs was associated with IFN-I release in the 
supernatants. Interestingly, IFN-I production was strongly reduced in the absence of Vpr 
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(Figure 6C). These results show that Vpr potentiates IFN-1 production both in activated CD4+ 
T cells and in dendritic cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Vpr potentiates HIV-1 induced IFN-I production in dendritic cells. 
(A) Experimental outline: MDDCs were pre-treated with Vpx VLPs to allow productive infection. 
MT4C5 cells were infected with HIV NL4-3 wild-type (WT) or vpr-deleted (dVpr) viruses and 
subsequently co-cultured with MDDCs. After 72 h, supernatant was harvested for quantification of IFN-
1 and infection was monitored by intracellular p24 staining. 
(B) Percentage of HIV-1 infected MDDCs (p24+). 
(C) IFN-I activity in supernatants of co-cultures. 
Graphs show data and mean of experiments in cells from 11 independent donors. ***p<0.001 
(Wilcoxon matched pairs test). 
 
Discussion 
We show that activated CD4+ T cells are able to sense HIV replication products and produce 
IFN-I through a post-integration mechanism that requires the cGAS receptor and its 
downstream signaling pathway. Furthermore, we found that this response is subject to both 
potentiation by Vpr and counteraction by Vpu. These findings are important, since part of the 
IFN-I released during the chronic phase of HIV infection is thus likely to originate from 
infected CD4+ T cells and may contribute to the detrimental high levels of immune activation 
that drive progression to AIDS. One can speculate that the incomplete repression by Vpu or 
the inherent property of Vpr to enable sensing, is the result of an evolutionary drive on the 
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virus to orchestrate innate immune responses to its benefit, e.g. by stimulating the 
recruitment or activation of potential target cells or by impeding antiviral T-cell responses 
(Boasso et al., 2008; Gonzalez-Navajas et al., 2012; Hardy et al., 2013), thereby ultimately 
enhancing viral replication and thus transmission rates. 
Triggering of an innate immune response during wild-type HIV-1 infection of non-manipulated 
primary cells has so far been observed in pDCs and aberrantly infected resting CD4+ T cells 
(Fonteneau et al., 2004, Doitsh et al., 2010). Except for two studies showing induction of 
ISGs (Nasr et al., 2012) or IFN-I protein (Imbeault et al., 2009), IFN-I production was not 
observed after HIV-1 infection of activated CD4+ T cells (Doehle et al., 2012a; Doehle et al., 
2009; Goldfeld et al., 1991; Yan et al., 2010). We noticed that detection of IFN-I was highly 
enhanced when HIV infection levels were higher, e.g. after spreading replication. In addition, 
IFN-I induction was absent in MT4 cells (Figure 4B) and other T cell lines (data not shown). 
These are possible reasons why IFN-I induction by HIV in T cells might have been 
overlooked in the past. It was previously shown that degradation of HIV DNA by the host 
protein TREX1 prevents sensing in macrophages and CD4+ T cells (Yan et al., 2010). 
However, in line with our data, DNA synthesized by HIV-1 mutants is sensed despite the 
presence of TREX1 in macrophages (Rasaiyaah et al., 2013) and probably also in aberrantly 
HIV-1 infected resting CD4+ T cells (Monroe et al., 2014). It is possible that certain DNA 
products are not detected by TREX1 or that DNA is shielded from both TREX1 and cGAS 
prior to integration. 
We show that activated CD4+ T cells are able to sense HIV through cGAS and produce IFN-I 
during productive infection. Since cGAS is considered to be activated by binding of cytosolic 
DNA (Kranzusch et al., 2013; Sun et al., 2013), the innate immune response is most likely 
triggered by HIV reverse transcription products. Our results also show that this response is 
only activated after integration of the virus and expression of new viral proteins, since 
integrase- or tat-deficient viruses or viruses cultured with an integrase inhibitor induced 
insignificant or strongly reduced levels of IFN-I. This indicates that sensing of HIV DNA in the 
cytoplasm is enabled through the action of newly expressed HIV replication products and 
implies that the simultaneous presence of both an integrated virus as well as DNA reverse 
transcription products in the cell is required. The latter could originate from either 
simultaneous or previous abortive infection events. As such, sensing in vivo is most likely to 
occur at sites where high viral infection rates are reached. The frequency of multiple 
infections per cell is still a topic of debate, but has been detected especially in splenic tissues 
of patients (Gratton et al., 2000; Jung et al., 2002; Suspene and Meyerhans, 2012). 
Interestingly, a study evaluating the nature of IFN-α producing cells in spleens of HIV+ 
patients, found that most of these cells were B and T lymphocytes, not pDCs (Nascimbeni et 
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al., 2009). In such niches, cGAS-mediated post-integration sensing could be a driving 
mechanism for IFN-I production. 
Our data indicate that sensing of HIV DNA products is efficiently prevented prior to 
integration. Therefore, innate triggering in activated CD4+ T cells seems to differ from the one 
in lymphoid tissue-derived resting CD4+ T cells, in which incomplete HIV RT products 
accumulate due to abortive infection and HIV DNA is sensed by the IFI16 protein prior to 
integration (Doitsh et al., 2010; Monroe et al., 2014). In macrophages, it was suggested that 
HIV DNA is “shielded” by the host proteins CypA and/or CPSF6 (Rasaiyaah et al., 2013) and 
a similar mechanism might prevent sensing in activated CD4+ T cells prior to integration. 
However, our results indicate that recognition of HIV DNA products in the cytosol is enabled 
after integration in activated CD4+ T cells. As mentioned in the results, a comparable 
phenomenon has been described in MDDCs during Vpx complemented HIV-1 infection, in 
which interaction of newly expressed capsid with CypA might unmask cytosolic HIV DNA 
(Manel et al., 2010; Manel and Littman, 2011). However, in activated CD4+ T cells, such an 
effect of newly expressed capsid was not observed by us, since normal levels of IFN-I were 
induced by viruses expressing different mutated capsid proteins, including the CypA 
interaction mutant G89V. Rather, we show the HIV-1 Vpr protein to be required for full post-
integration IFN-I induction: vpr-deleted viruses induced lower levels of IFN-I and virion 
complementation experiments indicate that virion packaged Vpr is insufficient for IFN-I 
induction.  
Our evaluation of Vpr-mutated viruses revealed that the interaction of Vpr with DCAF1 is 
important for potentiating the IFN-I response. DCAF1 is used by Vpr to recruit the DDB1-
Cul4 E3 ubiquitin ligase complex. Although this complex is involved in different Vpr functions 
(Casey et al., 2010), the activation of the DNA damage response by Vpr is particularly 
interesting in this regard, because of the large overlap and interplay between cellular DNA 
damage response and innate immune response pathways (reviewed in Chatzinikolaou et al., 
2014). Vpr might for instance enhance NF-ĸB activation or production of IRFs (and thereby 
IFN-I induction) as a consequence of its effect on DNA damage proteins (Brzostek-Racine et 
al., 2011; Hinz et al., 2010; Roshal et al., 2003). Activation of NF-ĸB by Vpr has indeed been 
demonstrated by several groups (Liu et al., 2014; Roux et al., 2000). Alternatively, Vpr might 
modify cGAS sensing itself e.g. by its binding to CypA (Zander et al., 2003) or unintegrated 
HIV DNA (de Rocquigny et al., 2000). Correlation studies of Vpr’s ability to potentiate IFN-I 
induction and other known Vpr functions will be required to obtain further mechanistic 
insights. In contrast to the integrase-mutant, IFN-I induction by the vpr-deleted viruses was 
not completely blocked in the CD4+ T cells. Especially in cells infected with vpu-vpr- deleted 
viruses, IFN-I was readily detectable. Therefore, Vpr is most likely an important, but not the 
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sole viral factor triggering post-integration IFN-I induction. A similar IFN-I potentiating effect 
of Vpr was recently described in monocyte-derived macrophages (MDMs) (Zahoor et al., 
2014) and confirmed herein for HIV-1 infection of Vpx treated MDDCs. In contrast, other 
studies have suggested a suppressive role of Vpr in IFN-I production, either in non-Vpx-
treated MDDCs (Harman et al., 2011), in MDMs (Mashiba et al., 2014) or in non-immune cell 
lines, such as HEK293 or HeLa (Doehle et al., 2009; Laguette et al., 2014; Okumura et al., 
2008). However, the mechanism of IFN-I induction in these cells by (vpr-deleted) HIV is not 
clear and is unlikely to occur through cGAS-mediated post-integration sensing, as in CD4+ T 
cells and Vpx-treated MDDCs (Lahaye et al., 2013). Our data strongly indicate that in these 
cell types, cGAS-mediated IFN-I induction is enhanced rather than suppressed by Vpr. We 
speculate that potentiation of post-integration IFN-I induction by Vpr results from a Vpr-host 
interaction with other indispensable beneficial effects during the viral life cycle, e.g. NF-ĸB 
activation to enhance proviral expression or as a consequence of G2 arrest. While the innate 
immune responses resulting from this post-integration Vpr interaction might on one hand 
enhance recruitment and activation of surrounding HIV target cells, high levels of IFN-I are 
likely to be avoided by virus. As such the virus might have employed another late HIV-1 
protein, Vpu, to partially counteract the Vpr effect and keep IFN-1 levels in check. 
In line with previous reports (Doehle et al., 2012a; Galao et al., 2012), we observed a higher 
IFN-I induction in CD4+ T cells by viruses lacking Vpu. This Vpu effect was previously 
attributed to either degradation of IRF3 (Doehle et al., 2012b) or tetherin counteraction, 
thereby preventing tetherin-mediated NF-ĸB activation (Galao et al., 2012). However, Vpu-
mediated IRF3 degradation was not observed by us and others (Galao et al., 2012; Hotter et 
al., 2013). Furthermore, the loss of IFN-I induction we observed after IRF3 knock-down, 
indicates that IRF3 is activated by HIV despite the presence of Vpu. In our experiments, IFN-
I induction was suppressed to an equal extent by viruses with and without tetherin-
antagonizing ability, indicating that targeting of tetherin and suppressing IFN-I are two 
separate functions of Vpu. However, a virus with a mutation in the β-TcrP binding domain 
(S52A) of Vpu failed to counteract IFN-I induction in CD4+ T cells. It was previously 
suggested in cell lines that sequestration of β-TcrP by Vpu could inhibit down-stream NF-ĸB 
activation (Besnard-Guerin et al., 2004; Bour et al., 2001). cGAS-mediated activation of 
STING is known to induce activation of NF-ĸB (Kato et al., 2013) and silencing of NF-ĸBp65 
was previously shown to partially decrease IFN-β production in response to dsDNA (Abe and 
Barber, 2014). Therefore, Vpu might dampen IFN-I induction in primary CD4+ T cells by 
interfering with cGAS-mediated NF-ĸB activation.  
Our work provides insight in the virus-host interplay that regulates HIV-1 sensing in its main 
target cells. Contribution of HIV infected CD4+ T cells to IFN-I levels in the chronic phase of 
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infection and as such to the natural disease course, might provide the basis for novel 
therapeutic strategies. 
 
Experimental Procedures 
Viral constructs, experimental outline and applied methods are indicated in figure legends 
and explained in detail in Extended Experimental Procedures.  
Quantification of IFN-I responses: IFN-α, IFN-β and IFIT1 mRNA levels were measured by 
qPCR using specific primers as listed in Table S1; IFN-I biological activity was measured in 
supernatant by HL-116-luciferase reporter cells; MxA protein levels were quantified by 
intracellular staining and flow cytometry. 
HIV viral constructs and infection: HIV NL4-3 derived constructs are listed in Table S2. 
Viruses were produced in 293T cells using standard methods, complemented if indicated by 
co-transfection with Gag- or Vpr-expressing plasmids. HIV-1 and HIV-2 isolates were 
propagated on peripheral blood mononuclear cells (PBMCs) and Jurkat CD4 CCR5 cells. 
Primary CD4+ T cells, obtained from blood of healthy donors, underwent extra pDC depletion 
and were infected with HIV by spinoculation. Antiretrovirals or IFN neutralizing antibodies 
were added prior or immediately after spinoculation respectively and maintained during 
culture. Monocytes were isolated from PBMCs and differentiated in presence of IL-4 and 
GM-CSF. MDDCs were treated with VLPs carrying Vpx and infected with HIV-1 through co-
culture with MT4C5 cells. 
Knock-down of host genes and co-culture with HIV-1 infected cells: origin and 
properties of pLKO.1-puro shRNA-encoding lentiviral construct are listed in Table S3. 
Lentiviruses were produced in 293T cells using MissionTM Lentiviral Packaging Mix. Primary 
CD4+ T cells were transduced using polybrene, stimulated with PHA/IL-2, selected with 
puromycin and co-cultured with HIV infected MT4 cells. 
Statistical analysis: Statistical tests were performed with GraphPad Prism 5.0 as indicated 
in the figure legends. 
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Characterization of IFN-I response during HIV infection primary CD4+ T cells.  
Related to Figure 1. 
(A) Experimental scheme to measure type 1 IFN response: PHA/IL-2 activated, pDC depleted primary 
CD4+ T cells are infected with HIV. IFN response is quantified by isolation of mRNA from the cells to 
measure IFN-α, IFN-β and IFN-stimulated gene (ISGs) expression by qPCR, by intracellular staining 
of the cells for MxA protein and by measuring IFN-I activity in the supernatant of the cells with the HL-
116 assay.  
(B) (Right) Fold change in IFN-β mRNA levels relative to non-infected cells and (middle) IFN-I 
biological activity for purified CD4+ T cells with or without additional pDC depletion at peak levels of 
HIV NL4-3-GFP-I or HIV NL4-3-HSA-I infection (4 or 6 days after infection) (n=6); (left) dot-plots of 
flow cytometric data showing expression of pDC markers (CD123-FITC versus CD303-APC) in 
PBMCs and purified CD4+ T cell populations with or without additional pDC depletion, immediately 
after isolation of cells in a representative experiment. Red dots represent cells gated on viable 
(propidium iodide-negative) cells, blue represents cells with additional gating on CD304+CD123+ cells. 
Numbers indicate the percentage of CD304+CD123+CD303+ cells among viable cells. Graph shows 
average number of CD304+CD123+CD303+ cells per 250,000 cells detected as described above 
(n=6). Purified CD4+ T cells populations typically contained around 20 pDC’s per culture of 250,000 
cells, while CD4+ T cells with additional pDC depletion contained ≤ 1 pDC per culture. 
(C) (Left) Fold change in IFN-β mRNA levels relative to non-infected cells, 4 days after HIV NL4-3-
GFP-I or HIV NL4-3-HSA-I infection of primary CD4+ T cells derived from 14 different donors; (right) 
percentage of HIV infected cells (left y-axis) and fold change in IFN-β mRNA levels relative to non-
infected cells (right y-axis) at different time points after infection in cells of two of these donors.  
(D) Infection levels and IFN-I response in primary CD4+ T cells infected with indicated amounts of HIV 
NL4-3 virus (n=3). (Left) Percentage of infected cells at different time points after infection, measured 
by intracellular p24 staining; (middle) IFN-I protein activity in supernatant of cells; (right) fold change in 
IFIT1 mRNA levels at different time points after infection, relative to non-infected cells at day 3.  
Graphs in (B), (E) represent mean ± SEM. *p<0.05 (Wilcoxon matched pairs test) 
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Figure S2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Requirement of HIV-1 integration and Tat-mediated viral gene expression for IFN-I induction in 
primary CD4+ T cells.  
Related to Figure 3. 
(Left) Fold change in IFN-α and IFIT1 mRNA relative to non-infected (non inf) cells; (right) dot-plots of 
flow cytometric data showing side scatter (SSC) versus p24-PE (A, B) or HSA-APC (C) fluorescent 
intensity levels in primary CD4+ T cells infected with:  
(A) HIV NL4-3 in presence of a reverse transcription inhibitor (nevirapine, nevi), integration inhibitor 
(raltegravir, ralt) or protease inhibitor (ritonavir, rito) 48 h after infection (n=8). 
(B) HIV NL4-3 wild-type (HIV WT) or D116N integrase mutant (HIV D116N) 24 h after infection (n=8).  
(C) HIV NL4-3-HSA-I wild-type (HIV WT) or Tat mutated virus (HIV TatStop) in the presence of 
ritonavir 48 h after infection (n=7). 
Graphs represent mean ± SEM.” ns” not significant, **p<0.01; ***p<0.001 (Friedman test followed by 
Dunn's multiple comparisons post hoc test, infected compared to non-infected control). 
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Figure S3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cGAS is required for IFN-I induction by HIV in primary CD4+ T cells.  
Related to Figure 4. 
(A) Percentage of remaining mRNA of the indicated genes in primary CD4+ T cells transduced with 
shRNA encoding pLKO.1 vectors targeting the indicated genes, relative to levels in cells transduced 
with a non-targeting shRNA control vector (100%) immediately prior to co-culture (n=2-4).  
(B) Fold change in IFN-β mRNA levels in cultures of non-infected primary CD4+ T cells transduced 
with the scrambled shRNA control vector (CD4+ T) (n=4), non-infected MT4 cells (MT4 NI), HIV NL4-3-
GFP-I infected MT4 cells (MT4 HIV-1) (n=3) or co-cultures of these cells (n=4), relative to levels in co-
cultures with non-infected MT4 cells.  
(C) (left) Fold change in IFN-β mRNA levels in co-cultures of non-infected (NI) or HIV NL4-3-GFP-I 
infected MT4 cells with primary CD4+ T cells transduced with shRNA targeting cGAS (#2 and #3 
represent use of different shRNA sequences) or the shRNA control vector (CTRL), relative to levels 
obtained in co-cultures of CTRL cells and HIV-infected MT4 cells (n=2); (right) percentage of 
remaining cGAS mRNA in primary CD4+ T cells described above immediately prior to co-culture, 
relative to levels in cells transduced with a non-targeting shRNA control vector (CTRL) (100 %) (n=2).  
Graphs in represent mean ± SEM. 
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Figure S4 
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Effect of HIV-1 Capsid-CypA interaction, Vpu and Vpr on HIV-induced IFN-I response in primary 
CD4+ T cells.  
Related to Figure 5. 
Infection levels and IFN-1 response in primary CD4+ T cells, relative to non-infected (non inf) cells.  
(A) Infection with VSV-pseudotyped HIV-1 LAI dEnv dNef viruses (WT) or with viruses with additional 
mutations in capsid (G89V, T54A/N57A,Q63A/Q67A), 48 h after infection (n=2). All viruses were 
complemented with wild-type capsid during production. (Left to right) Fold change in IFN-α, IFN-β or 
IFIT1, mRNA levels; percentage of infected cells (GFP+).  
(B) Infection with HIV NL4-3-HSA-I wild-type (WT) or vpr-mutated virus (dVpr), 48-72 h after infection 
(n=7). (Left and middle) fold change in IFN-α and IFIT1 mRNA levels; (right) percentage of infected 
(HSA+) cells.  
(C) Infection with HIV NL4-3 viruses: wild-type (WT), vpr-deleted (dVpr), viruses with Q65R or R77Q 
mutation in the vpr gene, 72 h after infection (n=4). (Left and middle) Fold change in IFN-α and IFIT1 
mRNA; (right) percentage of infected (p24+) cells.  
(D) Infection with HIV NL4-3-HSA-I vpr-mutated (dVpr) or wild-type (WT) virus, not complemented (-), 
complemented with a control vector (Ctrl) or with Vpr (Vpr) during production. Infection was done in 
the presence of ritonavir (n=5). Fold change in IFN-β mRNA levels 48 h after infection.  
(E) Infection with VSV-pseudotyped HIV NL4-3-I-EGFP vpu-deleted (dVpu) or wild-type (WT) virus, 48 
h after infection (n=7). (Left and middle) fold change in IFN-α and IFIT1 mRNA levels; (right) 
percentage of infected (GFP+) cells.  
(F) Infection with VSV-pseudotyped HIV-NL4-3-Vpu-IRES-Env viruses in which the original vpu allele 
was replaced by the vpu allele of the indicated HIV or SIV strain. Black bars show viruses with 
mutated NL4-3 vpu alleles, blue bars show viruses with vpu alleles that have antagonizing activity 
against human tetherin, red bars show viruses with vpu alleles that do not have antagonizing activity 
against human tetherin, 48 h after infection (n=4). (Left and middle) fold change in IFIT1 and IFN-β 
mRNA levels; (right) percentage of infected (p24+) cells.  
(G) Infection with VSV-pseudotyped HIV NL4-3-I-EGFP wild-type (WT), Vpu deleted (dVpu), Vpr 
deleted (dVpr) or Vpu and Vpr deleted (dVpu dVpr) viruses, 48 h after infection (n=4). (Left and 
middle) Fold change in IFN-α and IFIT1 mRNA levels; (right) percentage of infected (GFP+) cells.  
Graphs represent mean ± SEM. *p<0.05 (Wilcoxon matched pairs test) 
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Extended Experimental Procedures 
Isolation and culture of cells 
Primary CD4+ T cells were isolated from buffy coats of healthy donors (Red Cross, Ghent, 
Belgium), donated after informed consent, approved by Ghent University ethical committee. 
Peripheral blood mononuclear cells (PBMCs) were obtained on Lymphoprep (Axis-Shield 
PoC, Oslo, Norway) and used for CD4+ T cell isolation by negative selection with a 
commercial kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s 
instructions. Depletion of pDCs was done on PBMCs prior to isolation of CD4+ T cells, by 
negative selection after staining with CD304-PE antibody (clone AD5-17F6, Miltenyi Biotec) 
in the presence of human FcR blocking reagent (Miltenyi Biotec) and subsequent staining 
with anti-PE paramagnetic microbeads (Miltenyi Biotec). Purity of the CD4+ T cell population 
was measured by flow cytometry (MACSquant® Analyzer using MACSQuantify v2.4 
software, Miltenyi Biotec), showing a fraction of at least 95 % CD4+CD3+ double positive 
cells and less than 0.0004 % CD123+CD304+CD303+ cells (measured on 1.5 x106 cells, 
corresponds to ≤1 pDC per culture of 250,000 cells). Antibodies used for staining were CD3-
PE (clone SK7, Becton Dickinson (BD) Biosciences, Erembodegem, Belgium) and CD4-APC 
(clone MT4 66, Miltenyi Biotech) or CD123-FITC (clone AC145, Miltenyi Biotech), CD303-
APC (clone AC144, Miltenyi Biotech) and CD304-PE. Except when used for lentiviral 
transduction (see below), primary CD4+ T cells cells were cultured for 3 days after isolation at 
37 °C in a 5 % (v/v) CO2 humidified atmosphere in RPMIc: Gibco® RPMI medium 1640 (Life 
Technologies, Merelbeke, Belgium) supplemented with 2 mM L-glutamin (Life 
Technologies), 10 % (v/v) heat-inactivated fetal calf serum (Hyclone, Thermo Fisher 
Scientific, Waltham, MA), 100 U/mL penicillin and 100 µg/mL streptomycin (Life 
Technologies). RPMIc was supplemented with 20 ng/mL interleukin-2 (IL-2; specific activity 
10 U/ng, Peprotech, London, United Kingdom), and with 1 µg/mL phytohemagglutinin (PHA) 
mitogen (Thermo Fisher Scientific). Subsequently, cells were infected with HIV. 
293T cells (DZSM, Braunschweig, Germany), MT4 cells (kind gift from Dr. Katrien Fransen, 
Institute of Tropical Medicine, Antwerp, Belgium) used for co-culture with primary CD4+ T 
cells and Jurkat CD4 CCR5 cells (Programme EVA Centre for AIDS Reagents, NIBSC, UK) 
were cultured at 37°C in a 7 % (v/v) CO2 humidified atmosphere, in IMDMc: IMDM (Life 
Technologies) supplemented with 10 % (v/v) fetal bovine serum, 2 mM L-glutamin, 100 U/mL 
penicillin and 100 µg/mL streptomycin. MT4C5 cells (a derivate MT4 cells expressing CCR5) 
were used for co-culture with MDDCs and were cultured as described in Lepelley et al. 2011. 
HL-116 cells (kindly provided by Dr. Uze, University of Montpellier II, France (Uze et al., 
1994)) were cultured at 37 °C in a 7 % (v/v) CO2 humidified atmosphere in DMEM (Life 
Technologies) supplemented with 10 % fetal bovine serum and 2 mM L-glutamin (DMEMc). 
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Monocytes were isolated by positive CD14 immunomagnetic selection (Miltenyi Biotec) from 
PBMCs of healthy donors. MDDCs were generated by culturing monocytes for 5 days in 
presence of IL-4 (50 ng/mL) and GM-CSF (10 ng/mL) as described in (Puigdomenech et al., 
2013). 
 
Viral constructs  
Characteristics and sources of the plasmids used for production of HIV-1 in this study are 
described in Table S2. 
The tat-mutated and vpr-mutated NL4-3-IRES-HSA vectors were created by site directed 
mutagenesis on a part of the parental backbone, followed by substitution of the mutated 
fragment (with verified sequence) in the parental backbone. For mutation of tat, a TGA stop-
codon was introduced after the ATG start codon of the first exon of tat. For mutation of vpr, 
the CTAGAGCTTTTAGAGAA sequence at the end of the vif-vpr overlapping reading frame, 
was replaced by a CTAGTGATTGAATAGGAA sequence, thereby introducing a stop-codon 
in vpr in each of the reading frames after the end of vif.  
The HIV NL4-3 constructs encoding viruses with Q65R and R77Q mutations in Vpr, were 
generated by introducing punctual mutations in HIV NL4-3 WT with the QuikChange XL Site-
Directed Mutagenesis kit (Stratagene, Agilent Technologies, La Jolla, CA), using the 
following primers:  
Mutation Forward primer Reverse Primer 
Q65R 
5’-
agtggaagccataataagaattctgagacaactgctgtttattca
tttcaga-3’ 
5’-
tctgaaatgaataaacagcagttgtctcagaattcttattatggctt
ccact-3’ 
R77Q 
5’-
gaattatgcctattctgctatgttgacacccaattctgaaatgaata
-3’ 
5’-
tattcatttcagaattgggtgtcaacatagcagaataggcataat
tc-3’ 
 
The LZRS-Vpr-IRES-NGFR retroviral vector used for complementation of HIV viruses with a 
wild-type Vpr protein during production, was constructed by PCR amplification of the vpr 
gene from the NL4-3-IRES-HSA vector and introduction into LZRS-IRES-NGFR (Stove et al., 
2005), expressing Nerve Growth Factor Receptor as a marker gene. 
 
Production of HIV 
HIV production was done by transfection of 293T cells with Calcium Phosphate Transfection 
Kit (Life Technologies) or JetPei® (Polyplus, Sélestat, France), according to manufacturer’s 
instructions using 5 µg of HIV plasmid per 750,000 cells. For VSV-pseudotyped viruses, cells 
were transfected with 1 µg pMD.G plasmid (Stove et al., 2005) and 4 µg of HIV plasmid 
instead. Medium was refreshed 24 h after transfection. Viral supernatant was harvested after 
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48 h and centrifuged at 900 g for 10 min, to clarify the supernatant from remaining cells. Viral 
titer was determined by measuring reverse transcriptase activity in the supernatant with the 
SG-PERT assay (as described in Vermeire et al., 2012). Production of VSV-pseudotyped 
HIV NL4-3 WT and dVpr viruses used in context of MDDC experiments was performed as 
previously described (Puigdomenech et al., 2013). 
For production of wild-type and gag-mutated VSV-pseudotyped HIV-1 LAI dEnv dNef viruses 
complemented with a wild-type capsid protein, 293T cells were transfected with 2.7 µg HIV 
plasmid, 1.7 µg pCMV-ΔR8.91 (kindly provided by Dr. N. Manel (Manel et al. 2010)) and 0.7 
µg pMD.G plasmid using JetPei®. Viral supernatant was harvested as indicated above. 
For complementation of wild-type and mutated HIV NL4-3-HSA-I virions with a wild-type Vpr 
protein, 293T cells were transfected with 1.7 µg HIV plasmid and 3.3 µg LZRS-Vpr-IRES-
NGFR (Vpr complemented) or LZRS-IRES-NGFR (control vector) using JetPei®. Viral 
supernatant was harvested as indicated above and transfection efficiency was determined at 
moment of harvesting by surface staining with anti-CD24-APC and anti-NGFR-PE (clone 
ME20.4, Chromaprobe, Maryland Heights, MO). Percentage of CD24+NGFR+ cells was 
determined by flow cytometry (FACSCalibur, BD Biosciences) and always > 40 %. Efficacy of 
Vpr complementation using this protocol was previously validated by measurement of Vpr 
protein levels by Western Blot. In some experiments, supernatants of complemented viruses 
with low titer were concentrated using PEG-it precipitation of viral particles following 
manufacturer’s instructions (PEG-itTM Viral Precipitation Solution, System Biosciences, 
Mountain View, CA) and subsequent resuspension in IMDMc in 1/5 of the original volume.  
HIV-1 group M A8 isolate (92UG029) (Bachmann et al., 1994) was obtained from the NIH 
AIDS Research and Reference Reagent Program. The HIV-1 group M D2 (VI203) (Louwagie 
et al., 1993) and HIV-2 CI85 (Arien et al., 2005) were previously isolated from patients 
attending the AIDS clinic at the Institute of Tropical Medicine in Antwerp, Belgium, with the 
approval of the ethical committee after written informed consent. Virus stocks were initially 
obtained after propagation in short-term cultures of PBMCs as described before (Arien et al., 
2005) and subsequently expanded by infection and culture of Jurkat CD4 CCR5 cells. To this 
end, cells were plated at 5 x 105 cells per well of a 12-well flat-bottom plate (BD Biosciences) 
in 1 mL IMDMc and 1 mL of PBMC-derived viral supernatant was added to the cells (viral 
titer ranging from 350-1150 mU RT/ mL, equivalent to 35-210 ng p24/mL). Supernatant of the 
Jurkat CD4 CCR5 cells was collected at peak of infection and centrifuged at 900 g for 10 
min, to clarify the supernatant from remaining cells.  
 
Infection with HIV  
For HIV infection of primary CD4+ T cells, 250,000 cells were seeded per well in a 96-well 
flat-bottom plate (BD Biosciences) in RPMIc supplemented with 20 ng/mL IL-2 (final 
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concentration). Depending on the experiment 6-1700 mU RT (equivalent to 1 – 300 ng p24 of 
HIV virus was added per well in a final volume of 200 µL, with low concentrations (1-40 ng 
p24) used for long-term experiments (read-out until day 5-7 after infection) and high 
concentrations (60-300 ng p24) used for short-term experiments (last read-out at day 1-3 
after infection)). Cells were subsequently spinoculated at 950 g for 90 min at 32 °C. Medium 
was refreshed with RPMIc (+ IL-2) immediately after spinoculation and for half of the volume 
every 2 days during subsequent culture. At the indicated time points after infection, cells 
were harvested to determine HIV infection levels and remaining cells were lysed in 700 µL 
QIAZOL (miRNeasy mini kit, QIAGEN, Venlo, The Netherlands) according to manufacturer’s 
instruction. Supernatant of the cells was collected after spinoculation of the cells at 350 g for 
10 min at 4 °C. Lysates and supernatants were stored at -80 °C until further use.  
For HIV-1 infection in the presence of IFN-α and/or IFN-β neutralizing antibodies, primary 
CD4+ T cells were resuspended immediately after spinoculation in medium containing 
1/100,000x diluted goat anti-human IFN-β serum (925, kindly provided by Dr. Van Damme, 
Rega Institute, KUL, Belgium (Van Damme et al., 1987)) and/or 6,000 neutralizing units 
(NU)/ mL rabbit polyclonal anti-human IFN-α antibody (PBL Assay Science, Piscataway, NJ). 
Every 2 days, new medium with antibodies was added to the cells.  
For HIV-1 infection in the presence of antiretrovirals, primary CD4+ T cells were plated in 
medium with 5 µM nevirapine, 0.5 µM raltegravir or 1 µM ritonavir (AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH, Germantown, MD) 1 h before 
infection and antiretrovirals were maintained at these concentrations during infection 
MT4 cells were infected with HIV NL4-3-GFP-I viruses by plating 1.5 x 106 cells per well of a 
6-well flat-bottom plate (BD Biosciences) and addition of 165-350 mU RT (equivalent to 30-
60 ng p24) of virus in a total volume of 6 mL IMDMc. Cells were subsequently spinoculated 
at 950 g for 90 min at 32 °C. 48 h-72 h after infection, cells were collected and used for co-
culture with primary CD4+ T cells. 
For infection of MDDCs, 8 x 104 MDDCs were seeded in flat-bottomed 96-well plates. MT4C5 
cells were infected with VSV-pseudotyped HIV NL4-3 WT or dVpr, 24-48 h before the start of 
the co-culture. Donor T cells were stained with Far Red DDAO-SE (Life Technologies). 
MT4C5 cells were then co-cultured with MDDC at a 1:2 ratio (T:MDDC). Non-infected MT4C5 
cells were used as negative controls. Co-cultures were performed for 72 h. VLPs carrying 
Vpx were produced as previously described (Puigdomenech et al., 2013) and added to 
MDDCs 2 h before HIV-1 infection and maintained during the experiment. 
 
Origin and production of lentiviral vectors 
Lentiviral TRC1 pLKO.1-puro vectors (Sigma-Aldrich, St. Louis, MO) encoding shRNA are 
listed in Table S3 and were mostly obtained from the BCCM/LMBP Plasmid collection, 
Chapter III  Results 
 
117 
 
Department of Biomedical Molecular Biology, Ghent University, Belgium 
(http://bccm.belspo.be/about/lmbp.php). For knock-down of IRF3, a pLKO.1-puro vector 
targeting IRF3 was kindly provided by Dr. N. Manel (Institut Curie, Paris, France) (Manel et 
al. 2010). As a control, a pLKO.1-puro vector encoding a non-targeting scrambled shRNA 
(SHC-002) was purchased from Sigma-Aldrich. Lentiviruses were produced in 293T cells by 
transfection with the pLKO.1 vectors and the MISSION® Lentiviral Packaging Mix using 
FuGENE® HD Transfection Reagent (Promega, Leiden, The Netherlands) as described 
before (Landi et al., 2014). Medium was refreshed 24 h after transfection. Viral supernatant 
was harvested after 48 h and centrifuged at 900 g for 10 min, to clarify the supernatant from 
remaining cells.  
 
Knock-down of host genes by lentiviral vector transduction and co-culture with HIV-1 infected 
cells 
pDC depleted primary CD4+ T cells were transduced immediately after isolation from 
peripheral blood with pLKO.1 lentiviral vectors. Cells were plated at 300,000 cells in 55 µL 
RPMIc per well of a 96-well flat bottom plate and 45 µL of lentiviral vector supernatant was 
added to each well in the presence of 20 ng/mL IL-2, 1 µg/mL PHA and 8 µg/mL polybrene. 
Cells were then spinoculated for 30 min, 950 g at 32 °C. After 24 h, fresh RPMIc containing 
IL-2 and PHA was added to the cells. 48 h after transduction puromycin (1.2 µg/mL final 
concentration, Sigma Aldrich) was added to the cells. After 72 h, PHA/IL-2 stimulation was 
ended by removing all medium and adding fresh RPMIc containing IL-2 and puromycin. 5 
days after transduction cells were counted using MACSquant® Analyzer or using Flow-count 
Fluorospheres (Beckman Coulter, Suarlée, Belgium) and FACSCalibur flow cytometer, 
according to manufacturer’s instructions. Cells were subsequently plated at 1.2 x 105–1.5 x 
105 cells per well of a 96-well flat bottom plate and an equal amount of HIV-infected or non-
infected MT4 cells were added in a total volume of 200 µL fresh RPMIc (+ IL-2). Remaining 
primary CD4+ T cells were lysed in QIAZOL and used for target gene expression analysis. 24 
h after the start of the co-culture, cells were lysed in QIAZOL and used for IFN-β expression 
analysis. IFN-β mRNA induction was not observed after co-culture of HIV-infected MT4 cells 
and primary CD4+ T cells in the presence of the HIV-1 reverse transcriptase inhibitor 
nevirapine (data not shown). 
 
Quantitative real-time PCR (qPCR) 
RNA was isolated from QIAZOL lysates using the miRNeasy mini kit, either manually or with 
QIAcube (Qiagen), according to manufacturer’s instructions. RNA (max. 1 µg) was 
subsequently treated with amplification-grade DNAse I (Life Technologies) and used for 
synthesis of cDNA with Superscript® III reverse transcriptase and random primers (Life 
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Technologies), all according to manufacturer’s instructions. Depending on the gene to 
measure, cDNA was subsequently 3x (for target genes)-15x (for reference genes) diluted by 
addition of Nuclease-Free Water (NFW) (Ambion, Life Technologies) and 5 µL of diluted 
cDNA was used as input for qPCR. For qPCR measurement of YWHAZ, UBC, IFIT1, IFN-α 
and IRF3, forward (FWD) and reverse (REV) primers were used at a final concentration of 
300 nM in combination with 2x concentrated LightCycler® 480 SYBR Green I Master mix 
(Roche Diagnostics, Vilvoorde, Belgium) in a final reaction of 15 µL. For measurement of 
IFN-β (IFNB1), FWD and REV primers were used at a final concentration of 500 nM and a 
double-quencher probe (56-FAM/ZEN/3′ Iowa Black FQ) was used at a final concentration of 
250 nM in combination with 2x concentrated LightCycler® 480 Probes Master mix (Roche 
Diagnostics) in a final reaction of 15 µL. Primers and probe were manufactured by IDT 
(Leuven, Belgium). For measurement of MB21D1 (cGAS), TMEM173 (STING) and TBK1, 
20x concentrated commercial Prime PCR Sybr® Green assays (Bio-Rad Laboratories, 
Temse, Belgium) were used in combination with 2x concentrated LightCycler® 480 SYBR 
Green I Master mix in a final reaction of 15 µL. Primer/probe sequences or assay IDs are 
show in Table S1. qPCR reactions were performed in 384-well plates (LightCycler® 480 
Multiwell Plates 384, white, Roche Diagnostics) on the on the LightCycler® 480 II instrument 
(Roche Diagnostics) using following program: 10 min at 95 °C; 45 cycles of amplification: 10 
s at 95 °C, 1 min at 60 °C. 
For each sample, qPCR reactions were performed in duplo. A non-template control (NFW 
instead of cDNA) and a serial 10-fold dilution series of cDNA derived from poly I:C stimulated 
PBMCs (standard curve) was included for measurement of each gene on each plate. Cycles 
of quantification (Cq) values were generated by the LightCycler® 480 software 1.5.0 
according to the second-derivative maximum method. Amplification efficiency of each qPCR 
assay was tested during primer/assay validation and varied from 85-105 %. Melting curve 
analysis was performed for the not previously validated SYBR Green assays (IFIT1, IFN-α 
and IRF3) and showed a single peak. Calibrated normalized relative quantities (CNRQs) 
were calculated for each target gene in each sample based on obtained Cq values, with the 
qBasePlus Software (Biogazelle, Zwijnaarde, Belgium), using YWHAZ and UBC as reference 
genes and using target- and run- specific amplification efficiencies. GeNorm analysis 
(implemented in qBase Plus) was used to select YWHAZ and UBC as stable reference 
genes in prior experiments.  
 
Measurement of secreted type 1 IFN bioactivity 
HL-116 cells were plated 16 h prior to the assay at 40,000 cells per well of a 96-well-flat 
bottom plate in 200 µL DMEMc. Medium was removed and 100 µL culture supernatant or 
recombinant IFNα, together with 100 µL DMEMc was added. Cells were incubated for 7-8 h, 
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washed with PBS and lysed (Cell Culture Lysis 5X Reagent, Promega). Lysates were either 
processed immediately or stored at -80°C until further use. For measurement of luciferase 
activity, 20 µL cell lysate was transferred to 96-well white solid plates (Costar/Corning, 
Amsterdam, The Netherlands) and luciferase assay was conducted using 50 µL Luciferase 
reagent (Luciferase Assay System, Promega) in a TriStar LB 941 automated plate reader 
(Berthold Technologies, Bad Wildbad, Germany). IFN levels are expressed in IU/mL as 
equivalent of IFNα1b (Immunotools, Friesoythe, Germany) bioactivity for primary CD4+ T 
cells and as equivalent of IFNα2a (PBL Assay Science) bioactivity for MDDC experiments, 
both determined by inclusion of a dilution series of the recombinant IFNα in each experiment.  
 
Measurement of MxA and HIV infection levels. 
Intracellular staining for p24 or MxA in primary CD4+ T cells was performed with the Fix and 
Perm Cell kit (AN DER GRUB Bio Research, Susteren, The Netherlands) according to 
manufacturer’s instructions using following antibodies: HIV-1 core antigen PE 
(phycoerythrin)-conjugated mAb (Clone KC57, Beckman Coulter, Suarlée, Belgium) for p24 
or anti-MxA (anti-MX1) (rabbit polyclonal, Abcam, Cambridge, UK) as primary antibody and 
Alexa Fluor® 660 goat anti-rabbit IgG (Life Technologies) as secondary antibody for MxA. 
For HIV NL4-3-HSA-I infected cells, surface staining was performed with an anti-CD24-APC 
(allophycocyanin) antibody (HSA; mouse clone M1/69, BioLegend, San Diego, CA). Cells 
were analyzed by flow cytometry (FACSCalibur using CellQuest Pro software (BD 
Biosciences) or FlowJo 887 (Tree Star, Ashland, OR) or Flowing Software (Turku Centre for 
Biotechnology, University of Turku) for analysis). For HIV-2 CI85 infected cells, surface 
staining was performed with an anti-CD4-APC antibody (clone M-T466, Miltenyi Biotec). 
Percentage of HIV-1 infected cells was determined as percentage of HSA, GFP or p24 
expressing cells and for HIV-2 CI85 as percentage of CD4low cells. 
To evaluate HIV-1 infection levels in MDDCs, cells were intracellularly stained with anti-HIV-
Gag (KC57-PE, Beckman-Coulter) and Gag-PE and Far Red DDAO-SE levels were 
analyzed by flow cytometry.  
 
Statistical analysis and software  
Figures were created with Microsoft PowerPoint and GraphPad Prism 5.0 software. 
Statistical tests were performed with GraphPad Prism 5.0 as indicated in the figure legends  
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Table S1. Properties of the qPCR assays used. 
Related to Experimental Procedures. 
Official 
gene 
symbol 
Detected Refseq 
transcripts 
Primer/probe 
sequence source 
Primer/ 
probe 
identity 
Primer/probe sequence  Ampli
-con 
length 
YWHAZ 
NM_001135702.1, 
NM_001135701.1, 
NM_001135700.1, 
NM_001135699.1, 
NM_145690.2, 
NM_003406.3 
RTprimerDB ID: 9 
(Pattyn et al., 2003) 
FWD 5’-ACTTTTGGTACATTGTGGCTTCAA-3’ 
94 
REV 5’-CCGCCAGGACAAACCAGTAT-3’ 
UBC NM_021009.6 
RtprimerDB ID: 8 
(Pattyn et al., 2003) 
FWD 5’-ATTTGGGTCGCGGTTCTTG-3’ 
133 
REV 5’-TGCCTTGACATTCTCGATGGT-3’ 
IFIT1 NM_001548.4 
Designed with Primer-
BLAST (Ye et al., 2012) 
FWD 5’-GATCTCAGAGGAGCCTGGCTAA-3’ 
84 
REV 5’-TGATCATCACCATTTGTACTCATGG-3’ 
IFNA 
cluster 
(IFNA10, 
IFNA17, 
IFNA4, 
IFNA2, 
IFNA8, 
IFNA7, 
IFNA14, 
IFNA21, 
IFNA16, 
IFNA6, 
IFNA1, 
IFNA13, 
IFNA5) 
NM_002171.2, 
NM_021268.2, 
NM_021068.2, 
NM_000605.3, 
NM_002170.3, 
NM_021057.2, 
NM_002172.2, 
NM_002175.2, 
NM_002173.2, 
NM_021002.2, 
NM_024013.2, 
NM_006900.3, 
NM_002169.2 
RTprimerDB ID: 3541 
(Pattyn et al., 2003) 
FWD 5’-GTGAGGAAATACTTCCAAAGAATCAC-3’ 
93 
REV 5’-TCTCATGATTTCTGCTCTGACAA-3’ 
IFNB1 NM_002176.2 
Designed with 
PrimerQuest Assay 
design IDT 
FWD 5’-GCTTCTCCACTACAGCTCTTTC-3’ 
115 
REV ‘5-CAGTATTCAAGCCTCCCATTCA-3’ 
PROBE 
56-
FAMTTCAGTGTC/ZEN/AGAAGCTCCTGTGGC
AA/3IABkFQ 
IRF3 
NM_001197125.1, 
NM_001197124.1, 
NM_001197123.1, 
NM_001197122.1, 
NM_001571.5 
Viemann et al., 2011 
FWD 5’-AGGCCACTGGTGCATATGTTC-3’ 
108 
REV 5’-CCTCTGCTAAACGCAACCCTT-3’ 
MB21D1 n.a. 
qHsaCID0009796 Bio-
rad Laboratories 
/ n.a. 110 
TMEM173 n.a. 
qHsaCID0010565 Bio-
rad Laboratories 
/ n.a. 93 
TBK1 n.a. 
qHsaCID0018552 Bio-
rad Laboratories 
/ n.a. 141 
Table shows properties of primers used for qPCR: official gene symbol according to the HUGO Gene Nomenclature Committee 
database (www.genenames.org); detected Refseq transcripts are those obtained by Primer-BLAST (Ye et al. 2012) using the 
indicated primer sequences with default parameters; FWD: forward primerr, REV: reverse primer, n.a. not available  
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Table S2. HIV-1 encoding vectors used in this study. 
Related to Experimental Procedures. 
Parental vector Variant Virus referred to as: Source Reference 
NLENG1-IRES WT HIV NL4-3-GFP-I 
Dr. D.N. Levy, New 
York University 
college of Dentistry, 
New York, NY 
Kutsch et al., 2002; Levy 
et al., 2004 
NL4-3-IRES-
HSA 
WT HIV NL4-3-HSA-I 
Dr. M.J. Tremblay; 
Faculté de Médecine, 
Université Laval, 
Québec, Canada 
Imbeault et al., 2009 
Tat-mutated HIV NL4-3-HSA-I TatSTOP Constructed in house 
See Materials and 
methods 
Vpr-mutated HIV NL4-3-HSA-I dVpr Constructed in house See Materials and 
methods 
WT HIV NL4-3 
NIH AIDS Research 
and Reference 
Reagent Program 
Adachi et al., 1986 
pNL4-3 
Integrase-mutated HIV NL4-3 D116N 
Dr. Z. Debyser, 
Laboratory for 
Molecular Virology 
and Gene Therapy, 
KU Leuven, Belgium 
Mutation introduced in 
HIV NL4-3 (according to 
Engelman et al., 1995) 
Vpr-deleted HIV NL4-3 dVpr 
Dr. Margottin-Goguet, 
Institute Cochin, Paris, 
France 
Le Rouzic et al., 2008 
Vpr Q65R mutant HIV NL4-3 Q65R Constructed in house See Materials and 
methods 
Vpr R77Q mutant HIV NL4-3 R77Q Constructed in house See Materials and 
methods 
WT HIV LAI dEnv dNef Dr. N. Manel, Institut Curie, Paris, France Manel et al., 2010 
pLaiΔEnv-GFP3 
Capsid G89V mutant HIV LAI dEnv dNef G89V 
Dr. N. Manel, Institut 
Curie, Paris, France 
Constructed in house 
Manel et al., 2010 
Capsid T54A/N57A 
mutant 
HIV LAI dEnv dNef 
T54A/N57A Manel et al., 2010 
Capsid Q63A/Q67A 
mutant 
HIV LAI dEnv dNef 
Q63A/Q67A Manel et al., 2010 
WT HIV NL4-3-I-EGFP Schindler et al., 2003 
pBR-NL43-I-
EGFP 
Vpu-mutated HIV NL4-3-I-EGFP dVpu 
Constructed in house 
Rucker et al., 2004;  
nef-IRES-eGFP 
introduced as described 
in Sauter et al., 2009 
Vpr-mutated HIV NL4-3-I-EGFP dVpr 
Rucker et al., 2004;  
nef-IRES-eGFP 
introduced as described 
in Sauter et al., 2009 
Vpu-mutated and Vpr-
mutated 
HIV NL4-3-I-EGFP dVpu 
dVpr 
Rucker et al., 2004;  
nef-IRES-eGFP 
introduced as described 
in Sauter et al., 2009 
WT HIV NL4-3-Vpu-IRES-Env NL4-3 WT (M) Sauter et al., 2009 
pNL4-3 UIE 
Vpu NL4-3 S52 
mutant 
HIV NL4-3-Vpu-IRES-Env 
NL4-3 S52 
Constructed in house 
Sauter et al., 2009 
Vpu NL4-3 STOP HIV NL4-3-Vpu-IRES-Env NL4-3 STOP Sauter et al., 2009 
Vpu NL4-3 deleted HIV NL4-3-Vpu-IRES-Env NL4-3 deleted Sauter et al., 2009 
Vpu HIV-1 M JRCSF HIV NL4-3-Vpu-IRES-Env JRCSF (M) Sauter et al., 2009 
Vpu HIV-1 M Yu2 
(adapted) 
HIV NL4-3-Vpu-IRES-Env 
Yu2 (M) Sauter et al., 2009 
Vpu HIV-1 O 13127 HIV NL4-3-Vpu-IRES-Env 13127 (O) Sauter et al., 2009 
Vpu SIV Cpz Pts Tan1 HIV NL4-3-Vpu-IRES-Env Cpz Pts Tan1 Sauter et al., 2009 
Vpu SIV Cpz Ptt MP7 HIV NL4-3-Vpu-IRES-Env Cpz Ptt MP7 Sauter et al., 2009 
Table shows different HIV-1 constructs used in this study, indicating the parental wild-type (WT) vector and variants used; the 
name by which this virus is referred to in the study, the source of the vector and the reference describing construction of the 
vector if published. 
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Table S3. List of pLKO.1-puro shRNA-encoding lentiviral vectors used for knock-down of 
host proteins. Related to Experimental Procedures. 
Origin 
lentiviral 
vector 
Target 
gene 
(official 
symbol) 
Refseq TRC number / 
reference 
Target sequence Targeted 
gene 
region 
BCCM/LMBPa MB21D1 NM_138441.2 TRCN0000148694 CTGCCTTCTTTCACGTATGTA CDS 
BCCM/LMBPa MB21D1 (#2) NM_138441.2 TRCN0000149984 CAACTACGACTAAAGCCATTT CDS 
BCCM/LMBPa MB21D1 (#3) NM_138441.2 TRCN0000146282 CTTTGATAACTGCGTGACATA CDS 
BCCM/LMBPa TMEM173 NM_001301738.1, NM_198282.3 TRCN0000161052 GCTGGCATGGTCATATTACAT CDS 
BCCM/LMBPa TBK1 NM_013254.3 TRCN0000003182 GCAGAACGTAGATTAGCTTAT CDS 
Dr. N. Manel, 
Institut Curie, 
Paris, France 
IRF3 
NM_001197125.1, 
NM_001197126.1, 
NM_001197123.1, 
NM_001197122.1, 
NM_001571.5 
Manel et al. 2010 CTGCCTGGATGGCCAGTCACAC CDS 
Sigma-Aldrich 
Non-
targeting 
scrambled 
shRNA 
control 
(SHC-002) 
Not applicable Not applicable Not applicable Not 
applicable 
Table shows official gene symbol of the shRNA targeted gene according to the HUGO Gene Nomenclature Committee 
database (www.genenames.org); Refseq code of the targeted transcripts (Reference sequence database of National Center for 
Biotechnology Information (www.ncbi.nlm.nih.gov)); TRC number of the clone from the Sigma Mission® TRC1 lentiviral library, 
sequence in the gene transcript targeted by the shRNA and corresponding region in the transcripts targeted (CDS: coding 
sequence). 
aSigma Mission® TRC1 vector obtained through the BCCM/LMBP Plasmid collection, Department of Biomedical Molecular 
Biology, Ghent University, Belgium (http://bccm.belspo.be/about/lmbp.php) 
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The pathogenesis of HIV-1 infection is characterized by a long-lasting battle between the 
virus and the human immune system. Despite development of a very active immune 
response, the virus is never eliminated and rarely controlled during natural infection. 
Eventually, the immune system becomes exhausted and is no longer able to keep HIV 
replication (and other infections) at bay, leading to AIDS. A considerable part of HIV-1 
research has focused on defining immune responses against the virus as well as 
understanding the mechanisms that drive immune exhaustion and dysfunction. The final 
aim here is to artificially boost these responses or prevent/repair their deterioration in a way 
to functionally cure the infection [1]. Type 1 interferon (IFN-I) responses are an interesting 
target in this regard for several reasons. First, they are able to suppress HIV-1 replication in 
vitro and early in vivo responses are thought to play a crucial role in limiting the initial viral 
spread. Second, despite a beneficial effect of early responses, long-term exposure to IFN-I 
likely contributes to hyper-immune activation and dysfunction and may therefore drive 
immune exhaustion in the chronic phase of HIV-1 infection. Third, the virus has adopted 
strategies to counteract IFN-I responses, which further adds to immunological failure and 
may present alternative therapeutic targets [2-4]. A prerequisite for targeted modulation of 
these responses is an in depth understanding of the origin and mechanisms that regulate 
IFN-I secretion during HIV-1 infection. With this in mind, we aimed at evaluating the 
potential of the main HIV-1 targets, activated CD4+ T cells, to produce IFN-I in response to 
HIV and to subsequently asses host and viral factors that mediate IFN-I induction in these 
cells. 
SG-PERT assay as a valid alternative for retroviral quantification 
The mechanistic evaluation of IFN-I responses required the use of many HIV-1 variants and 
lentiviral vectors and introduced early-on the need for a fast retroviral quantification 
method. In Chapter III-1 we report on the optimization and evaluation of an SG-PERT assay 
that allows quantification by measurement of reverse transcriptase (RT) activity. We show 
that viral titer determination by SG-PERT correlates well with other frequently applied 
methods for retroviral quantification. Furthermore, it outperforms the “gold standard” 
method p24 ELISA by a lower inter-run variation, higher linear range and (much) lower cost. 
It is also considerably faster and more amenable to standardization than functional 
quantification methods, which are dependent on infection or transduction of cells. An 
overview of advantages and disadvantages of the SG-PERT assay is provided in Table 1. 
 
A primary field of application of this assay would be in virology and molecular biology 
research environments. Given the increased use of lentiviral vectors as a tool for high-
throughput screening, faster and cheaper methods for quantification are highly appealing. 
Measurement of RT activity further offers the advantage that theoretically any type of 
retrovirus can be detected with a single method, while other assays are usually limited to 
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detection of virus-specific proteins or nucleic acid sequences. For HIV research an additional 
advantage may be the shorter half-life of RT activity compared to p24 proteins as reported 
by others [5, 6], since this could provide a better estimation of active viral particle 
production during long-term culture. Lenti- and retroviral vectors are also increasingly used 
in gene therapy protocols, reaching over 20% of vector-based clinical trials in 2014 [7]. 
Quality control for clinical grade vectors often involves assessment of total/functional 
particle ratio’s and also requires screening for possible replication competent 
retroviruses/lentiviruses (RCR/RCL) [8]. The SG-PERT assay may also find applications in 
this regard, as alternative for p24 ELISA [9, 10] or more labor-intensive PERT assays [11, 
12]. Although our assay has a comparable sensitivity to standard p24 ELISA, this would be 
largely insufficient for use in a clinical setting as viral load assay. As discussed in Chapter 
III-1, we estimate that 20-50 particles per reaction can be accurately quantified by SG-PERT 
and fewer particles may even be detectable. However, the input of the reaction is currently 
limited to 0,5 µL. This is mainly due to an extensive dilution step of the viral lysates, that 
was added to avoid possible PCR inhibitory effects of culture medium [13]. When higher 
sensitivity is required, ultracentrifugation of the sample could be performed to allow prior 
removal of inhibitory substances and further concentration of viral particles. This strategy 
was successfully applied on patient plasma previously, for viral load assessment with a 
more labor-intensive PERT variant [14, 15]. In Switzerland, such PERT assays are 
standardly requested for HIV confirmation testing in patients with low viral load upon 
diagnosis [16]. In this context, the by nature sequence independent PERT is applied to avoid 
possible underestimation of viral load, which may arise from sub-optimal detection of 
certain HIV-1 variants by the sequence-based standard viral load test. If combined with 
ultracentrifugation or RT purification methods [17], the SG-PERT assay may also be able to 
quantify low viral load levels in patients under cART. However, given the requirement of 20-
50 particles per reaction for accurate quantification, the assay is unlikely to exceed 
sensitivity of current RNA-based viral load assays, which can detect as few as 20-40 RNA 
copies/mL in plasma without prior need for ultracentrifugation [18].  
 
Table 1. Strengths (+) and weaknesses (-) of the SG-PERT assay as a retroviral 
quantification method 
 
+ - 
High linear range Detection of non-functional viral particles 
Applicable for all types of retroviruses Lower sensitivity compared to eg. viral 
RNA quantification methods 
Relative low cost  
Fast procedure  
Low inter-run variation  
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HIV-infected CD4+ T cells as potential source of IFN-I 
In a first part of Chapter III-2 we employed several assays to evaluate the occurrence of 
IFN-I responses during HIV replication in primary CD4+ T cells. We found that both HIV-1 
laboratory adapted strains as well as different primary HIV-1 or HIV-2 isolates trigger a 
bioactive response in these cells, characterized by induction of IFN-I and several ISGs. This 
finding has some interesting implications. 
As discussed before, both correlative evidence [19-21] and in vivo manipulation of IFN-I 
responses [22-26] implicate IFN-I produced in the chronic phase of HIV/SIV infection as a 
potential driver of hyper-immune activation and dysfunction (and thus pathogenesis). Our 
data now indicate that part of this IFN-I may originate from HIV-infected CD4+ T cells. 
Indeed, although an IFN-I signature is evident in chronically infected patients or pathogenic 
models of SIV infection, the cellular sources of chronic IFN-I have remained elusive [27]. A 
recent study in humanized mice showed that targeted depletion of plasmacytoid dendritic 
cells (pDCs) led to a significant (although not complete) reduction of IFN-I levels during 
chronic HIV-1 infection [28]. In contrast, inhibition of pDC responses during pathogenic SIV 
infection indicated a rather transient contribution of these cells to the IFN-I response [29] 
and IFN-α producing pDCs were barely detected in spleens of chronically infected HIV-1 
patients. In the later study, IFN-α did co-localize with other cell types, including T cells [30]. 
Given the correlation between levels of HIV replication and IFN-I we observed, CD4+ T cells 
are most likely to contribute to IFN-I secretion in vivo mainly at sites where high levels of 
infection are reached, such as the lymph nodes or the GALT. The latter constitutes the 
largest reservoir of activated CD4+ T cells in the body and a marked IFN-I signature is 
indeed observed in gut biopsy samples from chronically infected HIV-1 patients [31, 32]. 
Future in situ or flow-cytometric evaluations of patient-derived lymphoid tissue will be 
needed to identify potential in vivo niches of IFN-I producing CD4+ T cells. In this regard, it 
will also be interesting to asses CD4+ T cells derived from different compartments and 
different CD4+ T cell subsets for their in vitro capacity to produce IFN-I during infection. 
Differences between peripheral CD4+ T cells and those derived from lymphoid tissue have 
been observed in terms of inflammasome activation by HIV-1 after innate signaling [33, 34]. 
Previous exposure of T cells to cytokines in the lymphoid tissue and upon T cell 
differentiation may affect their IFN-I production capacity by eg. modulating expression levels 
of the innate sensor or the NF-ĸB activation status [35].  
A second direct, but perhaps surprising implication is that HIV does not prevent its own 
innate sensing in its main target cells. Given the very adaptive nature of the virus and its 
wide ability to divert the host cellular pathways, induction of the primarily antiviral IFN-I 
cytokines by the virus might be unexpected. Our results indeed indicate an antiviral effect of 
HIV-induced IFN-I, since addition of IFN-I neutralizing antibodies enhanced viral replication. 
Certain ISGs with anti-HIV activity that are not counteracted by HIV-1 accessory proteins, 
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such as MX2 or other yet to be identified ISGs [36-38], are likely responsible for this effect. 
The extent of the antiviral effect we observed, was however rather modest. Previous studies 
have indicated a larger resistance of HIV-1 to IFN-I when added after initial establishment of 
infection in the culture (eg. after integration) and the remaining effect is highly dependent 
on the amount of IFN-I [39, 40]. We could therefore speculate that the virus allows a certain 
level of IFN-I induction -and its antiviral effect- as a trade-off for other effects of IFN-I or the 
innate immune response, that can be exploited to its advantage. This may be e.g. enhanced 
recruitment and activation of potential target cells, impeding antiviral T-cell responses or 
even direct stimulatory effects on viral replication [19, 41-44]. In this regard, it will be 
interesting to also assess the panel of chemokines and cytokines, besides IFN-I, that is 
induced by innate sensing of the virus in CD4+ T cells. Furthermore, it will be important to 
evaluate IFN-I induction with a larger panel of primary HIV-1 isolates. The use of HIV-1 
founder viruses might learn us if and how innate sensing in CD4+ T cells also affects early 
phases and establishment of infection, as this could reflect in a different induction ability of 
these viruses.  
IFN-I induction by post-integration cGAS-mediated sensing and 
regulation by Vpr and Vpu 
In the second part of Chapter III-2 we investigated the underlying mechanism of the HIV-
induced IFN-I response, both from a host and viral perspective. By using shRNA-mediated 
knock-down of cellular IFN pathway proteins and a panel of mutated HIV variants, we show 
that IFN-I is induced through a post-integration mechanisms that requires the cytosolic 
DNA sensor cGAS and its downstream signaling molecules. In addition, we demonstrate that 
this response is regulated by two newly expressed HIV-1 accessory proteins: Vpr potentiates 
induction, while Vpu suppresses the response. This indicates a mechanistic model in which 
HIV DNA is sensed by cGAS upon productive infection, through the assistance of newly 
expressed viral replication products. Especially the newly produced Vpr protein seems to be 
an important driver of sensing after integration, since a functional Vpr was required for full 
IFN-I induction and virion-incorporated Vpr seemed insufficient to mediate this effect 
(Figure 4.1).  
The ability of cGAS to sense HIV infection was demonstrated by several groups [45-48] soon 
after its initial identification as a DNA pattern recognition receptor [49]. Importantly, until 
now, activation of cGAS has never been observed under “natural” HIV-1 infection conditions. 
Indeed, while HIV-1 efficiently triggers cGAS in monocytic THP-1 cell lines [45, 48], its 
activation in primary DCs and macrophages only occurs upon addition of Vpx [45, 46] or 
when using specific HIV-1 capsid mutants [46, 47]. The loss of Vpx by HIV-1 and cloaking of 
the HIV-1 capsid with host proteins were consequently suggested as strategies specifically 
acquired by the virus to evade cGAS sensing [47, 50-52]. Our data now indicate that cGAS 
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activation can occur in a natural HIV-1 infection context. Consequently, this implicates the 
receptor for the first time as a potential mediator of IFN-I response in HIV-1 patients. A 
small-scale study by Nissen et al. did not detect an association between cGAS mRNA levels 
and markers of immune activation in HAART-naïve HIV-1 infected individuals [53]. However, 
variation in cGAS expression levels was very limited among the included subject, which may 
hamper efficient correlation assessment. It would be interesting to further evaluate cGAS 
activity in CD4+ T cells from different patient groups (eg. patients with different virological or 
immunological response to treatment, long-term non-progressors or elite controllers) or 
alternatively asses the occurrence of genetic variability in cGAS or STING (eg. single 
nucleotide polymorphisms) [54] among HIV-1 patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Mechanistic model of HIV innate sensing in activated CD4+ T cells. 
Productive HIV infection triggers the cytosolic sensor cGAS, which results in activation of 
the STING-TBK1-IRF3 signaling pathway and NF-κB. Both IRF3 and NF-κB subsequently 
bind to the IFN-β promoter to induce its expression. Given the known DNA sensing 
properties of cGAS, activation is most likely induced by HIV DNA products, created upon 
reverse transcription. However, IFN-I induction only occurs after integration and expression 
of the provirus, indicating that additional newly expressed viral products mediate the 
sensing . Newly expressed Vpr potentiates IFN-I induction by an unknown mechanism that 
is most likely dependent on its interaction with the host factor DCAF1. Vpr might enhance 
HIV DNA binding to cGAS by unmasking it from its capsid-host factor shield (1) or might 
potentiate downstream signaling by eg. activating NF-κB (2). Conversely, Vpu counteracts 
IFN-I induction possibly by recruiting the E3 ubiquitin ligase component β-TcrP and 
interfering with NF-κB activation (3). 
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An important point to consider in our model is the origin of the HIV DNA that is recognized 
by cGAS. Post-integration sensing of HIV DNA implicates that both an integrated viral copy 
and cytosolic HIV DNA need to be present in the cell. A successfully integrated virus is 
however not expected to leave cytosolic DNA fragments behind. As such, the DNA sensed by 
cGAS most likely originates from a separate infection event. In this regards, re-infection of 
cells containing an expressing virus might be rather rare in vivo since HIV-1 has developed 
several mechanism to prevent viral entry of productively infected cells [55, 56] and most 
infected CD4+ T cells have a relative short half-life [57]. HIV DNA can however stay behind in 
the cytosol due to the frequent failure of HIV-1 reverse transcription and/or nuclear import 
[58-61] and such cells could be targeted for subsequent productive infection. In HIV-1 
patients, the proportion of cells containing unintegrated DNA largely exceeds those with 
integrated DNA for both resting and activated CD4+ T cells. Most of this DNA is thought to 
consist of linear unintegrated DNA [62, 63], which may exist both in the cytoplasm and the 
nucleus. At sites where virus concentrations are high or cells are tightly packed, multiple 
simultaneous co-infections of a cell may also occur. Different studies employing in situ 
analysis of splenic tissue of HIV-1 patients have described the presence of multiple 
proviruses per cell [64-66] and co-infection of cells is a prerequisite for generation of 
recombinant HIV-1 variants [67]. Furthermore, formation of viral synapses between infected 
and uninfected cells is known to result in directed delivery of multiple virions at once [68-
71]. Even though most of these particles will fail to establish productive infection, their 
reverse transcription products could be targeted for cGAS detection by a successfully 
integrated virus. The simultaneous transmission of multiple “DNA-providing” virions during 
cell-to-cell transfer might contribute to the higher IFN-I production that is observed during 
infection of Vpx treated dendritic cells [72] and primary CD4+ T cells (see chapter III-2) by 
co-culture compared to infection with free virions, as IFN-I induction in both cell types is 
mediated by post-integration cGAS-dependent sensing. 
Although post-integration sensing of HIV DNA by cGAS has indeed been suggested before in 
Vpx treated dendritic cells [46, 50], we cannot rule out that other viral components (eg. RNA, 
proteins) are sensed after integration. A strong argument for a DNA-sensing driven process 
is the complete abrogation of IFN-I induction upon cGAS knock-down we observed, 
combined with observations that cGAS is a nucleic-acid binding protein but seems unable to 
recognize RNA or respond to RNA viruses without DNA replication intermediates [49, 73, 
74]. Two studies have suggested that cGAS would be able to co-operate with other sensors, 
although so far only other DNA sensors were found to collaborate with cGAS [48, 75]. To 
further define the sensing mechanism it will be important to determine which separate and 
combined viral products are able to induce IFN-I in primary CD4+ T cells and which of them 
are able to “rescue” IFN-I induction by an integrase deficient virus. 
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Another point worth discussing is the opposing effect of two viral proteins on the same 
process. HIV accessory proteins mediate their effects by hijacking specific host proteins and 
pathways. However, targeting of these factors could have unintended side-effects and might 
only be beneficial to the virus in certain target cells or at certain stages of the viral 
replication cycle. Induction of G2 arrest by Vpr and apoptotic effects of certain accessory 
proteins were suggested to be such by-products of accessory protein actions [76-79]. 
Furthermore, opposing effects of different accessory proteins on eg. apoptosis [80, 81], NF-
ĸB activation [82-84] and cell cycle progression [85-87] have been reported and could 
represent ways of the virus to deal with non-beneficial effects when they present. Given the 
antiviral nature of IFN-I, it is possible that potentiation of post-integration sensing by Vpr is 
such a side-effect of a required Vpr-host interaction. As discussed before, the innate 
immune responses resulting from this post-integration Vpr interaction may have certain 
benefits for viral spread, such as recruitment and activation of surrounding HIV target cells. 
However, high levels of IFN-I are likely to be avoided by the virus. As such, the virus may 
have employed another late HIV-1 protein, Vpu, to partially counteract the Vpr effect and 
keep IFN-I levels in check. Indeed, an IFN-I suppressing effect of Vpu was observed before 
[88-90], but the evolutionary drive of this effect remains unclear. Since Vpu is only present 
in the infected cell after viral integration, it is likely to counteract a mechanism of post-
integration IFN-I induction, which had not been reported during natural HIV-1 infection 
until now. In this regard it will be interesting to evaluate vpu and vpr alleles of the HIV-1 
ancestral lentiviruses and non-M HIV-1 viruses, to see if Vpr and Vpu effects have co-
evolved together. Furthermore, alleles of multiple HIV-1 M isolates should be tested to asses 
preservation of the Vpu and Vpr effect. While all primate lentiviruses encode a Vpr protein, 
some of them (eg. HIV-2) lack Vpu [91]. The one HIV-2 isolate tested in our study had a 
similar capacity to induce IFN-I as HIV-1 viruses. It will be interesting to see if Vpr proteins 
of these and other viruses without Vpu have with a weaker IFN-I potentiating ability or if 
these viruses might employ other viral proteins to counteract the Vpr effect.  
Future research will be required to fully understand the mechanism behind the HIV-1 Vpu 
and Vpr effect. Our model does provide some interesting clues for research. First, it will be 
important to asses if newly expressed Vpr can act as a sole factor to enable post-integration 
sensing or cooperates with other newly synthesized HIV products. As discussed above, we 
can evaluate if expression of Vpr in trans can rescue IFN-I induction by an integrase-
deficient virus. To avoid extensive cytopathic effects of long-term Vpr expression, the use of 
an inducible retro- or lentiviral construct to introduce Vpr in primary CD4+ T cells will likely 
be required. In order to envision how Vpr can enhance post-integration sensing, it is 
necessary to consider how sensing is prevented before integration. As discussed in Chapter 
III-2, it has been suggested that viral DNA is shielded by complexes of HIV-1 capsid and 
host factors cyclophilin A (CypA) [46, 50] and/or CPSF6 [47]. As such, newly expressed Vpr 
might play a role in unmasking DNA for cGAS binding. Interestingly, Vpr is also known to 
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interact with CypA [92, 93]. High levels of Vpr accumulating after integration might 
eventually compete with capsid for interaction. Alternatively, Vpr may expose HIV-1 DNA 
through direct interaction with DNA [94] or through HIV DNA binding proteins that are 
induced or relocated by Vpr, such as the DNA damage response proteins Ku70, Ku80 and 
PARP-1 [95-97]. In an alternative model, Vpr may influence factors of the cGAS pathway. A 
low efficiency of signaling transduction following DNA sensing has been suggested in CD4+ T 
cells by one group [98], although active signaling was implied by others [61, 95]. It is 
possible that Vpr enhances the threshold for successful signaling by eg. activation of a 
signaling protein such as NF-ĸB [83, 99] or by inducing proteasomal degradation of an 
inhibiting factor. To discriminate between these two models it will be interesting to evaluate 
if Vpr can potentiate IFN-I induction by alternative stimulators of the cGAS pathway (eg. 
dsDNA or DNA viruses [49, 100]) in primary CD4+ T cells. Evaluation of the intracellular 
redistribution and phosphorylation of different cGAS signaling proteins (eg. TBK1, IRF3 and 
members of the NF-ĸB pathway) can subsequently be used to pinpoint the stage of the Vpr 
effect in cGAS stimulated or HIV-infected cells. Alternatively, it may be useful to evaluate 
levels of 2′3′-cGAMP in HIV wild-type and ∆Vpr infected cells, which is produced by cGAS 
upon DNA binding [101, 102]. An HIV-specific effect of Vpr at this stage, would favor the 
first model in which Vpr enhances binding of HIV DNA to cGAS. Finally, future correlation 
studies of Vpr’s ability to potentiate IFN-I induction and other known Vpr functions, 
through use of Vpr mutants, knock-down of Vpr interacting proteins or treatment with 
inhibitors, can lead to further mechanistic insights. We already showed that Vpr-DCAF1 
interaction is important for its IFN-I potentiating effect. Many of the above suggested 
mechanisms might however depend on formation of this complex, given its broad and 
incompletely characterized role during HIV-1 replication [76, 103-105]. Since DCAF1 is used 
by Vpr to target cellular proteins for proteasomal degradation, it could be interesting to 
search for known cellular regulators of cGAS or NF-ĸB signaling among Vpr interacting 
proteins. Large scale in cellulo [106] and in silico [107-109] interactome studies aimed at 
identifying new viral-host protein interactions are actively being performed and multiple 
databases have been developed to explore identified HIV protein interaction partners [110, 
111]. Such tools and datasets may provide useful clues for future research.  
For Vpu, we show that suppression of IFN-I induction is independent of Vpu’s ability to 
counteract the host factor tetherin. This protein was previously reported to act as an innate 
sensor of budding viral particles, thereby inducing activation of NF-ĸB but not IRF3 [90, 
112]. Although tetherin-mediated sensing could therefore further enhance the innate 
response, on its own it is likely insufficient to induce IFN-I production [90]. The presence of 
a viral innate suppressive mechanism in addition to tetherin counteraction, indicates that 
other mechanisms of sensing need to be counteracted by the virus. In our study, IFN-I 
induction by a wild-type virus was completely blocked upon cGAS knockdown. It will 
however be interesting to also evaluate vpu-deleted viruses in cGAS knockdown cells, to see 
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if other types of sensing occur and are suppressed by Vpu in primary CD4+ T cells. Knock-
down of tetherin alone and in combination with cGAS could furthermore learn us if tetherin-
mediated NF-ĸB activation enhances cGAS-mediated IFN-I induction. To narrow down the 
stage of the Vpu effect in the IFN-I signaling pathway, similar strategies as proposed for Vpr 
can be employed. As discussed in Chapter III-2, previous Vpu studies may already provide 
some clues about the molecular mechanism in this regard: although sometimes 
controversial, Vpu has been described to deplete [113] or cleave IRF3 [114], as well as to 
directly suppress activation of NF-ĸB [82, 89, 115, 116]. Interestingly, the latter has been 
linked to recruitment of β-TcrP by Vpu [82, 115] and our results indicate a similar 
requirement for β-TcrP-Vpu interaction to counteract HIV-mediated IFN-I induction in 
primary CD4+ T cells. In these previous studies, Vpu was suggested to sequester β-TcrP and 
thereby prevent β-TrCP dependent degradation of the NF-ĸB inhibitor IĸBα, which in turn 
prevents translocation of NF-ĸB to the nucleus [82, 115]. It would therefore be interesting to 
evaluate if differences in IĸBα levels and subcellular localization of NF-ĸB upon HIV-1 wild-
type and HIV-1 ∆Vpu infection can be detected in primary CD4+ T cells.  
General conclusion and implications 
In this work we have extensively characterized the IFN-I response against the HIV-1 virus in 
its main target cells. We demonstrate that activated CD4+ T cells are able to sense HIV 
through cGAS and accordingly produce IFN-I, which indicates them as a potential source of 
elevated IFN-I in HIV-1 patients. Although this will require in vivo confirmation, they may 
represent new targets for strategies aimed at suppressing hyper-immune activation during 
HIV-1 infection. Inhibition of IFN-I production or signaling as a therapy is still at early 
stages of evaluation, but in different small trials a decrease in immune activation or disease 
progression was observed [22, 23, 25, 26]. One of the strategies used in this regard is 
treatment with chloroquine, which inhibits endosomal acidification and thereby TLR7-
dependent IFN-I production by pDC’s. However, cGAS-mediated sensing is unlikely to be 
affected and IFN-I production may therefore be incompletely counteracted with this strategy. 
Options for sensor- (and cell-) specific blocking of IFN-I production instead of IFN-I signaling 
could however be useful, since they are less likely to disturb global anti-viral and anti-tumor 
functions of IFN-I and would also prevent the pro-inflammatory effects of NF-ĸB activation 
upon sensing. Furthermore, the cellular origins of IFN-I may differ at different stages of the 
infection and cell-types may therefore differently contribute to beneficial (early) versus 
disease aggravating (late) effects of IFN-I. In one study, chloroquine administration to 
patients at early stages of infection actually led to an increase in viral replication [117], 
indicating blockage of antiviral IFN-I effects. Although this needs further in vivo 
confirmation, pDC’s are considered to be the main source of early IFN-I [27], while CD4+ T 
cells are more likely to contribute at chronic stages of infection. As such, targeting of cGAS 
may be worth considering in patients with insufficient immunological response to cART or 
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remaining signs of chronic immune activation under cART. Given the recent identification of 
cGAS as a DNA sensor, a specific inhibitor of the protein is not yet available. However, 
structural studies indicate that both the catalytic pocket of the cGAS enzyme as well as the 
cGAMP binding pocket of STING may be amendable to small molecule inhibition [101, 118].  
We further show that the innate immune response to HIV-1 in CD4+ T cells is subjected to a 
high level of viral regulation: IFN-I induction is efficiently prevented before integration and 
controlled by two viral accessory proteins after integration. The inability of HIV-1 to evade 
innate sensing, the potentiating effect of Vpr and the incomplete suppression by Vpu may 
indicate that the virus strives to reach a delicate balance in sensing. Following further 
mechanistic elucidation, development of strategies aimed at disturbing this balance could 
lead to new therapeutic options. Such strategies can serve two different goals: targeting the 
IFN-I suppressing effect of Vpu or disturbing the mechanisms that prevent viral sensing 
prior to integration (and Vpu expression) may elevate IFN-I induction to levels that are 
sufficient to hamper viral spread, while targeting the Vpr potentiating effect could 
alternatively be used limit production of IFN-I. Similarly to targeting cGAS, the latter may 
find an application in patients with insufficiently controlled hyper-immune activation under 
cART. For the former strategies, it is difficult to predict if they will confer any additional 
advantage in suppressing ongoing viral replication compared to current antiretroviral 
agents. However, they may be useful as part of an immunological booster in “shock and kill” 
strategies, in which enhancing antiviral immunity will most likely be required to clear the 
“awakened” virus [119]. Alternatively, they could find an application in prophylactic 
strategies. Allowing an adequate innate immune response upon initial exposure may be 
sufficient to prevent the struggling virus from establishing infection.     
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eraan! Jouw eindeloos relativeringsvermogen en morele steun hebben me door dit doctoraat 
gesleurd! Over enkele weken gaan we de vlieger op en laat je al je geliefde muziekbands hier 
achter om ons Amerikaans avontuur te starten (Seattle here we come!). Merci, merci, 
duizendmaal merci!! 
